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CHAPTER 1 
GENERAL INTRODUCTION 

1.1 AUTOIMMUNITY AND RHEUMATIC DISEASES. 
It is the primary task of the immune system to protect the body 
from harm caused by infection with foreign agents and therefore it 
must be able to discriminate between self and nonself. Failure of 
this discriminatory mechanism results in autoimmunity; a malfunc-
tion of the immunesystem in which the body attacks its own tissues 
1 2 
. Many rheumatologic disorders are autoimmune in nature and al-
most all rheumatic diseases are therefore characterized by the 
3 ij 5 
spontaneous occurrence of circulating autoantibodies 
It has long been thought that B-lymphocytes capable of reaction 
to self antigens were eliminated during ontogeny, and that self-
reactive B-cell clones in autoimmune patients had escaped this 
mechanism (Burnett's forbidden clone theory). From studies of an-
imal models of autoimmune diseases it is now clear, however, that 
these self-reactive B-cells are normally present in healthy indi-
viduals but in a suppressed or inactivated state. The production 
of autoantibodies is therefore assumed to be a result of a defec-
tive suppression or a direct stimulation of these self-reactive 
B-cells . A simplified schematical representation of the regula-
tion of B-cell activity is shown in figure 1. The B-cell shown 
contains membrane receptors, two of which are capable to respond 
to signals from another class of lymphocytes, the T-helper and T-
suppressor cells. A third receptor is formed by a specific immuno-
globulin, capable of binding antigen. In general, binding of an-
tigen (together with some other factors) triggers the immune 
respons followed by the differentiation of B-cells into plasma 
cells. T-helper cells interact with B-cells to amplify the produc-
tion of antibody, T-suppressor cells act thereby as a control 
mechanism. The mechanism(s) by which the suppression of self-
reactive B-cells in autoimmune patients is overruled is not yet 
understood. In many autoimmune diseases however, alterations in 
the function and number of immunoregulatory T-cells are common 
— 11 — 
As far as rheumatic diseases are concerned, depressed T-suppressor 
cell function has been described in systemic lupus erythematosus 
7 1 Ρ1 ft 
(SLE) , juvenile rheumatoid arthritis and progressive sys-
9 1 2° 
temic sclerosis ^. An increased T-helper cell function is also 
found in patients suffering from this latter syndrome and in pa­
tients with drug-induced lupus, as well as in mice with a genetic 
predisposition for an SLE-like syndrome, the MRL-lpr/lpr mice 
120 6 
antigen 
helper (j\ i ^T-suppressor 
В 
ψ 
antibody 
FIGURE 1 Schematic representation of the forces acting on B-
cells. 
Genetic factors have also been suggested to play a major role in 
human autoimmune diseases . These theories are substantiated by 
the finding of familial aggregations, especially for rheumatoid 
11 12 
arthritis (RA), SLE and Sjoegren's syndrome , and by the high 
1 Я 
rate of concordance of SLE in identical twins . Even more con­
vincing for the possible involvement of an underlying genetic 
predisposition is the finding of an association between RA and the 
1 4 
DR4 phenotype of the human major histocompatibility complex 
Other MHC antigens are also linked to particular rheumatic 
15 diseases; Sjoegren's syndrome is associated with DR3 and SLE is 
linked to DR2 and DR3 · All these connections however, are not 
absolute and therefore other (environmental) factors are suspected 
to play an important role. Hormones are thought to be involved 
— 12-
because of the fact that rheumatic diseases in general are more 
common in women . Another interesting observation in this 
respect is the protective effect of oral contraceptives against 
the development of rheumatoid arthritis . 
Viruses form another, most intriguing group of candidates to be 
involved in the autoimmune processes of rheumatic diseases . In 
•a very recent review, Notkins et al., considered four possible 
1 7 
mechanisms of virus-induced autoimmunity 
1 The virus alters the appearance of the host cell, or component 
of it, in such a way that the immunesystem reacts to this host 
antigen as if it were foreign . A possible mechanism for 
this phenomenon could be the incorporation of host antigen 
into the virus envelope or by the sudden release of 
sequestered antigen caused by infection and lysis of host 
cells. Rigorous prove for such a mechanism has not yet been 
provided. 
The virus acts directly on the immune system. A virus capable 
of infecting immunoregulatory lymphocytes could destroy or 
stimulate certain subpopulations and in this way trigger the 
production of autoantibodies. Numerous examples can be found 
in literature in which a virus infection is followed by au-
20 
toantibody production . Most of these autoantibodies, howev-
er, share the common feature that they are directed against 
ubiquitous autoantigens such as DNA, IgG, phospholipids, 
erythrocytes and lymphocytes . Certain drugs (methyldopa, 
21 22 23 
procainamide) or microorganisms (malaria infection) 
24 25 
are also capable to elicit the production of this kind 
of autoantibodies, whereas the same effect can be obtained by 
In vitro stimulation of lymphocytes from normal persons by 
non-specific mitogens . Therefore it is assumed that these 
kinds of autoantibodies form a separate group whose production 
is an inherent property of the normal immune system 
How to explain the production of the very specific autoantibo-
dies directed against minor intracellular antigens, often ob-
served in rheumatic diseases? For this aim two additional 
possibilities are considered: 
•13-
A mechanism referred to as "molecular mimicry". The idea is 
that certain antibodies raised against viral antigens may 
17 
crossreact with host molecules . A monoclonal antibody 
against a phosphcprotein of measles virus and another against 
a herpes virus protein have recently been shown to crossreact 
27 
with the intermediate filament protein vimentin . A further 
28 
example for this theory has been presented by Woodruff ; a 
monoclonal antibody raised against 65 Coxsackie В1» virus 
reacted with mouse myocardium cells in an indirect immu­
nofluorescence test. Infection of mice with a Coxsackie В1* 
virus can result in a severe myocarditis, and therefore this 
crossreaction may indicate a pathogenic effect of anti-virus 
antibodies. 
As a reaction to antibodies elicited against viral antigens, 
the immune system is able to produce the so-called anti­
idiotype antibodies which in turn could react with host cell 
29 
components (see figure 2) . Experimental data indeed show 
that some antiidiotype antibodies are capable of reacting 
both with e.g. reovirus receptors on the surface of lympho­
cytes as well as with monoclonal anti-reovirus antibodies . 
ANTI-ANTI-V - AUTOANTIBODY 
(ANTI-ID) 
FIGURE 2 How autoantibodies may be anti-idiotypes of anti-viral 
antibodies. 
— 14-
As far as information is available, any of the mechanisms dis­
cussed above may be involved in the pathogenesis of rheumatic 
diseases. New insights in the role_ of known and still unknown 
viruses is to be expected from hybridoma and recombinant DNA tech­
nology, while new methods for studying immunoregulation will 
further elucidate the complex mechanism of autoantibody produc­
tion. It may be expected that such investigations will ultimately 
lead to adequate therapies for rheumatic diseases. 
1.2 AIM OF THIS STUDY 
Diagnosis of rheumatic diseases is difficult because of the very 
ц 
diverse pattern of clinical symptoms and therefore often based 
3 
upon serological findings . This thesis deals primarily with two 
aspects of the serology of rheumatic diseases: 
1 As pointed out, knowledge about the exact autoantibody compo­
sition of the patients' serum can be of use in diagnosis, 
while insight in the molecular nature and cellular function of 
the target antigens may lead to a better understanding of the 
pathogenesis of rheumatic diseases. 
2 The use of human autoantibodies as tools in molecular biology. 
These aspects will now be discussed in more detail. 
1.3 CLINICAL-SEROLOGICAL CORRELATIONS OF ANTI-NUCLEAR ANTIBODIES. 
A Diagnostic relevance of anti-nuclear antibodies. 
In rheumatic diseases several clinical entitles can be dis­
tinguished. Many of them are syndromes with overlapping clinical 
features and only the expression of a certain combination of symp­
toms is determinative for the diagnosis. It is, therefore, not 
seldomly seen that one and the same patient evolves from one diag­
nosis to another in the course of the disease. Serology can often 
be helpful in this classification. Since the discovery of the 
LE-cell phenomenon by Hargraves et al., later identified to be 
— 15— 
caused by anti-DNA/histone antibodies, 3 2 3^ 3 ^5 many other 
anti-nuclear antibodies (ANA) have been described 3. The most in-
teresting from a diagnosticai point of view are the so-called 
"marker" antibodies which are more or less specific for a certain 
syndrome or disease. Table I presents the most important correla-
tions between clinical diagnosis and presence of specific ANA in 
119 
• the patients' serum 
Clinical Diagnosis "Marker" antibodies reactive with: 
Rheumatoid arthritis 
Sj oegren's syndrome 
-IgG (Rheumatoid factor) 
-RANA (EBNA(?)) 
-APF antigen 
-SS-A/Ro 
-SS-B/La 
Systemic lupus erythematosus 
Mixed connective tissue 
disease (MCTD) 
Progressive systemic sclerosis 
-diffuse 
-CREST 
Poly/dermatomyositis 
-scleroderma overlap 
-native DNA 
-ssDNA 
-Sm 
-histones 
-SS-A/Ro 
-(UI)RNP 
-Scl-70/Scl-86 
-centromere/kinetochore 
-Jo-1 
-PM-1 
-Ku 
TABLE 1. Correlations between diagnosis and presence of ANA. For references 
see text. 
-16-
Rheumatoid arthritis (RA) and related disorders. 
The most important serologic finding in RA is the elevated rheuma­
toid factor titer, present in over 75? of patients. Rheumatoid 
factors are mostly IgM immunoglobulins which react with the Fc 
portion of IgG and in this way form a circulating 22S immunoglobu­
lin complex in the patients' serum. As far as ANA are concerned, 
RA is characterized by a very high incidence (more than 90%) of 
39 
antibodies against rheumatoid arthritis nuclear antigen (RANA) 
HO 41 
Presence of anti-RANA antibodies, however, is not specific 
for RA because of its high incidence in a.o. SLE, SJoegren's syn-
88 
drome, and even normal controls . RANA can be detected by in­
direct immunofluorescence (I.I.F.) only in nuclei of Epstein-Barr 
virus (EBV) infected cells, such as WiL-2 cells . A recent study 
suggests that RANA might be identical with the independently iden­
tified Epstein-Barr nuclear antigen (EBNA), an EBV encoded, 
slightly polymorphic protein with a molecular weight of about 
80,000 Dalton . This finding lend additional support to the 
hypothesis (primarily based on clinical findings) that EBV might 
45 i)6 Ц7 Ц8 
be involved in the pathogenesis of RA 
Further, the high Incidence (50%) of the so-called antiperinuclear 
factor (APF) is noteworthy. The presence of this antibody is ex-
Н9 50 tremely specific for RA , but because its laboratory test 
(I.I.F. on buccal mucosa cells) hardly acquires any international 
attention, the nature of the antigen as yet remains obscure. 
Patients with Sjoegren's syndrome can be subdivided clinically 
into patients with the sicca complex (xerophtalmia and xerostomia, 
primary Sjoegren's syndrome) and patients with these symptoms in 
combination with rheumatoid arthritis (SS-RA). Because of this 
close association with RA, the high incidence of anti-RANA antibo­
dies in this latter syndrome is not surprising. More characteris­
tic for primary Sjoegren's syndrome is the incidence of antibodies 
against SS-A/Ro and SS-B/La antigens which are reported to occur 
1)2 52 53 54 in about 70% and 60% of the cases, respectively . The 
latter of these antibody systems is more specific for primary 
Sjoegren's syndrome whereas anti-SS-A/Ro antibodies also occur in 
SLE and scleroderma. The molecular nature of SS-A/Ro and SS-B/La 
•17-
antigens will be discussed below. 
Systemic Lupus Erythematosus (SLE) and drug-induced Lupus 
Erythematosus (drug-induced LE). 
Antibodies to DNA are considered as a hallmark for SLE, and can be 
divided primarily into two subgroups; one exclusively reactive 
with single stranded (ss) DNA and the other directed against both 
ssDNA and double stranded (ds) DNA . Usually, the 
latter ¿pecificity is referred to as anti-native DNA. Monospecif-
ic anti-dsDNA has been described in only a very few cases 
. Both anti-ssDNA and -native DNA are common in SLE, whereas 
3 
only anti-ssDNA occurs in procainamide-induced LE . An addition-
al common feature of both diseases is the presence of antibodies 
d directed 
56 57 58 
55 
against histones . These are of IgG and IgM class an
against the bimolecular complex of histone H2A and H2B 
Antibodies in hydralazine-induced disease are predominantly IgM in 
nature and directed against the НЗ-НІ complex . 
Anti-Sm has originally been described as an additional marker an-
59 ti body for SLE, with an incidence of over 30$ . Several large 
scale studies performed in Europe reported a much lower incidence 
of about 3-10Ï . Whether this discrepancy is caused by techn-* 
ical factors or by variations in the populations examined, is as 
yet not entirely clear. 
Mixed Connective Tissue Disease (MCTD). 
It is still a matter of dispute whether MCTD has to be considered 
as a distinct entity, but originally it has been described as an 
overlap syndrome with features of SLE, progressive systemic 
sclerosis and poly/dermatomyositis . The diagnosis is furth-
er based on the presence of a high titer of anti-(U1)RNP antibo-
dies, which explains the Incidence of 100$ of this type of anti-
body in the serum of MCTD patients. Anti-(U1)RNP sera always con-
tain antibodies against one or more out of three antigenic pro-
teins called 70K, A and С (see below). Anti-70K antibodies almost 
exclusively occur in sera from MCTD patients, whereas anti-(U1)RNP 
sera from patients with SLE mostly contain antl-A and/or anti-C 
-18-
t к ^ 4 ι u t -, 70 108, an ibodies (chapter 2, ) 
Progressive Systemic Sclerosis 
Two major forms of PSS can be distinguished, both with their own 
marker antibody. A diffuse form with multi-system involvement 
characterized by vascular abnormalities, atrophy of parenchymal 
structures in skin and various internal organs and by fibrous tis-
71 
sue deposition . A second form of PSS is called the CREST-
variant, characterized by calcinosis, Raynaud's phenomenon, 
(O)esophagitis, sclerodactyly and telangiectasia. PSS is a slowly 
progressive and often fatal disorder, the CREST variant is be­
lieved to have a more benign course and a more favorable prognosis 
74 
. Little is known about etiology and pathogenesis and no treat-
72 73 
ment is yet available . The presence of an antl-
centromere/kinetochore antibody (АСА) is highly correlative with 
гтс »T£ rjrj 
the CREST form of scleroderma . Noticeable is the presence 
of anti-centromere antibodies in sera from patients with Raynaud's 
phenomenon . Some of these patients have acquired clinical 
characteristics indicating a developing scleroderma, since the 
first blotting tests were performed (C. Kallenberg, personal com-
munication). The possible prognostic significance of АСА has al-
74 77 
ready been suggested earlier 
An antibody against Scl-70 appears to be characteristic for pro-
78 
gressive systemic sclerosis . Using the immunoblotting method 
our group found that all Scl-70 positive sera, as judged by immu­
nodiffusion, contained antibody against a rather insoluble nuclear 
79 
matrix protein ofapproximately 86,000 molecular weight , but no 
reaction with a 70,000 molecular weight protein could be detected. 
It is possible that sera of scleroderma patients contain a tandem 
antibody, one to Scl-70 and the other to Scl-86. However, another 
in our view more likely possibility is that both antigens are 
recognized by the same antibody, which means that both antigens 
have an extremely close chemical relationship. 
— 19— 
Poly/dermatomyositis 
Several antibody systems directed against proteins associated with 
tRNA have been detected in these diseases. One of them, designated 
80 
Jo-1, has been shown to react with histidyl-tRNA synthetase 
This antibody seems to be very specific for and occurs in a rela­
tively high incidence in polymyositis patients with pulmonary fi-
Q1 Op 
brosis . It is noteworthy in this respect that some picorna-
viruses are also capable of reacting with tRNA synthetase 
molecules. Based upon clinical findings in some cases of polymyo­
sitis a pathogenic role for a Coxsackie virus has been hy-
pothesized . Antibodies to PM-1 and Ku have been described to 
occur at a high incidence in a polymyositis/scleroderma overlap 
84 85 
syndrome 
В Pathogenic roles for ANA 
Recent data indicate that in some cases ANA can also serve as a 
ren as 
74 77 
89 109 
marker for the activity of a disease (chapter 3 ) or even 
an early symptom for the development of a certain syndrome 
79 
These and similar observations raise the question what exact 
role, if any, do ANA play in the pathogenesis of a disease. A most 
obvious role is the formation of circulating immune complexes 
which then deposit in kidneys and brain and in this way might con-
92 
tribute to the pathogenic defects observed in these organs . It 
is not very likely, however, that this is the only mechanism in­
volved in the pathogenesis of rheumatic diseases, because of the 
diversity of clinical symptoms. Another interesting theory is the 
90 
one postulated by a.o. Faaber et al., that crossreactive binding 
of anti-DNA antibodies to glycosaminoglycanes e.g. of the glomeru­
lar basement membrane can lead to tissue injuries and other clini­
cal features of SLE. 
Similar theories have been postulated for other ANA, but no extra­
cellular crossreactive antigens have been described as yet for 
these antibodies. Some workers therefore presuppose the penetra­
tion of cellular and nuclear membranes for the pathogenic effect 
of the specific antibody. This phenomenon has only once been ob-
-20-
served _in vivo for anti-(U1)RNP antibodies, penetrating T-
lymphocytes via their Fc receptors 91^
 T h i 3 h o w e v e r i s a s y e t t h e 
only example and should therefore be interpreted with care. Pene-
tration of somatic cells by antibodies has not been described in 
vivo and can also hardly be achieved under _in vitro conditions (E. 
Mariman, personal communication). Moreover, it is very difficult 
to understand how the sometimes very severe tissue injuries ob-
served in some rheumatic diseases, could be attributed to pene-
tration or destruction of some non-regulatory cells by specific 
antibodies. Therefore it seems unlikely that binding of ANA to 
their nuclear antigen in situ plays a direct role in pathogenesis. 
A finding which emphasizes their distinct character is, that in 
contrast to DNA and histones, most nuclear antigens listed in 
table I are fairly good immunogens. For some it has even been 
shown that, upon immunization, they can elicit antibodies idiotyp-
93 ically identical to autoantibodies present in patients' sera 
This is a very interesting observation, because it indicates that 
the production of at least some ANA in patients is triggered by 
the release of nuclear antigen itself, rather than by action of a 
crossreactive agent. However, a random cell lysis cannot be the 
only cause for the production of ANA taken into account the speci-
ficity of some patients' sera for only one autoantigen. To get in-
sight in this mechanism it is necessary to investigate the molecu-
lar nature and normal cellular function of nuclear antigens. 
1.4 BIOCHEMICAL CHARACTERIZATION OF NUCLEAR ANTIGENS. 
Sm and (UI)RNP antigens 
Anti-Sm and anti-(U1)RNP sera can be selected by analysis of immu-
noprecipitates obtained from ^ P-labeled extracts of cultured 
94 
cells . Anti-Sm sera precipitate small nuclear (sn)RNA species 
U1 , U2, U4, U5 and U6 (U1-U6), whereas anti-(U1)RNP sera ex-
clusively react with U1 RNPs. Some sera contain both specificities 
— 2 1 — 
and are referred to as anti-Sm/RNP (chapter 6, ). Protein 
analysis of immunopreclpitates obtained with anti-(U1)RNP sera re­
vealed that U1 snRNPs are complexed with at least nine differently 
OR Q7 Qfl 1 01 
sized proteins (70K, A, B', B, C, D, E, F and G, y i ) 
while U1 RNP-depleted Sm-precipitates contain B', B, D, E, F and G 
96 polypeptides , as well as some other minor species (see below). 
Association of these polypeptides with the various snRNAs is 
schematically represented in figure 3. 
Us 
45,6 
anti-OJ^RNP 
-(UrU2)RNP 
-Sm 
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FIGURE 3 Association of proteins with snRNAs 
Closed circles indicate the presence of a polypeptide in the 
respective snRNP particle. Shaded circles indicate the presence of 
antibodies against the respective polypeptides in the various 
sera. The open circle indicates cross-reactivity of anti-B" anti­
bodies with the A antigen. 
When tested by immunoblotting all anti-(U1)RNP sera recognize at 
least one of the Ul RNA-speciflc antigens 70K, A and C, but 
surprisingly some also showed a weak but evident reaction with the 
(U1-U6) associated B'/B antigens (chapter 6, ). This finding 
can be explained by assuming that most anti-(U1)RNP sera contain 
trace amounts of anti-Sm antibodies, not detectable in the (very 
sensitive) RNA-immunoprecipitation assay. Another possibility is 
that some epitopes on B' and В antigens become available for immu-
—22--
noreaction due to the various treatments in the blotting pro­
cedure, while these epitopes are buried inside the snRNP particle 
under the physiological conditions of the immunoprecipitation as­
say. 
Anti-70K, anti-Α and anti-C antibodies contained in anti-(U1)RNP 
sera were found to be monospecific (chapter 5, ). When immu-
noreactive antibodies are eluted from their respective antigen 
bands on immunoblots and reassessed on separate blot strips, they 
react selectively with the corresponding protein antigen from 
which they had been eluted. Moreover, when these same antibody 
fractions were used for RNA immunoprecipitation they all reacted 
exclusively with U1 snRNPs. A different situation is encountered 
when anti-Sm antibodies are eluted from immunoblots. Anti-B'/B an­
tibodies precipitate U1-U6 RNAs and crossreact with the D antigen 
and vice versa (chapter 5, ). Crossreactivity of B'/B and D an­
tigens with the same monoclonal antibody has been observed previ-
99 95 
ously . These findings lend additional support to the con­
clusion that 70K, A and С antigens are U1 RNP-specific and that 
B'/B and D antigens are common in U1-U6 RNPs (see also figure 3). 
As it became clear that U1 and U2 snRNP particles play a crucial 
role in the processing of pre-mRNA into mRNA, a rapidly increasing 
interest developed for such monospecific antibodies. With their 
use it is now possible to unravel details about snRNP primary 
11 Ц 
structure (chapter 8, ) and their exact molecular appearance 
(chapter 7, ). 
The U2 snRNP antigen 
Antibodies directed against U2 RNP-specific polypeptides occur at 
a low incidence in various types of autoimmune diseases. Such sera 
allowed the identification of two antigenic polypeptides specific 
for U2 RNA, designated A' and B " with approximate molecular 
99 
weights of 32,000 and 28,500, respectively (figure 3, chapter 
5, ). Purification of antibodies from nitrocellulose blots re­
vealed that antibodies directed against the B " antigen 
crossreact with the U1 RNA specific A antigen. Because of this 
32 
crossreactivity these sera precipitate also U1 RNA from a P-
labeled HeLa cell extract (chapter 5, ). 
—23— 
The SS-B antigen. 
The SS-B (or La) antigen is an antigen of 50,000 molecular weight 
associated with precursors of a number of small RNAs synthesized 
by RNA polymerase III, including Ro RNAs (chapter H, 
11 2 
). The antigen is very susceptible to proteolytic degradation 
•resulting in two major antigenic breakdown products of about 
40,000 and 25,000 molecular weight. A major part of the SS-B an­
tigen is present in a readily extractable or soluble form. The 
rest is found In an insoluble form tightly associated with the nu­
clear matrix (chapter 4, ). 
The SS-A/Ro antigen 
The SS-Α (or Ro) antigen is a polypeptide of 59,000 molecular 
107 
weight associated with a number of small cytoplasmic RNAs (Y-
102 101 
RNAs, ' ). The SS-Α antigen is predominantly localized in 
the cytoplasm and more stable as compared to the SS-B antigen. 
Anti-SS-A antibodies are mostly found in sera from patients with 
Sjoegren's syndrome or SLE and in most cases (90%) accompanied by 
anti-SS-B antibodies. 
The centromere antigen 
75 Recently Moroi and coworkers reported on an antibody, the 
anticentromere/klnetochore antibody, which is found predominantly 
in the sera of patients with the CREST syndrome. The centromere 
antigen is not extractable by physiological saline solutions, but 
can be dissolved in SDS-containing sample buffer allowing analysis 
by immunoblotting. In an investigation with more than 30 sera 
showing the typical anti-centromere immunofluorescent pattern, all 
sera recognized a 19,000 molecular weight protein on HeLa nuclear 
protein blots . These findings are in agreement with the 
103 
recently published results from Guldner et al. but do not 
"¡04 
agree with blotting data from Earnshaw et al. and Cox et 
105 
al. .At the moment we do not have a satisfying explanation for 
this discrepancy. 
-24-
The Scl-86 antigen 
Sera from patients with progressive systemic sclerosis have been 
found to inhibit adenovirus DNA replication in an jji vitro system 
. The mechanism seemed to involve the binding by an immunoglobu-
lin G of a factor necessary for elongation. Among the strongly in-
hibitory sera were those containing anti-Scl-86 antibodies. Two-
dimensiomal immunoblotting analysis of anti-Scl-86 sera subse-
quently revealed that Scl-86 in extracts of mouse 3T6 cells coin-
cided with topoisomerase I, an enzym catalysing DNA relaxation as 
required for elongation. Moreover, affinity purified anti-Scl-86 
antibodies were able to inhibit topoisomerase I activity in a 
specific in vitro assay 
The Jo-1 antigen. 
The Jo-1 antigen is a polypeptide with an approximate molecular 
weight of 50,000 associated with histidyl-tRNA . The an-
tigenic component is identical with the PL-1 antigen and has 
80 
recently been identified as histidyl-tRNA synthetase 
When analysed by immunoblotting, the Jo-1 antigen exhibits a 
slightly lower electrophoretic mobility as compared to the SS-B 
antigen, and we calculated its molecular weight to be 54,000 Da 
107 
Jo-1 is predominantly present in cytoplasmic extracts of 
(HeLa) cells as would be expected from its function. 
The 56K antigen 
The 56K antigen was detected in the routine immunoblotting 
screening of 400 sera from patients with connective tissue 
diseases and occurs at a low incidence (approximately 3%) in a 
variety of diseases . The antigen is predominantly 
present in cytoplasmic extracts but a significant moiety is 
also associated with the nuclear matrix, as is the case with the 
112 
SS-B antigen . However, we consider the 56K antigen to be a 
cytoplasmic antigen because, unlike anti-SS-B antibodies, most 
anti-56K sera produce a diffuse cytoplasmic immunofluorescence 
pattern on both HeLa and HEp-2 cells. Comparison by immunoblotting 
-25— 
using high resolution gels revealed that the 56K antigen is dis­
ti, net from vimentin, an intermediate filament polypeptide with a 
similar molecular weight, which recently has been described as an 
11 5 
autoanti gen 
Proliferating cell nuclear antigen (PCNA). 
Antibody to PCNA can be found at a very low incidence in patients 
with SLE. The antigen has been associated with cellular prolifera­
tion by indirect immunofluorescence and in freshly stimulat­
ed lymphocytes it appears first in the nucleolus, later moving to 
11 7 the nucleoplasm . The antigen, as detected by immunoblotting, 
is a protein with molecular weight of 35,000 Dalton and in two-
11 я 
dimensional gels it coincides with cyclin 
In this chapter several nuclear and cytoplasmic molecules have 
been described which are characterized with the help of autoimmune 
sera. This list cannot be fully exhaustive, neither is it possible 
to discuss here the entire literature on this subject. Rather it 
was tried to give an overview how research on autoantibodies can 
have an Influence on practical rheumatology and immunology and on 
a more fundamental level can add new dimensions to investigations 
towards the cellular function and structure of their target an­
tigens . 
CONCLUDING REMARK 
The discovery of a therapy must be the ultimate goal of all inves­
tigations in rheumatic diseases. Studies dealing with the charac­
terization of autoantigens as the ones described in this thesis, 
might not have direct clinical implications but nevertheless they 
have already proven their usefulness in diagnosis and, as many ex­
amples in history show, an improved diagnosis is often a 
forerunner of an improved therapy. 
— 2 6 — 
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SUMMARY 
Specific nuclear proteins, separated according to their molecular weight (mol wt) by 
Polyacrylamide gel electrophoresis (PAGE) and subsequently transferred to nitrocellulose 
sheets, are able to bind antibodies in sera from patients suiTermg from different types of 
connective tissue diseases Antibodies against a characteristic set of nuclear protein 
antigens are found in sera from patients with mixed connective tissue disease (MCTD) 
Screening of 21 MCTD sera revealed a typical immunoblot pattern with major protein 
antigens of mol wt 70,000 (20/21) (not identical with the Scl-70 antigen characteristic for 
scleroderma), mol wt 31,000 (17/21), two proteins around mol wt 23,000 (15/21) and two 
around mol wt 19,000 (10/21) The 70,000, 23,000 and 19,000 antigens appeared to be 
rather insoluble nuclear proteins (i e components of the nuclear matrix) On behalf of 
their structural character they were present in nuclei from several types of cells but only in 
low amounts detectable in salt extracts of thymus acetone powder The presence of 
antibodies directed against the mol wt 70,000 antigen correlated strongly with the 
diagnosis of MCTD This 70,000 antigen is not identical with the RNP antigen, a soluble 
nbonuclease sensitive ribonucleoprotein, since antibodies against nuclear RNP can be 
separated from anti-nuclear matrix antibodies by affinity chromatography using 
immobilized thymus salt extract The distinct character of soluble nuclear RNP and 
structural nuclear matrix antigens is further supported by the fact that from 14 other 
anti-RNP sera obtained from patients with systemic lupus erythematosus (SLE), only 
three contained antibodies against the mol wt 70,000 protein Since the immunoblot 
pattern obtained with MCTD sera mostly was clearly distinguishable from the patterns 
obtained with sera from patients with related connective tissue diseases our results suggest 
that the immunoblotting technique might be useful as a diagnostic tool and support the 
concept of MCTD as a distinct entity 
Keywords mixed connective tissue disease nuclear matrix immunoblotting 
ribonucleoprotein marker antibody 
INTRODUCTION 
Mixed connective tissue disease (MCTD) has been described as an apparently distinct rheumatic 
disease syndrome, characterized by a combination of features similar to those of systemic lupus 
erythematosus (SLE), systemic sclerosis (scleroderma) and polymyositis Serologically, MCTD is 
characterized by sometimes extremely high titres of antibody to ribonucleoprotein (RNP) (Sharp et 
Correspondence DrW J Habets, Department of Biochemistry, University of Nijmegen, Geert Grooteplein 
noord 21, Ρ O Box 9101, 6500 HB Nijmegen, The Netherlands 
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al., 1972, 1976). The protein component of this antigenic RNP complex, purified by affinity 
chromatography, has been described to consist of at least 7 different proteins with molecular 
weights (mol. wt) ranging from 9,000 to 40,000 (Lerner & Steitz, 1979; Takano, Agris & Sharp, 
1980; Lerner et ai, 1981; Kinlaw. Dusing-Swartz & Berget, 1982; Matter et al., 1982). 
Antigenic activity of RNP as demonstrated by immunodiffusion or counterimmunoelectro-
phoresis assays, can be destroyed by either ribonuclease (RNAase) or protease (Sharp et al., 1976: 
White, Gardner & Hoch, 1981), suggesting that the formation of the immunoprecipitate is 
dependent on the integrity of both ribonucleic acid (RNA) and protein, although the naked protein 
contains at least some antigenic sites (White & Hoch, 1981 ). RNP is further characterized as a set of 
soluble ribonucleoproteins, since it is present in salt extracts of (thymus) nuclei (Kurata & Tan, 
1976). 
. Recently it was shown by immunofluorescence that sera from MCTD patients also contain 
antibodies against other nuclear proteins which are components of a rather insoluble deoxyri-
bonuclease (DNAase), RNAase and high salt resistant proteinaceous structure, generally referred 
to as nuclear matrix (Salden et al., 1982). To investigate whether the occurrence of these antibodies 
is a more general phenomenon, the antibody composition of various patient sera was investigated 
using the immunoblotting technique (Towbin, Stachelin & Gordon, 1979). This technique seems to 
be very useful because of its capacity to demonstrate antigenic activity in a complex mixture of 
cellular components and, at the same time, providing information about the exact number and size 
of molecules that contain antigenic target sites. This latter aspect is a direct improvement when 
compared to affinity chromatography, in which no distinction can be made between molecules 
containing antigenic sites and components only associated with, or complexed to, antigens. In this 
study the immunoblotting technique is used as a routine assay to screen sera from patients with 
MCTD and other connective tissue diseases for the presence of antibodies against nuclear proteins. 
MATERIALS AND METHODS 
Patients. Sera from 102 patients with anti-nuclear antibodies (ANA) were used in this study. 
Most patients were seen in the Departments of Rheumatic Diseases of the University Hospital of 
Nijmegen and the St Maartens-kliniek in Nijmegen. In addition, 16 sera of SLE and MCTD 
patients with anti-RNP antibodies were obtained from the University Hospital of Groningen and 
from the Central Laboratory of the Blood Transfusion Service in Amsterdam, nine sera of patients 
with Sjogren's syndrome from the University Hospital of Leuven (Belgium), three sera of SLE 
patients with anti-Sm antibodies from the University of Montpellier (France), two anti-Scl-70 sera 
of patients with systemic sclerosis from the Royal National Hospital, Bath (England) and serum of 
one patient with MCTD from the Hospital Ziekenzorg, Enschede. 
Patients with MCTD had clinical features of SLE, systemic sclerosis and polymyositis and 
anti-RNP antibodies (Sharp et al., 1972), patients with SLE satisfied the preliminary American 
Rheumatism Association criteria for this disease and did not have features diagnostic of other 
connective tissue disorders (Cohen et al., 1971). Patients with systemic sclerosis satisfied the 
preliminary criteria for systemic sclerosis (Masi & Rodnan, 1981). Patients with polymyositis had 
proximal muscular weakness, elevated muscle enzymes, abnormal muscle biopsy and electromyo-
gram (Bohan et al., 1977). Patients with Sjogren's syndrome had keratoconjunctivitis sicca or 
salivary gland abnormalities with anti-SS-B antibodies. Rheumatoid arthritis patients had classical 
or definite disease (Ropes et al., 1958). 
All sera showed a positive nuclear immunofluorescent staining pattern when acetone fixed 
cryosections of rat liver tissue and monolayers of cultured cells were used as substrate. Clinical and 
serological characteristics of the 21 MCTD patients are presented in Table 1. All 21 sera from 
patients suffering from MCTD showed a speckled nuclear immunofluorescent pattern with nucleoli 
negative and antibodies to RNP when tested by counterimmunoelectrophoresis (CIE) using a saline 
extract of rabbit thymus powder (Pel Freez, Rogers, Arkansas) generally referred to as extractable 
nuclear antigen (ENA) as antigen source (Kurata & Tan, 1976), two of 21 showed anti-DNA 
antibodies in the Crithidia assay (Aarden et al., 1975), nine of 21 rheumatoid factor using the 
— 36—· 
Antibodies characteristic for MCTD 
Table 1. Clinical and serological characteristics of 21 patients with MCTD 
Characteristics 
Polyarthralgia/polyarlhrilis 
Raynaud's phenomenon 
Myalgia/myopathy 
Swollen hands 
Fever 
Decreased pulmonary diffusion capacity 
Myositis 
(elevated CPK., abnormal EMG or muscle biopsy) 
Skin rash 
(e g butterfly, sunlight sensitivity) 
Decreased oesophageal motility 
Sclerodermatous changes 
Lymphadenopathy/splenomegalie 
Sicca syndrome 
Serositis 
Neurological abnormalities 
Renal disease 
Laboratory features 
Positive for ANA, speckled pattern 
Positive for RNP (CIE) 
Positive for (Ui)RNP precipitation 
Positive for anti-dsDNA 
(cnthidia assay) 
Hypocomplementemia 
Positive for rheumatoid factor 
(Waaler-Rose, Latex) 
% 
100 
90 
62 
55 
43 
41 (17)* 
33 
29 
28 (18) 
19 
19 
10 
10 
5 
5 
100 
100 
100 
10 
19 
43 
* Figures in parentheses denote No of patients tested 
Waaler-Rose and Latex fixation tests (Cats & Klein, 1970) (Table 1 ) Three out of 36 sera from SLE 
patients were found to contain exclusively anti-Sm antibodies in CIE whereas 14 of 36 SLE sera 
contained anti-RNP antibodies Two of these contained weak anti-Sm activity as well Sera were, 
when not immediately used, stored in liquid Nj 
Reference sera Reference sera were obtained from the Central Laboratory of the Netherlands 
Red Cross Blood Transfusion Service, Amsterdam, and from the Division of Rheumatic Diseases, 
University of Colorado Health Sciences Center, Denver, USA, and used in the CIE assay Blotting 
data of these sera were not used since diagnostic parameters were not available 
Cells HeLa S3 cells were maintained in suspension culture as described (van Eekelen & van 
Venrooij, 1981) They were shown not to contain Epstein-Barr virus and regularly performed 
mycoplasma tests were always negative 
Preparation of HeLa cell total nuclear protein fraction All procedures were carried out at 0-4°C 
unless stated otherwise 
Cells were harvested on frozen NKM (130 т м NaCl, 5 т м KCl, 1 5 т м MgAci), pelleted by 
centrifugation (5 mm at 800^), washed once with NKM and pelleted again The cells were 
resuspended in cold buffer 1(10 т м NaCl, 10 т м Tns-HCl pH 7 4,1 5 т м MgCb) containing 0 5 
т м PMSC (phenyl methyl sulphonyl chloride) to inhibit endogenous proteolytic activities. After 
addition of a mixture of sodium deoxycholate (DOC) and Tween 40 (0 5% and 1 %, respectively), the 
cells were homogenized by 10 strokes of a motor driven teflon pestle in a Potter-Elvehjem type 
tissue homogenizer. The nuclei were pelleted (5 mm at 800;), washed once with buffer 1 containing 
0 5 т м PMSC and resuspended in buffer 2 (110 т м NaCl, 10 т м Tns-HCl pH 7 4,1 5 т м MgCb, 
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0·5 т м PMSC) at a density of 10" nuclei/ml. To degrade nucleic acids, the nuclei were incubated 
with SOO g^/ml DNAase 1 and lOO/jg/ml RNAase A for 1 h at 20 С. These nuclease treated nuclei 
are referred to as total nuclear protein fraction. 
Préparation of HeLa cell nuclear matrices. HeLa cell nuclei were treated with DNAase 1 (500 
¿jg/ml) for 1 h at 20 С Chromatin fragments and RNP complexes were removed by sedimentation 
through a 1 м sucrose layer in buffer 2 followed by an extraction with 0-4 M (NH4):S04 (van Eekelen 
& van Venrooij. 1981 ). The matrices were resuspended in buffer 1, treated with RNAase ( 100 ^ g ml) 
for 30 min at 20 С and dissolved completely in sample buffer for gel electrophoresis (see below). 
Morphological and biochemical characteristics of nuclear matrices isolated in this way have been 
described (van Eekelen et al.. 1982). 
Gel electrophoresis and protein blotting. Samples for Polyacrylamide gel electrophoresis (PAGE) 
in sodium dodccylsulphate (SDS) were prepared by dissolving the protein fraction in sample buffer 
(2°/ SDS, 10% glycerol, 5% /J-mercaptoethanol, ОТ м Tris-HCl pH 6-8). To ensure complete 
dissociation of the protein complexes, the samples were heated for 3 min at 100 С followed by gel 
electrophoresis in SDS on 13% Polyacrylamide slab gels (1 mm thick, 10 χ 16 cm). Proteins were 
loaded over the entire width of the gel ( 1 • 5 mg of protein per gel) and separated according to their 
molecular weight essentially as described by Laemmli (1970). After a 4 h run at 20 m A per gel, 
replicas of the gels were made on nitrocellulose (i.e. blotting) by transferring the proteins 
electrophoretically using a Bio-Rad trans-blot cell. Transfer was performed overnight at room 
temperature and at 60 V/0-3 A in 192 т м glycine, 25 т м Tris pH 8-3 and 20% methanol. After 
transfer the blots were dried and stored at room temperature. 
Detection of antigens. The protein blots were cut from top to bottom into strips of about 7 mm 
and treated with pre-incubation buffer (3% bovine serum albumin [BSA], 350 т м NaCI, 10 т м 
Tris-HCl pH 7-6, 0-5 т м PMSC) for 3 h at 2 0 ^ to saturate additional protein binding sites on the 
nitrocellulose. Incubation with diluted serum (mostly 1:50) was performed overnight in buffer 3 
(0-3% BSA, ISOmMNaCl, 10 т м Tris-HCl pH 7-6, 01 т м PMSC, 1% Triton X-100, 0-5% DOC 
and 0 1% SDS). After extensive washing with buffer 3 (3 χ 10 min) IgG immunecomplexes were 
detected by incubating the blots for 2 h with i:!5I-labelled protein A (spec. act. 1 mCi/mg) in buffer 3 
(2 μΟ in 20 ml) then washed again with buffer 3 (3 χ 10 min) and water (3x10 min), dried under a 
lamp and exposed to X-ray film for 2-16 h at —70 С using Ilford intensifying screens. 
In some blotting experiments l25I-labelled anti-human IgG or horse radish peroxidase 
conjugated anti-human IgG was used instead of protein A. The results were the same. 
Absorption of anti-nuclear RNP antibodies. Twenty milligrams of a saline extract of rabbit 
thymus powder (ENA) which has been shown to contain the soluble RNP antigens (Kurata & Tan, 
1976) was immobilized on 3 g (wet weight) of cyanogen bromide activated Sepharose (Pharmacia). 
Antibodies against nuclear RNP were absorbed by repeated incubation of 1 ml 1:10 diluted serum 
in BTP (0-5% BSA, 0-5% Triton X-100, in 10 т м PBS, pH 7-5) with 3 ml ENA-Sepharose for 5 h at 
20 С under continuous shaking. The supernatant was tested for remaining anti-nuclear RNP 
activity by counterimmunoelectrophoresis (CIE), ELISA and immunoblotting. The retained 
anti-RNP antibodies were eluted from the affinity column with 1 м acetic acid and subsequently 
neutralized with 1 м Tris. 
RESULTS 
Sera from 35 patients with anti-RNP antibodies (21 MCTD patients and 14 SLE patients) and 67 
other ANA positive sera (see Materials and Methods) were tested for the presence of antibodies 
against nuclear proteins using the immunoblotting technique. 
The immunoblotting assay 
The assay was routinely performed as described in the Methods section using as source of antigens 
the nuclear proteins of HeLa S3 cells. Special care was taken to ensure that all DNA and RNA was 
degraded completely by the incubation with DNAase I and RNAase A. Control experiments (van 
Eekelen et al., 1982) showed that about 0-5% of the DNA and less than 5% of the nuclear RNA 
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resisted the nuclease treatment probably as a result of protection by proteins. This heterogeneous 
mixture of nucleic acid fragments, however, is dissociated from their protecting proteins by the 
subsequent boiling in SDS. Therefore, under the electrophoretical conditions used in our assay 
these DNA and RNA fragments are in no way able to contribute to the distinct pattern of protein 
bands found (Fig. 1, lanes a and b). To prove the proteinaceous character of the antigens more 
unequivocally, the nuclear protein fraction was, after nuclease treatment, incubated with pronase. 
After gel electrophoresis and blotting of this mixture, no antigenic activity was detectable anymore 
(not shown). After electrophoretic transfer of the proteins, the nitrocellulose sheet can be used for 
the detection of antigens (Fig. 1, lanes с and d). The binding of proteins to nitrocellulose was always 
sufficient for recognition by antibodies. Binding of antibodies to slowly migrating high molecular 
weight proteins as large as mol. wt 120,000 could easily be detected when sera in a dilution of 1:50 
were used. 
When the total nuclear protein fraction was blotted and this blot was incubated with an MCTD 
serum a pattern of antigens as shown in Fig. 1c was obtained. As described in the Materials and 
Methods section, the total nuclear fraction can be subdivided in a nuclear matrix fraction and an 
(NH4)2S04-sucrose fraction. This lattern fraction contains most if not all of the chromatin and high 
ж 
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Fig. 1. Detection of nuclear and nuclear matrix antigens with an MCTD serum. HeLa S3 nuclear fractions, 
treated with DNAase I and RNAase A as described in the Materials and Methods section were completely 
dissolved in SDS containing sample buffer, heated for 3 min at 100 С and subjected to SDS-PAGE. 
Electrophoretic transfer of the proteins to nitrocellulose sheets and detection of the antigens was performed as 
described in the Materials and Methods section. (A) Coomassie brilliant blue stained pattern of total nuclear 
proteins of HeLa S3 cells; H = Histones. (B) Coomassie brilliant blue stained pattern of nuclear matrix proteins. 
(C) Immunodetection of nuclear antigens after blotting of lane A and incubation with MCTD serum No. 19. (D) 
Immunodetection ofnuclear matrix antigens after blotting oflane В and incubation with MCTD serum No. 19. 
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sait extractable RNP structures while the matrix fraction contains matrix components and matrix 
associated proteins resisting the high salt wash (van Eekelen et al.. 1982). The nuclear antigens 
recognized by the MCTD serum are predominantly present in the matrix fraction (lane d) and have 
mol. wts of 70,000. 23,000 and 19,000, respectively. 
The main advantages using the protein blotting technique for the detection of antibodies are its 
sensitivity and remarkable reproducibility. Serum from a patient used as a reference for a period of 
more than 1 year always showed the same characteristic immunoblot pattern, independent from the 
fact that nuclear protein fractions were used from various batches of HeLa S3 cells. It is by virtue of 
this reproducibility that we became aware of the characteristic set of antigens recognized by 
antibodies in sera from patients suffering from MCTD. 
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Fig. 2. Immunoblot patterns of patients sera. (A) MCTD sera. Protein blots of a total nuclear protein fraction 
from HeLa cells were pepared as described in the Methods section. One entire protein blot was cut into strips and 
each strip was incubated with serum of a patient suffering from MCTD (clinical and serological parameters of 
these patients are presented in Table I ). Detection of IgG-antigen complexes was performed by incubation with 
'•^¡-labelled protein A. (B) Anti-RNP containing SLE sera Protein blots were incubated with anti-RNP sera 
obtained from 14 SLE patients (see Methods section). NHS; protein blot incubated with normal human serum 
obtained from a pool of 40 healthy individuals. 
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Correlation between MCTD diagnosis and presence of specific antibodies 
Comparing the protein blot patterns of sera from MCTD patients (Fig 2A) and SLE sera 
containing anti-RNP activity (Fig 2B) it was striking that the presence of the mol wt 70,000 band 
correlated strongly with the diagnosis of MCTD (Table 2) As is shown in Fig 2,95% of the MCTD 
sera (20 of 21 ) recognized the mol wt 70,000 protein, whereas of the remaining 14 anti-RNP sera, all 
from SLE patients, only three (21%) did recognize the mol wt 70,000 antigen Other commonly 
found target antigens for antibodies m the MCTD and SLE anti-RNP sera tested were a doublet at 
mol wt 23,000 (80%, 28 of 35), two proteins around mol wt 19,000 (43%, 15 of 35) and a single 
protein with mol wt 31,000 (69%, 24 of 35) The presence of multiple other (low molecular weight) 
antigen bands is particularly evident in the SLE sera Antibodies against the mol wt 23,000 doublet, 
probably identical to the С proteins of Lerner et al (1979) were also found in anti-Sm sera (three of 
three, Table 2) 
Table 2. Occurrence of antibodies against MCTD associated antigens in various sera 
Diagnosis 
MCTD 
SLE anti-RNP 
anti-Sm 
other 
all 
PM* 
RA 
PSS 
SS 
Number of 
patients 
21 
14t 
3 
19 
36 
S 
10 
14 
13 
70 
20 (95%) 
3 (21%) 
0 
1 (5%) 
4 (11%) 
0 
0 
0 
0 
Molecular weight χ 10 3 
31 
17 (81%) 
7 (50%) 
2 (67%) 
6 (32%) 
15 (42%) 
3 (38%) 
0 
0 
1 (8%) 
23 
15 (71%) 
13 (93%) 
3 (100%) 
7 (37%) 
23 (64%) 
1 (13%) 
0 
3 (21%) 
0 
19 
10 (48%) 
5 (36%) 
0 
1 (5%) 
6 (17%) 
1 (13%) 
0 
0 
0 
* PM = polymyositis, RA = rheumatoid arthritis, PSS = progressive sys­
temic sclerosis, SS = Sjogren's syndrome 
t Two of these sera contained some anti-Sm activity as veil 
Other чего 
Although the majority of other investigated ANA positive sera (including sera from patients 
suffering from Sjogren's syndrome, « = 1 3 , progressive systemic sclerosis, n= 14, systemic lupus 
erythematosus, η = 22, polymyositis, я = 8 and rheumatic arthritis, и =10) contained antibodies 
against distinct nuclear proteins (data not shown), the pattern of the target antigens of these sera 
(number and molecular weights of antigen bands) always was clearly distinguishable from the 
MCTD type pattern shown in Fig 2A (see also Table 2) 
Ргечепсе of the MCTD associated antigens m other cell types 
An important and often neglected point in the discussion about the character of nuclear antigens 
has been the nature of the antigen preparation used in various studies The fact that antigens might 
be present both in a soluble (Kurata & Tan, 1976, Sharp et al, 1976) and an insoluble form (White, 
Billings & Hoch, 1982, Salden et al, 1982) has prompted us to use in our blotting assay the total 
nuclear protein fraction containing structural as well as soluble components of the HeLa cell 
nucleus In Fig 1 we have shown that the insoluble nuclear matrix fraction, after dissolving it in 
SDS containing buffer, contained the mol wt 70,000, 23,000 and 19,000 proteins as the major 
antigens when an MCTD serum was used Since these structural proteins constitute only a small 
fraction of the total cellular protein and thereby are rather insoluble in physiological salt solutions, 
it is not unexpected that the concentration of these antigens in the commonly used salt extracts of 
thymus powder is very low as compared with total thymus powder (Fig 3, lanes F and G) Better 
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Fig. 3. Occurrence of MCTD associated antigens in various cell lines and tissues. Purified nuclei from (A) HeLa 
S3 cells, (B) human lymphoblasts in culture (Rosenfeld et al., 1977), (С) cultured hepatoma cells (Alexander el 
al., 1976) and (E) hamster lens cells (Bloemendal el al., 1980) were prepared as described for HeLa cells in the 
Methods section. Nuclei from rat liver tissue (D) were prepared as described (Blobel & Potter, 1966). The 
nuclear protein fractions from these nuclei were prepared by DNAase I and RNAase A digestion followed by 
SDS solubilization as described in the Methods section. Total rabbit thymus powder (F) was sonicated prior to 
DNAase 1 and RNAase A digestion and SDS solubilization. Salt extractable nuclear proteins (G) were isolated 
from rabbit thymus powder using the procedure of Kurata & Tan (1976). Equivalent amounts of all protein 
samples were used in the protein blotting assay. All strips were incubated with scrum from MCTD patient No. 3 
and after l25I-labelled protein A treatment autoradiographed for 16 h. 
sources of these antigens, therefore, are purified nuclei from either cultured cells or tissues. Fig. 3, 
lanes A to E, show the antigens recognized by an MCTD serum in nuclear proteins from various 
types of cultured cells and rat liver tissue. It is interesting to note here that, for example, in HeLa and 
lymphocyte nuclear proteins there is a double mol.wt 23,000 antigen band, whereas in rat liver and 
hamster lens nuclear proteins this antigen appears as a single polypeptide. This phenomenon might 
be caused by post-synthetic modification of the 23,000 protein which occurs in one type of cell but 
not in another. 
MCTD-70 is not identical with Scl-70 
Because of the similarity in molecular weight it was investigated whether the MCTD 70,000 antigen 
could be identical with the Scl-70 antigen that is often found in sera from patients with progressive 
systemic sclerosis (Douvas, Achten & Tan, 1979). When Scl-70 sera, which had been shown to react 
positively in immunodiffusion and immunofluorescence tests (Catoggio et ai, 1982) were examined 
in the protein blotting assay, they did not recognize an antigen of mol. wt 70,000. This strongly 
suggests that the Scl-70 and the MCTD-70 antigens are not identical. Moreover, none of the 14 sera 
from scleroderma patients showed antibodies against an mol. wt 70,000 protein in the blotting 
assay. It is possible that the antibodies against Scl-70 recognize a delicate three-dimensional 
conformation of the antigen in situ that is destroyed during our preparation procedure. 
MCTD associated nuclear matrix antigens are distinct from nuclear RNP 
The distinct character of nuclear RNP and the MCTD associated nuclear matrix antigens is already 
indicated by the fact that from 14 anti-RNP sera (all obtained from SLE patients) only three did 
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recognize the mol. wt 70,000 nuclear matrix antigen. Moreover, none of the matrix antigens were 
detectable in a saline extract of rabbit thymus (ENA, Fig. 3 lane G). To prove the distinct character 
of the nuclear matrix antigens more unequivocally the following experiment was performed. An 
MCTD serum was passed over an ENA-Sepharose column (see Materials and Methods) to remove 
the antibodies against nuclear RNP. To make sure that the absorption was quantitative, the 
non-bound antibody fraction was tested in counter-immunoelectrophoresis, by immunoblotting 
and in a very sensitive ELISA technique, always using ENA as the substrate. No reactivity towards 
soluble nuclear RNP antigens was detectable anymore (not shown). However, anti-nuclear matrix 
antibodies were still present in the non-bound antibody fraction as is shown in Fig. 4 lane B. When 
the retained anti-nuclear RNP antibodies were eluted from the affinity column, they did not show 
any reactivity towards the nuclear matrix antigens (Fig. 4 lane C) but appeared to be enriched in 
activity towards polypeptides with mol. wts of 9,000-14,000. 
Summarizing we conclude that MCTD sera recognize a specific set of nuclear protein antigens of 
mol. wt 70,000, 31,000, 23,000 and 19,000. Some of these proteins are also recognized by other 
anti-RNP sera (Table 2 & Fig. 2B). However, the presence of antibodies against a mol. wt 70,000 
antigen, mostly in combination with (some of) the other three antigens is highly characteristic for 
MCTD. 
19-ИИІ-
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Fig. 4. Detection ofseparated anti-RNP and anti-nuclear matrix antibodies. Serum from MCTD patient No. 19 
was depleted from antibodies against nuclear RNP by absorption on an ENA-Scpharose affinity column. The 
non-bound fraction and the eluate were tested by immunoblotting. Three identical strips of the same protein 
blot ofa HeLa total nuclear protein fraction were incubated with: (A) Serum before absorption; (B) serum after 
absorption (non-bound fraction); (C) purified anti-nuclear RNP antibodies (eluate). The strips were incubated 
for 1 h with horse radish peroxidase conjugated anti-human IgG and peroxidase activity was detected by 
incubating the washed blots in PBS (10 m.M phosphate buffer in 0-9% NaCl, pH 7-5) containing 
4-chloro-l-naphtol (0-5 mg/ml) and H2O2 (006%). 
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DISCUSSION 
The use of the immunoblotting technique for the detection of specific antigens recognized by 
antibodies in autoimmune sera has several advantages Because not only the soluble but also the 
insoluble antigens are dissolved in SDS before gelelectrophoresis, more complete information is 
obtained about the number and size of the antigens In contrast to affinity chromatography or 
immunoprecipitation, in the immunoblotting technique the antigenic complexes are first separated 
into their individual constituents, so that only the antigenic sites bearing polypeptides are detected 
Moreover, the method is extremely sensitive (Towbin et al, 1979) and reproducible as has been 
pointed out already in the Results section Finally the blotting technique can be used for the 
screening of large groups of patient sera 
The group of 21 MCTD patients examined in this study is a rather heterogeneous one as far as 
their clinical characteristics are concerned (Table 1) All 21 MCTD sera, however, showed a 
speckled nuclear immunofluorescent pattern, a finding not only characteristic for MCTD sera but 
also often found when, for example, SLE sera are used Furthermore, all 21 sera contained 
precipitating antibodies to (Ui)RNP when tested in countenmmunoelectrophoresis and immuno­
precipitation studies (Table 1) The antibodies to RNP have been described as being characteristic 
for MCTD (Sharp et al, 1972) although they can be found also (in somewhat lower titres and 
frequency) in sera from patients suffering from SLE, rheumatoid arthritis, Sjogren's'syndrome and 
progressive systemic sclerosis (Notman, Kurata & Tan, 1975) Although all ANA positive sera 
tested with immunoblotting contained antibodies against a great variety of nuclear proteins, the 
antigen patterns obtained with sera from MCTD patients were surprisingly similar In particular 
the presence of antibodies against a mol wt 70,000 antigen in almost all MCTD sera was striking 
and allowed us to distinguish them easily among immunoblot patterns of about 100 sera from 
patients with various types of connective tissue diseases, even when these sera contained anti-RNP 
activity (Table 2 & Fig 2) 
It is commonly agreed upon that the soluble RNP complex precipitated by anti-RNP sera 
contains at least seven proteins in the range of mol wt 9,000-40,000 (Lerner & Steitz, 1979, Takano 
et al, 1980, Sri-Widada et al, 1982, Lenk, Maizel & Crouch, 1982, Matter et al, 1982, Kinlaw et al, 
1982) although some reports suggest the presence of mol wt 70,000 and 65,000 proteins as well 
(White et al, 1982, Takano et al, 1981 ) 
However, these soluble antigens are distinct from the nuclear matrix antigens since we have 
demonstrated here than an MCTD serum, completely depleted from anti-nuclear RNP antibodies 
still contains anti-nuclear matrix activity The fraction containing the antibodies against nuclear 
RNP showed reactivity towards polypeptides with mol wts of 9,000-14,000 present in a total 
(soluble as well as insoluble) nuclear protein fraction from HeLa cells Antibodies against such low 
molecular weight proteins in this region are commonly found in anti-RNP sera (White et al, 1981, 
Sri-Widada et al, 1982, Lenk et al, 1982) It is interesting to note further that these low molecular 
weight proteins are recognized in a higher frequency by RNP sera obtained from SLE patients ( 11 of 
14) than by the MCTD sera 
In summary we conclude that the presence of antibodies against a mol wt 70,000 nuclear matrix 
antigen is strongly correlated with the diagnosis of MCTD (Table 2) suggesting that this disease 
indeed might be considered as a distinct entity Our results further demonstrate the immunoblotting 
technique to be a powerful diagnostic tool 
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S U M M A R Y 
A quantitative immunoblotting assay (QIBA) for the determination of specific antibody 
titres in human autoimmune sera is described. In this assay, a total HeLa nuclear protein 
fraction, immobilized on nitrocellulose blot strips, was used as source of antigens and 
immunoreactive species of autoantibodies were quantitated by an enzyme linked second 
antibody procedure. Besides being more discriminative, QIBA appeared to be up to 500 
times more sensitive than immunodiffusion or Immunoelectrophoresis. In this study we 
used 21 sera from patients with SLE or MCTD for a quantitative analysis of their specific 
autoantibody content. Within this group, a very diverse spectrum of antibody popula­
tions was observed; anti-RNP sera appeared to contain, among others, high titred 
antibody versus 70K and 31К polypeptides while all (и = 6) anti-Sm sera recognized a 
25kD protein doublet. In a follow-up study of two MCTD patients significant flares in 
specific antibody content could be observed. 
Keywords immunoblotting Sm/RNP SLE/MCTD quantitation 
I N T R O D U C T I O N 
Autoantibodies directed against intracellular (mostly nuclear) antigens are frequently found in 
association with rheumatic diseases (Tan, 1982). Some of these antibodies are characteristic for 
certain syndromes and therefore of diagnostic value. For example, anti-Sm and high titres of 
anti-RNP antibodies are found to be associated with systemic lupus erythematosus (SLE) and 
mixed connective tissue disease (MCTD), respectively (Sharp et al., 1972, 1976). Much effort has 
been made to elucidate the clinical significance of the presence of these anti-Sm or anti-RNP 
antibodies (Williamson, Pennebaker & Boyle, 1983, Field Munves & Schur 1983, Barada et al., 
1981, Sharp et ai, 1972, 1976) but until now no clear correlations have been found. 
Attempts to elucidate the molecular composition of the Sm and RNP antigens were more 
successful. Both appeared to be a ribonucleoprotein complex consisting of one or more small 
nuclear RNA species, termed U l , U2, U4, U5 and U6, and a set of five to eight nuclear proteins 
(Lerner & Steitz 1979). The target for the anti-RNP antibody reaction has been shown by 
non-immunological isolation procedures to consist of one single RNA species (Ul snRNA) and a 
set of eight different nuclear polypeptides varying in mol. wt from 70,000 to 9,000 daltons (D) 
(Kinlaw, Robberson & Berget, 1983, Hinterberger, Pettersson & Steitz, 1983). Polypeptides 70K, A 
and С (of 70,31 and 19 kD, respectively) are unique for the Ul snRNA particle and therefore it can 
be assumed that the U l - R N P specific epitopes are formed by at least one of these proteins. The 
Correspondence: Dr W. J. Habets, Department of Biochemistry, University of Nijmegen, Geert Grooteplein 
noord 21, PO Box 9101, 6500 HB Nijmegen, The Netherlands. 
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other five proteins B,D,E,F and G (mol wt 25,13,11,10 and 9 kD, respectively) are also found to be 
associated with the LI2, U4, U5 and U6 snRNA which are among the targets of the anti-Sm 
reaction It is not clear yet which of these five proteins carry the Sm specific determmant(s) but the 
25 kD B-B' doublet and the 13 kD D protein are common targets when anti-Sm sera are tested in 
immunoblotting (White, Billings & Hoch, 1982, Billings et al, 1982) 
Quantitation of these antibodies has, until now, only been performed using conventional 
semi-quantitative techniques as counter-immunoelectrophoresis (CIE) (Field Munves & Schur, 
1983, Barada et al, 1981 ) or haemagglutination (HA) (Sharp et al., 1976,1972) which both are only 
capable of measuring the total amount of reactive antibody The assay we present here has a higher 
discriminative power in that it measures the amount of antibody directed against each antigenic 
polypeptide separately This assay makes it possible to investigate whether there are correlations 
between the quantity of these specific antibodies and distinct clinical features. We tested 21 MCTD 
•and SLE sera and followed two MCTD patients in a longitudinal study for a period of 2 years 
MATERIALS AND METHODS 
Patients. Most patients with MCTD or SLE were seen in the St Radboud hospital or the St 
Maartensclinic in Nijmegen, and diagnoses were reached as described (Habetser al, 1983a, 1983b). 
Clinical characteristics of these patients are presented in Table 1. 
Table 1. Clinical and laboratory features of patients with MCTD or SLE 
Characteristics 
Polyarthralgia/polyarlhritis 
Raynaud's phenomenon 
Swollen hands 
Myalgia/myopalhy 
Skin rash (e g butterfly, sunlight sensitivity) 
Fever 
Myositis (elevated CPK, abnormal EMG or muscle biopsy) 
Sclerodermatous changes 
Vasculitis 
Pleuro/pencarditis 
Sjogren's syndrome 
Lymphadenopathy 
Renal disease 
CNS involvement 
Decreased pulmonary diffusion capacity 
Decreased oesophageal motility 
Laboratory features 
Positive for ANA, speckled pattern 
Positive for RNP (CIE) 
Positive for Sm (CIE) 
Positive for Sm + RNP (CIE) 
Hypergammaglobulinaemia 
Leuco/thrombopema 
Positive for rheumatoid factor (Waaler-Rose, Latex) 
Hypocomplementaemia 
Positive for anti-dsDNA (Fair assay) 
Code 
A 
В 
С 
D 
E 
F 
G 
H 
I 
J 
К 
L 
M 
N 
О 
Ρ 
Q 
R 
S 
Τ 
и 
% 
100 
89 
58 
52 
37 
32 
26 
21 
21 
16 
11 
11 
5 
5 
38(16)* 
35(17) 
100 
68 
21 
11 
58 
47 
42 
32 
32 
1
 Figures in parentheses denote number of patients tested. 
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Reference sera. Sera containing anti-nuclear antibodies (ANA) were selected essentially as 
described (Habets et α/., 1983b, Kurata & Tan, 1976). Reference anti-RNP, anti-Sm and anti-SS-B 
sera were a gift of the Centers for Disease Control, Atlanta, Georgia, USA. Anti-Scl-70 reference 
sera (Douvas, Achten & Tan, 1979) were a kind gift of Dr E. Penner (Vienna). 
Culturing and labeling of HeLa S3 cells. HeLa S3 cells were grown in suspension cultures as 
described (van Eekelen & van Venrooij, 1981). They were shown to contain no Epstein-Barr or 
Adenovirus and regularly performed mycoplasma tests were always negative. 
RNA was labelled for 48 h with 3 /iCi/ml 3H-uridine and 1 /¿Ci/ml 3H-cytidine at a density of 
0-5 χ 106 cells/ml. 
Preparation of antigenic protein fractions. Extractable nuclear antigen was prepared by a 4 h 
extraction at 4 0 C of rabbit thymus powder (Pel-Freez, Arkansas, USA) with PBS (Зшм NaH2P04,7 
т м Na2HP04, 0-9% NaCl, pH 7-6) containing &.5тм PMSC (phenyl-methyl-sulphonyl chloride) 
to inhibit proteolytic activity followed by centrifugation for 30 min at 20,000^ (Kurata & Tan, 
1976). 
Hela nuclear protein fraction for blotting analyses was prepared as described earlier (Habets et 
al., 1983b). 
Qualitative immunoblotting. Transfer of proteins from 13 or 15% Polyacrylamide gels onto 
nitrocellulose sheets was performed as described (Habets et al., 1983b). After transfer the blots were 
dried, cut into strips and stored at room temperature. Immediately before use additional protein 
Immunoblotting RNA precipitation 
mol wt xlO 3 
70-
31 -
2 5 -
1 9 -
r « I 
1 3 -
*•"• *"" нищ 
tRNA 
NS В Total 
RNA 
NS 
Fig. 1. Characterization of sera by qualitative immunoblotting and RNA precipitation analysis. Immunoblot­
ting: identical strips from one HeLa nuclear protein blot were incubated with 1:100 diluted normal human 
serum (NS), three different 1:100 diluted human anti-RNP sera (lanes А, В and D), a 1 ; 50 diluted monoclonal 
anti-70K RNP culture supernatant (White et al., 1982, lane С) and a human anti-Sm serum, 1:100 diluted (lane 
E). RNA precipitation: Polyacrylamide gel analysis of RNA precipitated from a nuclear supernatant of HeLa 
cells prepared as described by Hinterberger et al. ( 1983) either directly extracted with phenol (lane total RNA) or 
immunoprecipitated with normal human serum (lane NS), anti-(U 1 )RNP specific serum (lane F), anti-RNP, U1 
plus U2 specific serum (lane G) and anti-Sm serum (lane H). Identity of snRNA was verified by precipitation 
with anti-2,2,7 trimethylguanosine specific antibody (Bringmann et al., 1983). 
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binding sites on the strips were blocked by incubation in buffer A (3% bovine serum albumin [BSA], 
350 т м NaCl, 10 т м Tris-HCl, pH 7· 6) for 1 h followed by a 2 h incubation in 1:100 diluted serum 
in buffer В (0-3% BSA, ISOmMNaCl, 10 т м Tris-HCl, pH 7-6, \% Triton X-100, 0-5% DOC and 
0 1 % SOS). After extensive washing (3 χ 10 min) in PBS containing 0-5%. (Triton X-100, the strips 
were incubated for 1 h in 1:1,000 diluted horseradish peroxidase labelled human IgG heavy and 
light chain specific second antibody (Nordic, Tilburg, The Netherlands) in PBS containing 0-5% 
Triton X-100 and 0-5% BSA (referred to as PTB buffer) and washed again. Immune complexes on 
the strips were visualized by incubation in substrate solution 1 (PBS containing 0-5 mg/ml 
4-chloro-l-naphtol and 0012% H2O2). 
Quantitative immunoblotting. Several (mostly 15) identical strips were cut from nitrocellulose 
blots prepared as described above. In all quantitative experiments two strips from every new sheet 
of nitrocellulose were always tested with the same reference serum sample as an internal standard. 
Specific antibody titres were determined by incubating the strips with appropriate dilutions of the 
test serum in buffer В for 2 h. Then the strips were washed three times for 10 min in PBS containing 
0-5% Triton X-100, followed by incubation with horseradish peroxidase labelled anti-human IgG 
diluted 1:1,000 in PTB buffer. The antigen-antibody complexes formed on the strip with the highest 
serum concentration were visualized by a 2 min incubation in substrate solution 1. The 
corresponding regions on the other strips were then cut out and incubated separately in 0·5 ml 
substrate solution 2 (50 т м PO4 buffer pH 60 containing 0-8 mg/ml 5-aminosalicylic acid and 
0024% H2O2) in a 24 well multidish (NUNC). After 30 min the extinction at 492 nm (E492) of this 
substrate solution was determined in a Titertek multiscan. From the results obtained with the 
reference anti-RNP serum a standard dose-response curve for each of the specific antibody 
populations was established (see Results section). Shapes of the dose-response curves of 10 patients 
sera tested, closely fitted with the standard curves. Therefore, binding values for other sera were 
read directly from these standard curves and expressed in arbitrary units (AU) that we define here as 
the product of the multiplication factor (MF) read from the standard curve and the corresponding 
dilution factor. The multiplication factors in the standard curves are chosen in such a way that the 
standard anti-RNP serum contains 100 AU/ml of all three of the antibody populations measured 
(see also Fig. 2). 
For the longitudinal studies all the serum samples from one patient were tested with identical 
blot strips originating from one transfer to ensure optimal reproducibility. As a consequence of this 
modification, standard deviations never exceeded 15% as was established by incubation of a 1:500 
diluted serum sample with 10 identical blot strips. 
RESULTS 
The specific autoantibody composition of 21 anti-Sm and/or anti-RNP sera, as such characterized 
by CIE, was established by qualitative immunoblotting and RNA precipitation analysis. 
Qualitative laboratory parameters 
With purified HeLa S3 nuclei as antigen source a remarkable diversity was observed between the 
various sera tested. Most anti-RNP sera (11 out of 13) recognized a 70,000 D antigen and six of 
these recognized in addition an antigenic polypeptide of 31 kD (70K and 31K, Fig. 1, lane A). Two 
sera recognized exclusively the 31K and 19K proteins called A and С in the Steitz nomenclature 
.(Lerner & Steitz, 1979, Fig. 1, lane B). Eight sera showed a (weak) reaction with a 25K antigen 
doublet identical with the B-B' protein doublet of the Steitz nomenclature (Fig. 1, lane D). The six 
anti-Sm sera tested, on the other hand, recognized this doublet as most prominent antigens (Fig. 1, 
lane E). As a reference also the blot pattern of a monoclonal anti-RNP serum is shown (Fig. 1, lane 
C, Billings et ai, 1982). 
The possibility that this multiple band pattern is caused by cross-reaction of one antibody type 
with more than one of these polypeptides can be ruled out, because antibodies eluted from one 
polypeptide band do not react with one of the other bands as was shown by Guldner, Lakomek & 
Bautz (1983) and confirmed by us (data not shown). Moreover, the monoclonal anti-70K antibody 
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exclusively recognizes the 70,000 D antigen Therefore it is clear that at least the 70K,A,B and С 
antigen bands represent distinct polypeptides and are not breakdown products of each other as 
occasionally has been suggested (White et al, 1982, Wooley, Zukerberg & Chung, 1983) 
A comparable heterogeneity as described above for the protein antigens was also observed when 
the results from RNA precipitation analysis of the 21 anti-Sm and anti-RNP sera were compared 
Within the anti-RNP group (n = 13) three reaction types were observed exclusively anti-U 1 (n = 6, 
Fig I J a n e F , anti-Ul plus U 2 ( n = l , Fig 1, lane G) and anti-U 1.2,4,5,6 (л = 6, Fig 1, lane H) 
Anti-Sm sera (n = 6) or anti-RNP plus anti-Sm sera (и = 2) all precipitated U1,2,4.5,6 (see also Table 
2) 
Sensitivity of immunoblotting 
.One major advantage of immunoblotting lies in its ability to detect insoluble antigens, as is 
illustrated by the recognition of the mol wt 70,000 nuclear matrix associated protein (Salden et al, 
1982, Habets et al, 1983b, Fntzler, Ali & Tan, 1984) Antigens from this nuclear substructure 
cannot be detected in double diffusion assays as has been shown previously (Habets et al, 1983a) 
The detection level of the immunoblotting assay was determined as follows Varying amounts of 
human IgG were spotted directly onto small nitrocellulose squares The total amount of protein was 
immediately bound as was verified by control experiments with l25I-labelled human IgG After 
incubation with goat anti-human IgG, bound IgG was quantitated as described in the Materials and 
Methods section using 5-amino salicylic acid as substrate When performed in this way, amounts of 
8 ng IgG could easily be detected 
Standard serum curves 
We have chosen for the quantitation of antibodies versus the 70K and 31K (Ul)RNP associated 
antigens and the 25K doublet, the most prominent target for the anti-Sm antibodies These 
antibodies are of IgG class, and no reaction could be detected when peroxidase linked anti-IgA, 
IgM or IgD was used instead of anti-IgG as the second antibody 
Three separate dose-response curves were produced for the antibodies versus the 70K, 31К and 
25K antigens by incubating eight identical nitrocellulose strips, prepared as described in the 
Materials and Methods section, with serial dilutions of a standard serum The amount of antibody 
bound to one distinct polypeptide band was then quantitated by an incubation with peroxidase 
2 0 -
I 0 
_L 
MF 
'dilulion 
2 
50 
ЮО 
0 5 
200 
0 2 5 
4 0 0 
0 125 
8 0 0 
0 0 6 3 0 031 
1,600 3,200 
Fig. 2. Standard dose-response curves of three different antibody populations (anti-70K = O, anti-31K = · , 
anti-25K = D) in an anti-RNP reference serum Seven identical protein blot strips were probed with senal 
dilutions of an anti-RNP reference serum, followed by excision of the regions at mol wl 70,000, 31,000 and 
28,000 D Bound IgG on these fragments were quantitated as described in the Materials and Methods section 
MF = multiplication factor See text for details 
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ι 
ι 
I 
I 
Patient 
Al 
D l 
G15 
КЗ 
K4 
Т2 
S2 
сз 
D4 
Н13 
S3 
W1 
W2 
В1б 
D2 
С12 
Н И 
МІЗ 
R U 
Diagnosis 
MCTD 
MCTD 
MCTD 
MCTD 
MCTD 
MCTD 
MCTD 
MCTD 
MCTD 
MCTD 
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MCTD 
SLE/MCTD 
MCTD 
SLE 
SLE 
SLE 
SLE 
CDC REF Sm§ 
A'DAM REF Sm§ 
Control 
N S ( n = 
SS-B (n 
Scl-70 (i 
sera 
10) 
= 10) 
1=10) 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
В 
В 
В 
В 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
в 
с 
с 
с 
с 
с 
с 
с 
с 
с 
с 
с 
с 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
E 
E 
E 
E 
E 
E 
E 
E 
F 
F 
F 
F 
F 
F 
F 
G 
G 
G 
G 
G 
G 
H 
H 
H 
H 
H 
Clinical features* 
I J 
I 
1 
J 
I J 
1 
J 
к 
к 
к 
L 
L 
L 
Μ N 
N 
M 
О 
О 
о 
о 
о 
о 
о 
Ρ 
1' 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Q 
Q 
Q 
Q 
Q 
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Q 
Q 
Q 
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R 
R 
R 
R 
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S 
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s 
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υ 
υ 
υ 
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RNP 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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+ 
+ 
+ 
NEG 
N E G 
NEG 
Sm 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
NEG 
NEG 
NEG 
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UI 
UI 
UI 
UI 
UI 
UI 
U 1 + U 2 
U1-U6Î 
U1-U6 
U1-U6 
U I - U 6 
U1-U6 
U I - U 6 
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U1-U6 
U1-U6 
U1-U6 
U1-U6 
U1-U6 
U1-U6 
U1-U6 
NEG 
NDH 
ND 
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Anti-70K 
48 
100 
8 
60 
16 
32 
95 
48 
60 
120 
97 
400 
28 
450 
300 
82 
14 
17 
14 
70 
30 
< 11 
< 19 
< 20 
Anti-31K 
200 
150 
50 
160 
36 
100 
84 
500 
230 
90 
110 
72 
100 
1,000 
500 
200 
120 
280 
104 
350 
300 
< 35 
< 40 
< 30 
Anti-25K 
36 
120 
10 
40 
24 
20 
48 
150 
50 
60 
240 
46 
40 
400 
300 
520 
600 
108 
100 
> 1,600 
600 
< 20 
< 20 
< 20 
* In code, see Table 1. 
t In arbitrary units. 
% UI-U6 denotes the precipitation of UI, U2, U4, U5 and U6 snRNPs. 
§ No clinical data available. 
Τ ND = not determined. 
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linked human IgG specific second antibody, followed by excision of the antigen band concerned, 
and incubation of this fragment in a substrate solution (see Materials and Methods). The 
colorimetrie change at 492 nm of this substrate solution after 30 min appeared to be a measure for 
the amount of anti-70K, 31K and 25K antibody in the diluted serum sample (Fig. 2). As a 
consequence standard curves can be used for the quantitation of these antibodies in various patients 
sera. 
Patients sera 
We quantitated the specific antibody content of 51 different sera (21 anti-RNP or anti-Sm, 10 
anti-SS-B, 10 anti-Scl-70 and 10 normal human sera). From triplicate analysis of every serum 
sample the average anti-70K, 31K and 25K. antibody content was calculated and expressed in AU. 
Significant differences in antibody content could be observed between the sera tested; for the 
antibodies against the 70K protein, none of the SS-B, Scl-70 or normal human sera showed binding 
values above 20 AU/ml, while from the anti-RNP group only two sera contained less than 20 
AU/ml of anti-70K antibody. These two sera decorated exclusively the 31К and the 19K band in the 
qualitative immunoblotting procedure (see Fig. 1, lane D). Normal binding values for the 31K 
protein are somewhat higher than for the 70K protein, but the group of anti-Sm and anti-RNP sera 
had much higher antibody titres against this antigen when compared to the anti-SS-B/anti-Scl-70/ 
normal control group. High anti-25K activity was mainly found in the anti-Sm group. 
Other laboratory parameters such as RNA precipitation analysis from the anti-Sm/RNP group 
are presented in Table 2 together with some clinical features. 
Longitudinal studies 
In a follow-up study we determined the titres of three distinct antibody populations in sera from 2 
MCTD patients collected during a period of 2 years. Therefore every serum sample was analysed in 
duplicate with identical protein blot strips at three different dilutions chosen in an appropriate 
range. Binding values were read directly from the standard curves (see Materials and Methods). The 
fluctuations of the separate antibody populations, expressed in arbitrary units, are shown in Figs 3 
&4. 
Patient КЗ, a 77 year old woman had since 1974 episodes of Raynauds phenomenon, diffuse 
swelling of the hands, polyarthralgia, leucocytopenia and thrombocytopenia. During follow-up 
most symptoms subsided, Raynauds phenomenon and arthralgia remained. All three antibody 
populations were present in low titres and showed a rather stable course during follow-up as is 
shown in Fig. 3. 
(a) 40 
20 
0 
3 0 0
 [(b) 
E 200 -
< 1 0 0 -
0 
(c) 
2 0 -
Ι9Θ2 
- o - C b - c / 3 " 0 ^ 
-O-Q
 0 _ 0 ^ 
\ 
^ о ^ о - о Л 
1983 1984 
Fig. 3. Longitudinal anti-70K (a), 31К (b) and 25K (с) antibody profiles of MCTD patient КЗ. AU = arbitrary 
units. 
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Fig. 4. Longitudinal anti-70K (a), 31К (b) and 25K (c) antibody profiles of MCTD patient D2 
Patient D2, a 32 year old woman developed in 1980 Raynauds phenomenon, polyarthritis, 
swollen hands and severe polymyositis treated with high doses of prednisone At the start of 
follow-up myositis symptoms subsided, mid-1982 she had a flare in disease activity with arthritis, 
pleuritis, fever, Raynauds phenomenon and cutaneous vasculitis Antibody populations were 
present in rather high titres and profiles showed a fluctuating course with two peaks during the 
period of follow-up (Fig 4), from which the first coincided with a flare in disease activity Treatment 
with low dose of prednisone had a stabilizing effect on her symptoms and all three antibody profiles 
showed a decline after start of medication While the patient was still under treatment with 
prednisone, the second peak in the antibody profile was not accompanied by a clinical flare 
Fluctuations in the antibody profiles were not reflected in total serum IgG patterns and could not be 
detected by CIE (data not shown) 
DISCUSSION 
The purpose of our investigation is to establish a possible correlation between the presence and titre 
of autoantibodies and clinical features of patients with rheumatic diseases We therefore developed 
a QIBA as described in this study From a group of 300 anti-nuclear antibody containing sera we 
selected 21 with antibodies to Sm, RNP or both, using CIE and immunodiffusion (ID) Almost all 
patients from which these sera were obtained were diagnosed by one of us (DJdeR) and their files 
were screened for the clinical features shown in Table 1 
It has recently become clear that the anti-Sm and anti-RNP reaction is directed against several 
distinct nuclear polypeptides, all complexed in vivo in RNA-protein particles (Hinterberger et al, 
1983, Kinlaw et al, 1983) When tested by qualitative immunoblotting, all anti-RNP sera 
recognized two to four different antigenic polypeptides with mol wt of 70, 31, 25 and 19 kD All 
anti-Sm sera (n = 6) contained antibodies against a 25kD doublet and five recognized also a 13K 
single polypeptide With the QIBA we were able to quantitate antibody populations against each of 
these antigenic polypeptides separately Other laboratory parameters were determined as well using 
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conventional techniques as CIE or ID (for a review see Tan, 1982) and the more recently described 
RNA precipitation technique (Lerner & Steitz, 1979, Fisher et al., 1983). 
Anti-RNP and anti-Sm specificity as established by CIE correlated with the diagnosis of MCTD 
and SLE, respectively. Among the 13 anti-RNP sera however, only six appeared to be exclusively 
anti-(U 1 )RNP, while one showed anti-U 1 plus U2 activity, a finding not reported earlier in MCTD. 
The remaining six anti-RNP sera also contained some anti-U2,4,5,6 activity which correlated in five 
cases with elevated ( > 40 AU/ml) anti-25K levels in QIBA. These samples were negative for anti-Sm 
antibodies in CIE and immunodiffusion, using RNAase digested cxtractable nuclear antigen from 
rabbit thymus. Presence of low titres of anti-Sm antibodies in MCTD has been reported earlier 
(Williamson et al., 1982) using haemagglutination (HA) techniques. In this respect one should 
realize that the association of anti-RNP and anti-Sm antibodies with MCTD and SLE, respectively, 
has been established using conventional techniques as CIE or ID, and that this concept might need 
some reconsideration now that more sophisticated and more sensitive techniques have become 
available. 
The antigen of 70,000 D (70K) seems to be a triplet of bands (see Fig. 1) reactive with patients 
sera as well as with the monoclonal anti-70K antibody. Whether this represents a genuine in vivo 
situation or is a result of in vitro modification of the antigen is subject of present investigations. 
Considerable variations in anti-70K activity (from 8 to 400 AU/ml) were observed within our 
population of 21 patients, but high levels were mainly found in MCTD patients (see Habets et al., 
1983b). High anti-25K activity ( > 100 AU/ml) was always found in sera exhibiting anti-Sm activity 
in CIE, while high anti-31К activity was found in SLE as well as in MCTD patients. Anti-(U 1 )RNP 
was found equally distributed in mild and severe cases of MCTD, this in contrast with the findings 
of Assens et al. (1982) who reported a correlation between presence of these antibodies and a mild 
course of disease. 
Fisher et al. (1983) have suggested that some antibodies in anti-Sm and anti-RNP sera could be 
directed against SDS sensitive epitopes. Since immunoblotting is based on SDS-PAGE, at least 
some of these sites are destroyed during preparation of the blot strips. As a consequence it might be 
possible that the lack of any apparent correlation between distinct clinical features and levels of 
antibodies measured in QIBA is caused by this phenomenon. 
To investigate whether such a correlation would exist within the same patient we followed two 
patients with MCTD in a longitudinal study. One of them, having a stable course of disease showed 
almost no significant fluctuations (see Fig. 3) with respect to the three antibody populations 
measured. Antibody profiles of the other, clinically unstable patient, showed two peaks from which 
one coincided with a flare in disease activity that was treated with low dose of prednisone. 
Thereafter, while still on medication, the second peak in the antibody profiles did not correlate with 
a recognizable change in clinical symptoms. Most interesting was the observation that profiles of the 
anti-70K, anti-31К as well as anti-25K antibodies appeared to be of an identical shape which could 
point towards a coupled mechanism of autoantibody production. 
The unique aspect of our study is the separate quantitative determination of anti-70K, 31К and 
25K antibodies in anti-RNP and anti-Sm sera and the possibility of measuring titres of these 
antibodies in longitudinal studies. Our results with a group of 21 patients with anti-Sm and/or 
anti-RNP antibodies show a great quantitative diversity in the subpopulations of these antibodies 
which together are responsible for the Sm or the RNP precipitation reaction. The three 
subpopulations of antibodies we investigated showed no apparent correlation with diagnosis or 
clinical parameters but peaks in longitudinal antibody profiles were found to correlate with a flare in 
disease activity in one patient. This finding might lend support to the concept that anti-Sm and 
anti-RNP antibodies play a pathophysiological role in systemic diseases. In this respect clinically 
useful data might be obtained by quantitating anti-Sm and anti-RNP antibody subpopulations. 
The quantitative immunoblotting described here is to our knowledge the only technique sufficiently 
sensitive for such an analysis. Performed on a large scale, QIBA therefore might be an aid in the 
management of systemic diseases. 
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quantitative determination of total serum IgG, A Groencveld for excellent technical assistance, Dr Ρ Faaber 
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work was supported in part by grants from the Netherlands League against Rheumatism, WJH was a recipient 
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The molecular composition and subcellular localization of the 
antigens recognized by antl-SS-B (La or Ha) antibodies was 
investigated. Ten anti-SS-B sera were selected by indirect 
immunofluorescence and by their immunological idendly in 
counter-immunoelectrophoresis (CIE) with an anti-SS-B 
reference serum. All sera precipitated virus-associated (VA) 
RNA from cellular extracts of adenovirus-infected HeLa 
cells. Earlier results had shown that in adenovirus-infected 
HeLa cells a cellular SO 000 mol. wt. protein was tightly 
associated with VA RNA in situ. Our present results indicate 
that this 50 000 protein is the only SS-B antigen present in 
adenovirus-infected as well as in uninfected cells. A major 
part (>80%) of the SS-B antigen Is present in a readily ex-
tractable, soluble form. The rest is found in an insoluble form 
tightly associated with an internal nuclear structure that is 
mostly referred to as the nuclear matrix. Both forms are very 
susceptible to proteolytic degradation resulting in at least two 
distinct breakdown products of mol. wts. 40 000 and 25 000. 
The cellular 50 000 polypeptide is present in extracts of 
various types of cells and tissues, indicating that this antigen 
is very well conserved during evolution. The association of 
the 50 000 mol. wt. antigen with host- as well as viral-coded 
RNA polymerase III products also suggests an important 
function for this protein in the metabolism of these small 
RNAs. 
Key words: adenovirus/autoimmune antibodies/immuno-
blotting/SS-B antigen/VA RNA 
Introduction 
Sera from patients with connective tissue diseases often 
contain antibodies against cellular components consisting of 
protein associated with small RNA molecules of - 8 0 - 2 0 0 
nucleotides in length (Lerner and Steitz, 1981). The RNA 
moiety of some of these ribonucleoprotein particles (RNPs) 
has already been elucidated. Anti-RNP sera [most commonly 
obtained from patients with mixed connective tissue disease 
(MCTD)] include antibodies directed against RNP panicles 
containing one discrete small nuclear RNA called Ul snRNA 
(Lerner and Steitz, 1979). Anti-Sm sera [mostly obtained 
from patients with systemic lupus erythematosus (SLE)] 
recognize particles containing various snRNAs namely Ul, 
m , U4, U5 and U6 (Lerner and Steitz, 1979). The U-snRNAs 
precipitated by anti-Sm and anti-RNP antibodies are thought 
to be RNA polymerase II products (Zieve, 1982). A third 
•To whom reprint requests should be sent. 
© IRL Press Limited, Oxford, England. • — ' i l 
adenovirus-infected 
class of RNP precipitating antibodies is referred to as anti-SS-
B (La or Ha) and is often found in sera from patients with 
Sjogren's syndrome (Akizuki et al., 1977). These antibodies 
precipitate a great variety of nuclear RNPs in mouse cells and 
uninfected HeLa cells (Lerner et al., 1981a). The RNA moiety 
of these RNPs can be separated on acrylamide gels yielding a 
highly banded pattern of RNAs ranging in size between 80 
and 120 nucleotides (Lerner and Steitz, 1981). These small 
RNAs are all RNA polymerase III products and some of 
them have been shown to be precursor molecules (Rinke and 
Steitz, 1982). From extracts of adenovirus-infected HeLa cells 
the anti-SS-B sera are able to precipitate a vims-associated 
RNA (VA RNA) of 158 nucleotides length (Lerner et al., 
1981a; Franceour and Mathews, 1982), while from Epstein-
Barr virus-infected primate cells the vims-encoded EBER I 
and II RNAs (180 nucleotides) are precipitated (Lerner et al., 
1981b). Both VA and EBER RNA are also RNA polymerase 
III transcripts (Söderlund et al., 1976). 
The protein moiety of the RNPs precipitated by the three 
categories of sera just described is less well documented. It 
has been established, however, that it is the protein moiety 
and not the RNA that carries the antigenic determinants 
(Lerner and Steitz, 1979). The antigens associated with the 
U-snRNAs have been described as a group of proteins with 
mol. wts. between 7000 and 70 000 (Lerner et al., 1981b; 
Takano et al., 1980; White et al., 1981). Recently some ap-
parently conflicting reports have been published on the nature 
of the SS-B protein antigens. Franceour and Mathews (1982) 
found a 45 000 mol. wt. protein to be antigenic while Matter 
et al. (1982) showed that anti-SS-B sera recognize polypep-
tides of mol. wts. 55 000 and 45 000. Venables et al. (1983) 
also found two antigenic SS-B proteins with mol. wts. of 
40 000 and 29 000, and Lieu et al. (1982) detected a major 
30 000 mol. wt. SS-B antigen, van Eekelen et al. (1982a) 
however, showed that VA RNA in the intact cell is tightly 
associated with only one protein with a mol. wt. of 50 000. 
This suggests that, at least in adenovirus-infected cells, this 
protein is the antigen recognized by anti-SS-B antibodies able 
to precipitate VA RNA. Here we show that the SS-B antigen 
both in adenovirus-infected and in uninfected HeLa cells is a 
cellular 50 000 mol. wt. protein that is very susceptible to 
proteolytic degradation. This instability might be the reason 
for the apparently conflicting results obtained so far. 
Results 
Specificity of the anti-SS-B sera 
To define patient sera as anti-SS-B, they had to fulfill each 
of the following four criteria. (I) Positive nuclear staining in 
indirect immunofluorescence on HeLa monolayer cells. (II) 
Anti-SS-B positive reaction in a counter-immunoelectro-
phoresis (CIE) assay, i.e., (a) RNase-insensitive, trypsin-
sensitive precipitation reaction with a rabbit thymus extract, 
mostly referred to as ENA (extractable nuclear antigen) as 
substrate (not shown), (b) Immunological identity with a 
reference anti-SS-B serum and no (partial) identity with RNP 
or Sm reference sera (not shown). (Ill) Precipitation of VA 
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Table I. Clinical and serological features of 10 patients with ami-SS-B 
antibodies 
Patient 
number 
1 
2 
3 
4 
J 
ft 
7 
8 
9 
1Ü 
Sex 
M 
F 
M 
F 
F 
1 
F 
F 
F 
F 
Age at 
testing 
33 
57 
36 
MS 
42 
GO 
82 
41 
31 
20 
Diagnosis' 
UCTD 
SS/arthralgia 
SLE 
SS/SLE 
SLE 
SS/RA 
RA 
UCTD 
SLE 
SS/RA 
Ami-DNA 
antibodies 
_ 
-
-
_ 
+ 
-
-
-
+ 
-
aUCTD, Undifferentiated connective tissue disease; RA, rheumatoid ar-
thritis; SS/SLE, Sjogren's syndrome with systemic lupus erythematosus; 
SS/RA, rheumatoid arthritis with sicca syndrome. 
I HeLa S3 CELLS | 
swelling in hypotonic buffer 
homogenization (Dounce) 
low speed centrifugation 
NHS S m 1 2 3 4 5 6 7 8 9 10 
ant i SS В sera 
Fig. 1. Characterization of anti-SS-B sera by RNA precipitation. For the 
precipitation with normal human serum (NHS) and anli-SS-B sera, an ex­
tract from adenovirus-infected HeLa cells was used as source of antigens. 
U-snRNAs were precipitated from an uninfected HeLa cell extract (see 
Materials and methods). The figure shows a fluorogram of immunoprecipi-
tated [3H]uridine-labeled RNAs using NHS, reference anti-Sm serum, and 
10 anti-SS-B .sera selected by immunofluorescence and CÍE as described in 
the text. 
RNA from adenovirus-infected HeLa cells (Figure 1). (IV) 
No U-snRNAs precipitated from uninfected HeLa cells (not 
shown). 
Ten sera, at first selected via criteria I and 11, were subse-
quently shown to fulfill the other criteria as well. These anti-
SS-B sera were obtained from patients mostly diagnosed as 
SLE, using the 1982 revised criteria for the classification of 
SLE, (Tan et al., 1982), or as secondary Sjogren's syndrome 
(Table I). For the diagnosis of Sjogren's syndrome the patient 
had to have at least two of the following clinical features of 
the sicca complex: xerophthalmia, xerostomia or salivary 
gland enlargement. 
Cellular localization of the SS-B antigen using the indirect 
immunofluorescence technique 
It is known that the SS-B antigen(s) are primarily localized 
in the nucleus when tested by indirect immunofluorescence on 
various types of cells (Tan, 1982). In HeLa cells, a speckled 
nuclear fluorescent pattern is observed with slight cytoplasmic 
staining depending on the particular serum tested. Since anti-
SS-B sera are able to precipitate VA RNA from a cytoplasmic 
extract of adenovirus-infected cells, we investigated whether 
SS-B specific antigens could be detected in the cytoplasm of 
HeLa cells late after infection with adenovirus. Indirect 
immunofluorescence studies were performed on HeLa S3 
monolayers 14 h after infection. Control experiments using 
anti-total adenovirus protein antibodies raised in rabbits, 
LOW SPEED PELLET LOW SPEED SUPERNATANT 
homogenization in 
DOC/Tween 40, low 
speed centrifugation 
high speed 
centrifugation 
pellet discarded 
[FREE CYTOPLASMIC FRACTION I 
LOW SPEED SUPERNATANT 
i wash high speed centrifugation 
w pellet discarded 
[INSOLUBLE NUCLEAR FRACTION] [NUCLEOPLASMIC FRACTION 
LOW SPEED PELLET 
DNase/RNase treatment 
centrifugation over 1 M sucrose 
0.4 M (NHJjSO, extraction 
[NUCLEAR MATRIX FRACT10N| 
Hg. 2. Isolation scheme of HeLa cell protein fractions. 
showed that 95-100% of the HeLa cells were infected. 
Nevertheless, the fluorescence of the SS-B antigen in these in-
fected cells is still predominantly nuclear as it is in uninfected 
cells (data not shown). With almost all anti-SS-B sera some 
discrete fine speckles in the cytoplasm of infected cells could 
be observed. These speckles were not specific for anti-SS-B 
sera since several normal human control sera showed exactly 
the same phenomenon. It is possible that this cytoplasmic 
staining is due to the fact that almost every (human) serum 
contains, to some extent, antibodies directed against adeno-
virus proteins, and the fine speckles, therefore, might repre-
sent an accumulation of these antigens at specific locations in 
the cytoplasm of infected HeLa cells. It should be emphasized 
that the nuclear fluorescence was typical for the anti-SS-B 
sera; none of the human control sera showed nuclear 
fluorescence neither in adenovirus-infected nor in uninfected 
HeLa cells. 
These indirect immunofluorescence experiments do not ex-
clude the possibility that the SS-B antigen is located in the 
-62—· 
Characlerizaiion of the SS-B 
. Detection of SS-B antigens in HeLa cell protein fractions and ENA 
jnter-Immunoelectrophoresis. The cell fractions were prepared as 
ed in Figure 2. IN; insoluble nuclear fraction; N; nucleoplasmic frac-
~; cytoplasmic fraction. 
plasm in vivo. After serum incubation of the alcohol/ 
зпе fixed slides the unbound immunoglobulins and other 
m proteins were removed from the preparation by several 
íes with barbitone buffer. Even after high speed cen-
gation (15 min, 8000 g) the collected washing buffer con-
id SS-B antigens in very easily detectable amounts, when 
d by immunoblotting. This suggests that at least part of 
!S-B antigen may not be detected by the indirect immuno-
rescence technique since it can be washed out of the fixed 
olayer cells. 
•clion of SS-B antigens in HeLa cell f radions by CIE and 
unoblotting 
зг the localization of antigens a cell fractionation pro-
re was used that resulted in a free cytoplasmic, a nucleo-
Tiic and an insoluble nuclear fraction (Figure 2). The free 
plasmic fraction probably also contains some readily 
ble components of the nucleoplasm, due to the Dounce 
ogenization procedure in hypotonic buffer. The nucleo-
•nic fraction certainly contains cytoskeleton components 
bilized during the detergent treatment. Finally, the insolu-
nuclear fraction contains chromatin and nuclear RNA 
ein complexes associated with the internal nuclear ultra-
;ture generally referred to as nuclear matrix. 
lese three cellular fractions were tested by CIE with all 
SS-B sera. As is shown in Figure 3, the free cytoplasmic 
nucleoplasmic fractions apparently contain (an) identical 
5en(s). They also show identical precipitation lines with 
;ens extracted from rabbit thymus powder (ENA). No 
ipitation lines could be observed with the insoluble 
ear fraction, indicating that this fraction does not contain 
cient amounts of soluble antigens any more. No different 
ificities could be detected between sera with and without 
DNA antibodies. All sera gave a CIE precipitation pat-
identical to the one shown in Figure 3 (serum no. 1). 
sr the detection of both soluble and insoluble antigens the 
unoblotting technique is very well suited. After 
bilization of the antigen-containing fractions in 2% SDS-
aining sample buffer, antigens can be separated accor­
to their mol. wt. by Polyacrylamide gel electrophoresis 
GE), blotted onto nitrocellulose, and used as a substrate 
he immunoreaction (see Materials and methods). For the 
lunoblotting experiments a nuclear matrix preparation 
also used as a source of antigen(s). This fraction was 
Mr -
xlO J * 
l o s ­
es— 
50 
40 
2 5 I 
1 2 3 4 5 1 2 3 
ß 
Fig. 4, Detection of SS-B antigens by immunoblotting. (A) ENA ant 
uninfected HeLa cell protein fractions were isolated as described in 
Materials and methods and separated into their individual polypeptic 
stituents by SDS-PAGE. Subsequently the gel was blotted electro-
phoretically onto nitrocellulose and probed with anti-SS-B serum no 
Immunoreactive species were detected using lz5l-labeled protein Α. Ρ 
fractions used were; lane 1. ENA; lane 2. free cytoplasmic fraction; 
nucleoplasmic fraction; lane 4, insoluble nuclear fraction; lane 5, nut 
matrix fraction. (B) Detection of antigens in adenovirus-infected Hel 
protein fractions. Lane 1, free cytoplasmic fraction; lane 2, nucleopl 
fraction; lane 3. insoluble nuclear fraction; lane 4, nuclear matrix fn 
prepared from the insoluble nuclear fraction by subse 
DNase/RNase treatment and sucrose - high salt extri 
as described in Materials and methods. After separati 
PAGE, the four cellular fractions and ENA all shoi 
specific polypeptide pattern. After immunoblotting, 
these fractions the same 50 000 mol. wt. antigen 
recognized by SS-B serum no. 1 (Figure 4A). In the 
plasmic fraction this 50 000 polypeptide seems to be thi 
antigen, in contrast to the other fractions and ENA, 
appeared also to contain an antigenic polypeptide of mc 
40 000. This antigen will be shown to be an in 
breakdown product of the 50 000 protein (see below). 
Since all sera precipitate a viral-coded (VA) RNA frc 
tracts of adenovirus-infected cells, we investigated wl 
SS-B specific proteins of viral origin exist. The fractioi 
and immunoblotting experiments were repeated with 
cells 4 and 16 h after infection with adenovirus serot; 
The polypeptide pattern and immunoblotting results obi 
with the 4 h infected cells were identical with those obi 
with the uninfected cells (not shown). In the late in 
cells, however, some additional reactive polypeptides 
be observed (Figure 4B). These major viral antigens ha 
proximate mol. wts. of 80 000 and 105 000 and the 
could be identical to the viral hexon and penton capsit 
teins. The antibodies against these viral antigens were ob 
ly not characteristic for anti-SS-B sera since these an 
were also recognized by antibodies present in normal h 
control sera (from 20 normal sera tested, 18 containec 
bodies against the 80 000 protein and three sera showec 
anti-105 000 activity). We therefore conclude that a 
adenovirus-infected cells a host-coded 50 000 mol. wt 
tein is the major antigen recognized by anti-SS-B antib 
-63—-
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Table П. Distribution of VA RNA, protein and SS-B antigen in various cell 
fractions 
Proteina 
VARNAb 
SS-B antigen' 
Uninfected cells 
c
d 
40 
-
20 
Ν 
36 
-
M 
IN 
24 
-
16 
Adenovirus-infected cells 
С 
47 
-Ό 
IO 
N 
31 
14 
84 
IN 
22 
16 
6 
• Π — , 
Ч^еііз were labeled with [35S]methionme as described (van Eekelen and van 
Venrooij, 1981). Total 35S radioactivity in TCA-precipitable material in 
each cell fraction was used for the calculation of protein distribution. 
bAdenovirus 2-infected cells were labeled with [3H]undine (2 μΟ/ηιΙ) from 
14- 16 h after infection. Cell fractions were prepared as described in the 
methods section. Total RNA (van Eekelen and van Venrooij, 1981) was 
jcparafed on 10% Polyacrylamide slab gels in 8 M urea/40 mM Tris-
-^etate pH 7.8, 0.1% SDS, 2 mM EDTA. The VA RNA in the gel, 
,ualized by fluorography, was solubilized in 0.5 ml Soluene (Packard) for 
2ч h at 55CC and measured in a liquid scintillation counter. 
cThe SS-B antigen was quantitated as described in Materials and methods. 
С = free cytoplasmic fraction, N = nucleoplasmic fraction; IN = in­
soluble nuclear fraction 
M 
105 
Fig. 5. In vitro degradation of the SS В antigen from rabbit thymus- Rab­
bit thymus acetone powder (Pel Freez) was extracted at 4°C with PBS con­
taining 0.5 mM PMSC to inhibit proteolytic activities. Aliquots were 
removed at different time intervals and centrifuged for 5 min at 10 000 % at 
40C. Both pellet and supernatant were analysed after SDS gel electro­
phoresis by immunoblotting Lane I, total rabbit acetone thymus powder; 
lane 2, pellet after JO mm extraction; lane J. supernatatit after 10 min ex­
traction, lane 4, supernatant after 4 h extraction (ENA); lane 5, ENA after 
2 month storage at - 20oC; lane 6, ENA after incubation at 37°C over­
night. 
Most of the SS-B antigen is present in the nucleoplasmic frac­
tion 
To obtain more quantitative information about the 
distribution of the SS-B antigen in the various cell fractions, a 
semi-quantitative immunoblotting analysis (see Materials and 
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Fig. 6. Analysis by immunoblotting of anti SS В sera and reference sera (A) The protein blot from one gel loaded over the entire width with a 
nuclear protein fraction of uninfected Hela cells, was cut into strips and 
probed with vanous anti-SS-B sera (lane* I - 10) and relerence anti-SS-B, 
anti RNP and anti-Sm sera. NHS: normal human serum (B) as A, but 
now a nucleoplasmic extract from adenovirus inlected cells was used as 
source ol antigens. 
methods) was carried out. The results, obtained with various 
batches of cells, clearly show that the majority of the SS-B 
antigen in uninfected as well as in infected cells was present in 
the nucleoplasmic fraction (Table II). These results indicate 
that the bulk of the SS-B antigen is released from the nucleus 
by the DOC-Tween 40 treatment (see Materials and 
methods). Using adenovirus-infected cells we also quantitated 
the relative amounts of VA RNA in each cell fraction. About 
70% of the VA RNA was found in the free cytoplasmic frac­
tion which contains only 8-12% of the total cellular content 
of SS-B antigen. Immunoprecipitation studies have shown 
that VA RNA is almost quantitatively associated with the SS-
B antigen (Lerner et al., 1981a; our unpublished observa­
tions). In other words, - 8 - 1 2 % of the SS-B antigen in the 
free cytoplasmic fraction is probably sufficient to complex 
70% of the VA RNA (Table II). Since about eight times as 
much SS-B antigen is present in the nucleoplasmic fraction, 
this strongly suggests that at least part of the SS-B antigen is 
present in the nucleus in an uncomplexed, i.e., a not RNA-
associated form. 
In vitro breakdown of the SS-B antigens 
Because all sera recognized always both the 50 000 and 
40 000 polypeptides with about the same relative efficiency, 
the possibility that they were related to each other was in­
vestigated. When commercially available acetone extracted 
rabbit thymus powder was sonicated, solubilized in 2% SDS-
Characterization of the SS-B anUgn 
containing sample buffer and tested by immunoblotting, only 
the 50 000 antigen was detectable (Figuie 5, lane 1). ENA, 
prepared by extraction of this thymus powder with phosphate 
buffered saline (PBS), contained additional 40 000 and 
25 000 antigens (Figure 5, lane 4) although extraction was 
performed under sterile and RNase-free conditions with 
0 5 mM phenylmethylsulphonyl chloride (PMSC) as an in­
hibitor of proteolysis added to the extraction buffer In fact, 
this breakdown occurs very rapidly, since a 10 mm extraction 
already induces the presence of the 40 000 antigen (Figure 5, 
lane 3). The pellet remaining after 10 mm extraction was 
washed twice with PBS but nevertheless still contained the 
40 000 as well as the 50 000 antigen (Figure 5, lane 2). The 
breakdown of the SS-B antigen into a 25 000 polypeptide oc­
curs at a somewhat slower rate, but is completed after incuba­
tion of the ENA overnight at Ъ1°С (Figure 5, lanes 5 and 6). 
It should be pointed out that the 40 000 and 25 000 poly­
peptides are discrete breakdown products carrying the SS-B 
specific determinant(s). Some other breakdown products 
might also exist which do not carry an antigenic determinant 
and are therefore not recognized in immunoblotting ex-
реп men ts 
All anti-SS-B sera recognize the same protein antigen 
From earlier work we know that a particular type of 
human auto-antibodies (for example anti-RNP or anti-Sm), 
although precipitating a specific set of small RNAs, may 
recognize a greatly varying set of proteins (Habets et al, 
1983) We therefore investigated whether such a diversity also 
existed among the anti-SS-B sera As is shown in Figure 6A, 
all anti-SS-B sera, including the SS-B reference serum, only 
recognized the 50 000 mol wt antigen and its breakdown 
products in an insoluble nuclear fraction from uninfected 
HeLa cells 
This same cellular 50 000 antigen was also recognized by all 
these sera in adenovirus-infected cells (Figure 6B) Such a 
specific recognition of only one antigen by a class of human 
auto-immune sera is in contrast with the findings reported for 
anti-RNP and anti-Sm sera. With such sera, mostly several 
antigens are detected by the immunoblotting method (Habets 
et al, 1983) The immunoblot patterns of these anti-RNP and 
anti-Sm sera also depend on the cellular substrate offered 
(Figure 6A,B) Furthermore, there is also a great variation in 
antigen patterns within one class (Habets et al, 1983), a 
phenomenon that is also not observed with anti-SS-B sera As 
discussed above for serum no. 1 (Figure 4), the other SS-B 
sera also have rather high levels of antibodies against 
adenovirus-coded proteins Sera 2 and 4 show a strong reac­
tion against the 105 000 mol. wt protein, and eight out of 10 
anti-SS-B sera recognize the 80 000 mol wt adenoprotein. 
As expected, all sera (10 anti-SS-B, the three reference 
sera and 20 tested normal human control sera) reacted 
positively in an enzyme-linked immunosorbent assay that 
measured the anti-adenovirus protein antibody titer (A van 
Loon, personal communication) 
The RNA binding 50 000 mol. wt. SS-B antigen ts evolu-
tionanly highly conserved 
Various types of RNA molecules can be precipitated by 
anti-SS-B sera when extracts from either uninfected mouse 
cells or human cells are used as a substrate. For this reason it 
was concluded that the SS-B RNPs were evolutionanly not as 
highly conserved as, for example, the U-snRNPs (Lerner et 
al, 1981a). Our results show that in rabbit thymus extracts 
and human HeLa cells only one protein antigen is recognized 
by anti-SS-B sera {Figure 4). This 50 000 mol wt protein is 
also the only antigen recognized by anti-SS-B sera in other 
types of cells and tissues like rat liver, hamster lens, human 
lymphoblasts in culture (Rosenfeld et al., 1977) and cultured 
hepatoma cells (Alexander et al, 1976) (data not shown) 
Since in all these types of cells the breakdown produas of the 
50 000 antigen are also identical, it seems that the protein part 
of the SS-B antigen is very highly conserved. 
Discussion 
We have shown that the SS-B antigen is a cellular protein 
with a mol wt. of 50 000. This prolein is the only SS-B 
specific antigen in uninfected as well as in adenovirus-infected 
cells Several RNA species, in particular precursors of RNA 
polymerase III transcripts, can be precipitated by anti-SS-B 
sera by virtue of their association with the SS-B specific an­
tigen. For this reason, we assume that the 50 000 mol. wt an­
tigen is associated with all these RNA species. This assump­
tion is supported by the fact that VA RNA specifically 
recognizes a 50 000 mol wt protein in a cytoplasmic extra« 
immobilized on nitrocellulose sheets (van Hekelen et al., 
1982a) Furthermore, VA RNA has been shown to be 
associated with a 50 000 mol wt protein in the intact cell 
after RNA-protein cross-linking in vivo by u.v irradiation of 
adenovirus-infected HeLa cells (van Eekelen et al, 1982a) 
AU these results strongly point to the fact that SS-B specific 
RNAs (including EBER and the RNA polymerase III precur­
sors), at least for some time during their life cycle are 
associated m vivo with the 50 000 protein 
The 50 000 SS-B antigen is very susceptible to proteolytic 
degradation Even after 10 mm extraction of rabbit thymus 
powder, a 40 000 degradation product, derived from the 
50 000 antigen, can be detected in the ENA extract as well as 
in the residual pellet (Figure 5). After a 4 h extraction, both 
the 40 000 and a 25 000 degradation product are detectable. 
These degradation products are not found in cytoplasmic ex­
tracts of HeLa cells except when detergents are used. We 
assume that the detergent treatment releases proteolytic ac­
tivities by permeabilmng or dissolving cytoplasmic structures 
like lysosomes. In rabbit thymus powder, the source of ENA, 
such structures are already severely damaged and 
permeabilized by the acetone extraction and proteolytic ac­
tivities might therefore have been released. The rapid rate of 
degradation of the SS-B antigen explains why it has been 
described as a protein with mol wt varying from 29 000 to 
45 000 (Franceour and Mathews, 1982, Matter et ai, 1982; 
Venables et al, 1983; Lieu et al, 1982) 
The quantitation of the SS-B antigen in the various cell 
fractions showed that most of the SS-B antigen is present in 
the nucleoplasmic fraction Because immunofluorescence ex­
periments clearly indicate that the SS-B antigen is located in 
the nucleus, we conclude that the majority of the SS-B an­
tigen is readily extracted from the nucleus by simple detergent 
treatment Nevertheless, since the detergent-extracted nuclei, 
even after repeated washing, still contain -6-16% of the 
total cellular amount of SS-B antigen (Table II) we must also 
conclude that part of the SS-B antigen is present in the 
nucleus in a rather insoluble form. Removal of the chromatin 
and most of the nuclear RNA by nuclease treatment and high 
salt extraction does not remove these residual SS-B antigens. 
It is therefore probable that this portion of the SS-B antigen is 
W J Habéis et al 
associated with the nuclear matrix (compare Figure 4), a 
nuclear ultrastructure that is involved in the processing of 
\anous RNA transcripts like pre-5S RNA and pre-mRNA se-
quences (Cicjek et al, 1982, Manman et al, 1982; Ross et al, 
1982). The free cytoplasmic fraction of uninfected as well as 
infected cells also contains 10-20*70 of the SS-B antigen. It 
might be possible that these antigens are extracted from the 
nucleus during homogenization of the cell suspension in 
hypotonic medium. However, since the SS-B antigen in 
adenovirus-infected cells is associated m vivo with VA RNA 
(Lerner et al
 t 1981a, van Eekelen et al., 1982a) and VA RNA 
has a cytoplasmic localization (Table II) and most probably a 
cytoplasmic function as well (Thimmappaya et al, 1982), one 
would expect some of the SS-B antigen to be present in the 
cytoplasm of infected cells Indirect immunofluorescence ex-
periments that point to an exclusive nuclear localization do 
not contradict such a statement because we have observed 
that soluble SS-B antigens are easily extracted from the 
acetone-fixed cells during the subsequent washing with buffer 
solutions. It is therefore possible that cytoplasm-localized SS-
B antigens not associated with structural cell components are 
noi detected by the indirect immunofluorescence assay 
because of their extreme solubility 
Another point of interest is the fact that the amount of SS-
B antigen in the cytoplasmic fraction of adenovirus-infected 
cells (8-12% of the total cellular amount) is sufficient to 
complex - 70% of the cellular VA RNA (Lerner et al, 
1981a, our unpublished observations) The nucleoplasmic 
fraction, however, contains about eight times as much SS-B 
antigen and only a small part of the VA RNA. These data 
suggest strongly that part of the SS-B antigen in the nucleus 
of adenovirus-infected cells is present in an uncomplexed, not 
RNA associated form. 
Materials and methods 
Sera 
Sera from paüents [mostly with SLE or Sjogren's syndrome associated with 
rheumatoid arthritis (RA) or SLE] were obtained from the St Radboud 
Hospildl in Nijmegen They were first screened for anti-nuclear antibodies 
(ANA) b> the indirect immunofluorescence test on HeLa cell monolayers 
essentially as described (van Eekelen el al, 1982b) 
All ANA-containing sera were then screened for anti SS-B antibodies by 
CIE using a saline extract (ENA) of rabbit thymus pov-der (Pel Freez, Rogers, 
AK) as antigen source (Kurala and Tan, 1976) The sera which showed an 
RNase insensitive, trypsin-sensitive precipttauon reaction, were tested for 
identity with anti SS-B, anti Sm and anti RNP reference sera Using these 
criteria, we selected - 10 anti-SS-B sera with which this study was performed 
All these sera were anti Sm and and RNP negative Only two contained anti-
DNA antibodies as tested by the Cnthidia assay (Aarden et al, 1975) 
Reference sera were obtained from the Centers for Disease Control, Atlan-
ta, GA 
Cultunng and infection of cells 
HeLa S3 cells were grown in suspension and monolayer cultures as describ-
ed (van Eekelen and van Venrooij, 1981) They were shown not to contain 
Epstein-Barr virus and regularly performed mycoplasma tests were always 
negative 
HeLa S3 cells were in fea ed with purified adenovirus serotype 2 as describ-
ed (van Eekelen er σ/, 1981) The percentage of infected cells, 14 h after infec 
tion (mostly 95-100^0), was determined by indirect immunofluorescence 
with an anu-total adenovirus-protein serum [kindly provided by F Asselbergs 
(Assclbergs et al, Ι983)| 
RNA immunoprecipitaiion 
HeLa S3 suspension culture cells were labeled with 2 /tCi/ml [3H]und]ne at 
a density of 0 5 χ IO6 cells/ml for 24 h Nuclear supemalanls were prepared 
by the following procedure earned out at 0-4 o C Cells were harvested at 
800 g for 5 mm on frozen NKM [130 mM NaCl. 5 mM KCl, 1 5 mM 
Mg(Ac)2], washed once with NKM, pelleted and resuspended in reticulocyte 
suspension buffer (RSB, 10 m4Tns(pH 7 4) lSmMMgCI2 10 mM NaCl 
0 5 mM РМЬС) Cells were then broken by 15 stroke1^ in a Dounte 
homogenizer and the crude nudei were pelleted at 800 g (5 mm) The crude 
nuclei were resuspended in RSB and som La ted 2 χ 15 s uith а Вгапьоп 
sonifier at selling 2 After centnfugation (5400 f> 5 mm) this nuclear super 
natant was used as source of antigens for the immunoprecipuation of 
U snRNPs 
Extraction of antigens from adenovirus infected cells was performed slight 
ly differently because most of the VARNA is present in ihc cytoplasm Label 
ing from 14-16 h afta infection and harvesting procedures of cells were 
identical but then the cell pellet was resuspended in RSB A mixture of sodium 
deoxycholatc (DOC) and Tween 40 was added (final concentrations 0 5*0 and 
14Ό, respectively), cells were broken by brief shaking on a vortex shaker and 
pelleted at 2000g for 5 mm The supernatant was used for the immiino 
precipitation of VA RNA 
In a typical RNA precipitation experiment, 15 μΐ of IgG selected by protein 
A Sepharose affinity chromatography was incubated at 0oC for 20 nun with 
the nuclear or cellular extract from 50 χ IO6 cells Then 200 μΐ lO o^ protein 
A-Scpharose m PBS (3 mM NaHîPO«, 7 mM Na2HP04 0 Wo NaCl, pH 
7 6) was added and the mixture was left on ice for 20 mm Immune complexes 
were isolated by centnfugation, and washed 5 times with PBS The 
precipitated RNAs were extracted with phenol and analysed on 10% poly 
acrylamide slab gels in 8 M urea/40 mM Tns acetate pH 7 8/0 1% 
SDS/2 mM EDTA After electrophoresis overnight, gels were prepared for 
fluorography 
Preparation of HeLa cell fractions 
The fractionation procedure (Figure 2) was carried out at 0-4oC unless 
otherwise stated A hypotonic swelling method was used to prepare cyto-
plasmic extracts Cells were harvested on frozen NKM, washed with NKM, 
resuspended in hypotonic buffer (RSB) and left on ice for 5 mm The cells 
were then disrupted in an all glass Dounce homogenizer (Type B, seven 
strokes) followed by low speed (1000 g 5 min) centnfugation to pellet the 
nuclei The supernatant was clarified by high speed centnfugation (8000 g, 
15 mm) and is referred to hereafter as free cytoplasmic extract The crude 
nuclei were resuspended in RSB and a DOC/Tween 40 mixture (final concen 
trations 0 ЪЩ and 14Ό, respectively) was added followed by homogenizalion 
with 10 strokes of a motor-driven Teflon pestle in a Potter Elvehjem tissue 
homogenizer The homogenate was centnfuged at low speed, the supernatant 
was then clanficd by high speed centnfugation (8000 g, 15 mm) and is refer­
red to hereafter as nucleoplasmic fraction The low speed pellet was washed 
twice with RSB, resuspended in RSB and is further referred to as insoluble 
nuclear fraction 
In some experiments this insoluble nuclear fraction was sub fractionated in 
to a chromatin fraction and a nuclear matrix fraction (Figure 2) For this pur 
pose the insoluble nuclear fraction was resuspended in HRSB [110 mM NaCl, 
10 mM Tris (pH 7 4), 1 5 mM MgCl, and 0 5 mM PMSC] at a density of 10· 
nuclei/ml and treated with DNase I and RNase A (500 /ig/ml and 100 pg/ml, 
respectively) for 1 h at 20oC Fragmented chromatin and RNP complexes 
were removed by sedimentation through a 1 M sucrose layer in HRSB 
(2000 g, 10 mm) followed by an extraction with 0 4 M ( N H ^ O , The pellet 
was washed and resuspended in RSB and is referred to hereafter as nuclear 
matrix fraction Morphological and biochemical characteristics of nuclear 
mamces isolated m this way have been described (van Eekelen et af, 1982b) 
Gel electrophoresis and protein blotting 
Samples for PAGE in SDS were prepared by dissolving the protein fraction 
in sample buffer (2% SDS, 10% glycerol, 5% β mercaptoethanol, 0 I M 
Tns HCl pH 6 8) To ensure complete dissociation of the protein complexes, 
the samples were heated for 3 mm at 100оС followed by gel electrophoresis in 
SDS on 10% Polyacrylamide slab gels (1 mm thick, 10 χ 16 cm) In most ex-
penments proteins were loaded over the entire width of the gel (1 5 mg protein 
per gel) and separated according to their mol wt essentially as described 
(Laemmli. 1970) After a 4 h шп at 20 mA per gel, replicas of the gels were 
made on nitrocellulose (i e , blotting) by transfemng the proteins electro-
phoretically using a Bio-Rad trans blot cell Transfer was performed over­
night at room temperature and at 60 V/0 3 A in 192 mM glycine, 25 mM Tns 
pH 8 3 and 20% methanol After transfer the blots were dned and stored al 
room temperature 
Detection of antigens 
The protein blots were cut from top to bottom into stnps of -7 mm and 
treated with pre-mcubatton buffer (3% bovine serum albumin (BSA), 
350 mM NaCl, 10 mM Tns HCl pH 7 6, 0 5 mM PMSC] for 3 h at 20oC to 
saturate additional protein binding sites on the nitrocellulose Incubation with 
diluted serum (mostly 1 50) was performed overnight in buffer 1 (0 3% BSA, 
150 mM NaCl. 10 mM Tris HCl pH 7 6, 0 1 mM PMSC, 1% Triton X-100, 
0 5% DOC and 0 1% SDS) After extensive washing with buffer 1 (Э χ 
Ckaracleriadon of the SS-B «ntlgen 
10 mm) IgCi immune complexes were delected b\ incubating the blots Гот 2 h 
with , HI labeled protein A (sp act I mCi/mg) in ivffer I (2 μΟ in 10 ml) 
then washed again with buffer I (3 χ 10 min) and water (3 χ IO min), dned 
under a lamp and exposed to X ray film for 2 —16 h at - 70oC using Ilford 
intensifying screens 
In some blotting experiments, 13sl labeled anti human IgG was used instead 
of protein Λ The results were the same (not shown) 
Quannration of the SS-tí anngen 
For the quantitation of the SS-B antigen in the vanous cell fractions, serial 
dilutions of the antigen containing fractions were subjected to PAGE and 
subsequently blotted onto nitrocellulose For these expenments we used the 
horizontal protein blotting procedure as described by Vaessen et al (1981), 
that resulted in a >90(?o efficient transfer of the proteins (This percentage 
was calculated from transfers earned out with [35S]methionine-labeled cell 
fractions) Protein blots containing serial dilutions of the vanous cell fractions 
were incubated with excess anti SS-B serum for 2 h and then washed with 
PBS containing 0 5% Tnton X100 Immune complexes were detected either 
with horseradish peroxidase labeled ami human IgG (Nordic, Tilburg, The 
Netherlands) or with l a l labeled protein A as desenbed (Habets el al, 1983) 
Results were read in several ways In the case of the peroxidase-labeled second 
antibody the highest dilution that gave a signal above background was deter-
mined visually In the case of the lnl-labeled protein A the autoradiograms 
were scanned and quantitated as described (van Eekelen et al, 1982c) Both 
ways of reading gave identical results 
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CHAPTER 5 
AUTOANTIBODIES TO RIBONUCLEOPROTEIN 
PARTICLES CONTAINING U2 SMALL NUCLEAR RNA 
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Autoantibodies to ribonucleoprotein particles containing 
U2 small nuclear RNA 
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fiir Molekulare Genetik. Dinestrasse 6 3 - 7 3 , D-1000 Berlin 33. FRG 
Communicated by H Bloemendal 
Autoantibodies exclusively precipitating Ul and 12 small 
nuclear ribonucleoprotein (snRNP) particles [anti-
(U1,U2)RNP] were detected in sera from four patients with 
autoimmune disorders. When tested by immunoblotting, these 
sera recognized up to four different protein antigens in 
purified mixtures of Ul - U 6 RNP particles. With purified 
antibody fractions eluted from individual antigen bands on 
nitrocellulose blots, each anti-(Ul,U2)RNP serum precipitated 
U2 RNP by virtue of the recognition of a U2 RJ4P-specific 
B" antigen (mol. wt. 28 500). Antibodies to the 12 RNP-
specific A' protein (mol. wt. 31 000) were found in only one 
serum. The B" antigen differs slightly in mol. wt. from the 
Ul - U 6 RNA-associated B/B' antigens and can be separated 
from this doublet by two-dimensional gel electrophoresis, due 
to its more acidic pi. In immunoprecipitation assays, the 
purified anti-B" antibody specificity also reacts with Ul RNPs 
which is due to cross-reactivity of the antibody with the Ul 
RNA-speciflc A protein, as demonstrated by immunoblotting 
using proteins from isolated Ul RNPs as antigenic material. 
Thus the A antigen not only bears unique antigenic sites for 
anti-Α antibodies contained in anti-(Ul)RNP sera, it also 
shares epitopes with the U2 RNP-specific B" antigen. 
Key words: autoantibodies/snRNP/antibody-elution/immunoblot-
ting/ U2 snRNA 
Introduction 
Sera from patients with connective tissue diseases often contain 
antibodies against nuclear RNA-protein complexes (Tan, 1982; 
Lemer and Steitz, 1981). The RNA moiety of some of these anti­
genic complexes has been identified as U snRNAs, a discrete 
class of stable and highly conserved small nuclear RNAs (for 
reviews, see Steitz et ai, 1983; Reddy and Busch, 1983). Ul 
RNPs have been shown to function in the splicing of pre­
messenger RNAs in in vitro systems (Yang et ai, 1981 ; Padgett 
et ai, 1983; Krämer et ai, 1984). A similar function has been 
postulated for U2 RNA (Ohshima et ai, 1981), but experimen-
tal evidence is still lacking. U4 RNA has been proposed to be 
involved in the 3' processing of pre-mRNA (Berget, 1984). All 
of the snRNAs are commonly found to be associated with hnRNP 
particles (Sekeris and Niessing, 1975; Gallinaro and Jacob, 1979). 
Some of the snRNAs (Ul, U2 and U4) could even be cross-linked 
to hnRNA by a psoralen derivative (Calvet and Pederson, 1981 ; 
Calvet et ai, 1982). All of these considerations suggest that the 
nucleoplasmic U-snRNAs play closely related fiinctions in mRNA 
processing or transport. 
Anti-Sm antibodies react with the complete set of Ul, U2, U4, 
U5 and U6 (Ul -U6) RNP particles whereas anti-(Ul)RNP sera 
specifically precipitate particles containing Ul RNA, the most 
abundant species of snRNAs (Lemer and Steitz, 1979). Anti-
(U2)RNP activity has recently been found in a patient with a 
scleroderma-polymyositis overlap syndrome (Mimori et ai, 
1984). In contrast, with anti-Sm and anti-(Ul)RNP antibodies 
which are rather common in sera from patients with SLE and 
MCTD, respectively, exclusive anti-(U2)RNP specificity is very 
rarely found (Pettersson et ai, 1984; Mimori et ai, 1984). 
At least 10 polypeptides are associated with snRNAs from 
which Ul RNP particles contain at least nine, with mol. wts. 
of 70 000 (70 K), 33 000 (A), 29 000 (B'), 28 000 (B), 22 000 
(C), 16 000 (D) and a triplet around mol. wt. 12 000 (E, F and 
G, Lemer and Steitz, 1979; Brunei et al. ,1984; Billings and 
Hoch, 1984; Pettersson et ai, 1984). Polypeptides 70 К, A and 
С have recently been reported to be present only in Ul RNPs 
(Pettersson et ai ,1984; Billings and Hoch, 1984) whereas Β/Β', 
D, E, F and G are associated with Ul - U 6 RNAs. Immuno-
punfied U2 RNPs contain at least one additional polypeptide call-
- Σ 1 2 3 4 5 6 7 8 
5 8 S -
5 S -
- U 2 
Ul 
- U 4 
- U 5 
- U 6 
tRNA 
Fig. 1. Polyacrylamide gel fractionation of 32P-labeled immunoprecipitated 
RNAs Precipitates were obtained from a total HeLa cell extract (lane Σ) 
using normal human serum (lane I). anti-(Ul)RNP serum (lane 2), anti-Sm 
serum (lane 3). anti-La semm (lane 4) and four different anti-(UI.U2)RNP 
sera from patients B25. G18. V26 and P21, respectively (lanes 5 - 8 ) 
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Table I 
Patient 
B25 
GI8 
V26 
P21 
. Immunodiffusion and immunofluorescence data obtained with the four ami 
Sex 
F 
F 
F 
F 
Age 
52 
19 
50 
34 
Diagnosis'1 
RA + SS 
MCTD 
SLE 
SLE 
•(U1.U2) RNF sera. 
Immunofluorescenceb 
cyt 
-
-
+ 
-
nucl 
+ + 
+ -
+ + 
+ + 
and patients' 
nucleol 
-
+ / -
+ / -
+ / -
chmcal data 
Immunodiffusion0 
Sm 
+ 
(Ul)RNP 
t 
+ 
+ 
+ 
La 
+ 
aRA = rheumatoid arthritis, SS = Sjögrens syndrome. MCTD • mixed connective tissue disease. SLE = systemic lupus erythematosus 
bcyt = cytoplasmic immunofluorescence pattem. nucl = fine speckled nuclear immunofluorescence pattern, nucleol = nucleolar immunofluorescence pattern; 
+ / - denotes a signal at the limit of detection + denotes a standard signal. + + denotes a strong signal 
c
 + Indicates a (partial) identity with a reference serum in immunodiffusion tests. 
NHS aRNP 1 2 3 4 5 aRNP 1 2 3 4 1 2 3 4 5 1 2 
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Fig. 2. Immunoblot analysis of anti-{L]l.U2)RNF sera Nitrocellulose blots contained HeLa total nuclear proteins (panels A and D). anti-mjG purified 
UI — U6 snRNPs (panel B) or purified UI snRNPs (panel C) All blot strips presented in one panel originate from the same blot (see Materials and 
methods) Stnps were probed with normal human serum (NHS). ami-(UI)RNP serum (aRNP), anti-Sm senim (lanes 1) or the anti-(Ul.U2)RNP sera B25 
(lanes 2). V26 (lanes 3). GI8 (lanes 4) and P21 (lanes 5) Immunoreactive proteins were detected using '"Llabeled protein A The protein blots shown in 
panel D differ from those in panels Α - C in that they onginate from high resolution (40 cm) 13% Polyacrylamide gels The blot strip incubated with serum 
P21 from panel В was lost due to an experimental error and could not be repeated because more serum was not available Sera V26 and GI8 also recognized 
the 70-K antigen on (UI)RNP blots (panel C) as visualized on autoradiograms after a four times longer exposure However, the С antigen recognized by 
senim G18 (panel B, lane 4) could not be detected in these longer exposures, probably due to some loss of this antigen during the further purification of 
UI RNPs on DEAE-Sepharose 
ed A' (Mimori et al., 1984) or P27 (Kinlaw et al., 1982, 1983), 
both migrating just below the A antigen upon Polyacrylamide 
gel electrophoresis (PAGE). 
Here we describe four human autoimmune sera which selec­
tively react with snRNPs UI and U2. Precipitation of U2 RNPs 
is due to the presence of two antibody specificities reactive with 
U2 RNP-specific polypeptides of mol. wt. 31 000 (A') in one 
serum and of mol. wt. 28 500 (B") in all four sera. Interesting­
ly this latter antibody specificity cross-reacts with the UI RNP-
specific A protein demonstrating that both antigens share at least 
one common epitope. 
Results 
RNA immunoprecipitation 
From 400 sera of patients with connective tissue diseases, four 
sera were selected that precipitated snRNP species UI and U2 
from a 32P-labeled HeLa cell extract (Figure 1, lanes 5 — 8). As 
a reference, sera with previously described specificities are 
shown; anti-(Ul)RNP (lane 2) and anti-Sm antibodies (lane 3) 
precipitate UI RNA and UI — U6 RNAs, respectively, whereas 
anti-La antibodies (lane 4) precipitate RNAs of ~ 95 nucleotides 
representing tRNA precursors. Immunoprecipitates obtained from 
•72-
Antibodies to U2 snRNP 
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в'/в"/в~ -+ •* ^ 
Fig. 3 Two-dimensiona] protein blots Total proteins from nuclear extracts 
of HeLa cells were separated in the first dimension by non-equilibraied pH 
gradient electrophoresis (NEPHGE, + = acidic — = basic side) which 
was followed by separation in Ihe second dimension by SDS PAGE (15%) 
(O Farrell el at 1977) Immunoslaining was perfonned with anti 
(U1,U2)RNP serum B25 and peroxidase conjugated an« human IgG (filled 
arrow) Subsequently the same blot was incubated with equal amounts of 
anti (Ul)RNP and anti Sm sera followed by staining with peroxidase 
conjugated ami human IgG (open arrow) 
32P-labeled Ehrlich ascites mouse cells revealed identical patterns 
(not shown), supporting the observations that the structure of the 
U snRNA-associated proteins are highly conserved during evolu­
tion Serum from patient B25 also contains anti-La antibodies 
(Figure 1, lane 5), whereas the other three anti-(U 1 ,U2)RNP sera 
(sera G18, V26 and P21) exclusively precipitate Ul and U2 
RNA Even upon a six times longer exposure of autoradiograms, 
no other discrete low mol wt RNA species could be detected 
in immunoprecipitates obtained with these sera 
Immunodiffusion and immunofluorescence data obtained with 
the four anti-(U 1 ,U2)RNP sera, together with some clinical data 
of the patients are listed in Table I 
Immunobbttmg 
Identical nitrocellulose strips from electroblots of proteins from 
a total nuclear extract of HeLa cells (Habets et al , 1983a) were 
probed with the four dnti-(Ul,U2) sera As is shown in Figure 
2A, these sera share reactivity with two polypeptides, one of 
which is located in the region of the BIB' antigens (and which 
will be termed B" hereafter), the other very heavily stained anti­
gen being identical with the U1 RNA-associated A antigen (see 
below) Sera G18 and V26 also contain antibodies against the 
70 К Ul RNA-specific antigen while serum V26 reacts with a 
single polypeptide of mol wt 31 000 (A') as well Serum B25 
reacts with the La antigen [(mol wt 50 000) Habets et al , 
(1983b)] consistent with the finding that B25 precipitated LaRNAs 
from J2P-labeled HeLa extracts (see Figure 1, lane 5) 
To investigate which of the antigens recognized by these anti-
(U1,U2)RNP sera actually were associated with snRNAs, 
purified (Ul -U6) snRNP particles, isolated by immuno-affimty 
chromatography with anti-2,2,7-trimethylguanosine (тэС) IgGs, 
were used as a source of antigen for immunoblotting These ex­
periments demonstrated that the B", A' and A antigens iden­
tified by anti-(Ul,U2)RNP sera indeed represent proteins of 
snRNP particles (Figure 2B) Intensities of individual bands on 
the autoradiograms vary among the blots obtained with total 
nuclear extract and purified snRNPs This is probably due to dif­
ferences in the concentration of the respective proteins in these 
two sources of antigenic material Figure 2C shows the immuno­
blotting patterns of the same sera when purified Ul RNP par­
ticles were used as source of antigen In this case the four sera 
only recognized the A antigen and no reaction with the protems 
A' or B" could be observed 
These results demonstrated that the B" antigen is not contain­
ed in purified Ul RNP particles and suggested further that the B" 
protein is distinct from the proteins В and B', a notion which is 
corroborated by the data shown in Figure 2D In a high resolution 
gel the В " protein can be shown to have an electrophoretic mobil­
ity in between the Ul - U 6 RNA-associated proteins В and B' 
Two-dimensional protein blots 
Two-dimensional (2D) gels from a total nuclear HeLa extract 
were blotted onto nitrocellulose sheets, probed with serum B25 
and immunostamed with peroxidase-conjugated anti-human IgG 
Due to the limited amount of antigen that can be applied to the 
first dimension Polyacrylamide gel (NEPHGE), only the domi­
nant antigens A and B" could be visualized on 2D blots (Figure 
3, filled arrow) The same blot was subsequently reacted with 
an anti-Sm and an anti-(Ul)RNP serum Antigens recognized by 
these sera are marked by an open arrow in Figure 3 The A anti­
gen recognized by serum B25 appeared as a heterogeneous smear 
of slightly basic pi and no extra spots showed up in this region 
after incubation with an anti-(Ul)RNP serum The same result 
was obtained when the order of incubation of the 2D blots with 
the sera was reversed, indicating that the same A polypeptide(s) 
are recognized by anti-(Ul)RNP and the anti-(Ul ,U2)RNP sera 
When probed with an anti-Sm serum, the B/B' antigens always 
appeared as a quadruplet of spots on 2D blots Subsequent in­
cubation of the blot with an anti-(Ul,U2)RNP serum showed that 
the B" antigen had a more acidic pi, corroborating the idea that 
the B" antigen is distinct from the B/B' proteins 
Reactivin of antibody specificities elutedfrom individual protein 
bands of immunoblots 
To trace the antibodies that contribute to the precipitation of U2 
snRNA, antibodies hound to individual bands on nitrocellulose 
blots were eluted and directly used for immunoblotting and im-
munoprecipitation of snRNPs from extracts of 32P-labeled HeLa 
cells 
As a control, we punfied antibodies from a blot incubated with 
a serum containing anti-Sm as well as anti-(Ul)RNP antibodies 
In agreement with earlier observations (Habets et al , in prepara­
tion), punfied anti-70 K, anti-A and anti-C antibodies precipitated 
exclusively Ul RNP, whereas anti-B/B' and anti-D antibodies 
recognized Ul — U6 RNPs (Figure 4A, lanes 8—14) When pro­
tein blot strips were probed with each of the above punfied anti­
body fractions, antibodies eluted from protein bands 70 К, A 
and С reacted selectively with the corresponding protein antigen 
from which they had been eluted Antibodies eluted from pro­
tein bands B, B' or D, however, reacted with all of the three 
antigens on immunoblots demonstrating that these antigens share 
common epitopes (Figure 4A, lanes 1 - 7) 
Antibody specificities contained in serum B2S were also 
purified from the several reactive regions on a total nuclear pro­
tein blot Figure 4B shows that antibodies eluted from the mol 
wt 50 000 region precipitate La RNAs (lane 7) and that anti-A 
antibodies from this particular serum selectively react with Ul 
RNP (lane 8) Surpnsingly, anti-B" antibodies precipitated both 
Ul and U2 RNPs (lane 9) This was unexpected in view of our 
finding that the B" protein is not contained in punfied Ul snRNP 
particles (see Figure 2C) On inspection of the immunoblots ob­
tained with purified anti-B" antibodies, however, the co-
precipitation of both Ul and U2 RNPs by this antibody specificity 
can be explained anti-B" antibodies cross-react with the Ul 
RNP-specific A protein (Figure 4B, lane 4) Thus these two pro-
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Fig. 4. Purification of antibodies from nitrocellulose blots HeLa total nuclear protein blots were incubated with an anti-Sm/RNP serum (panel A), anti-
ÍUI,U2)RNP sera B25 (panel B) or V26 (panel C) The reactive regions marked on the left of each panel were excised and bound antibodies were eluted 
(Smith and Fisher, 1984)- These fractions were re-used for immunoblotting or RNA precipitation as indicated on the top of each lane Immunoblots of 
purified antibodies were stained for 15 mm whereas strips incubated with whole serum (lanes 1) were stained for 5 min 
teins must share at least one common epitope. Purified anti-A 
antibodies react exclusively with the A antigen (Figure 4B, lane 
3) and eluted anti-La antibodies show a monospecific reaction 
with the La antigen of mol. wt. 50 000 (lane 2). No reaction 
was found when a control region of the nitrocellulose blots was 
extracted and the eluted fraction was used for immunoblotting 
and RNA immunoprecipitation (lanes 5 and 10). 
The same elution experiments were also performed with serum 
V26. Anti-70 К antibodies again precipitated exclusively Ul RNP 
(Figure 4C, lane 8), but in contrast with the findings in serum 
— 7 4 -
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B2S, anti-A antibodies punned from serum V26 precipitated Ш 
and U2 RNA (Figure 4C, lane 9) and reacted with A as well 
as B" on protein blots (Figure 4C, lane 3) Purified anti-A' anti­
bodies precipitated predominantly 1)2 RNPs (Figure 4C, lane 10) 
in accordance with the previous demonstration that the A' pro­
tein is unique to U2 RNP particles (Mimon et al, 1984) The 
co-precipitation of the low amounts of Ul RNPs observed with 
the anti-A' antibody is most probably due to contamination with 
anti-A antibodies from the nearby A protein band In fact some 
reaction with the A protein is also observed with the A'-specific 
antibody fraction on immunoblots (Figure 4C, lane 4) Such dual 
contamination can be avoided if proteins are separated m high 
resolution gels (data not shown) Anti-B" antibodies reacted in 
the same way as those purified from serum B25, ι e , they selec­
tively precipitate snRNPs Ul and U2 (Figure 4C, lane 11) and 
cross-react with the A antigen on protein blots (Figure 4C, lane 
5) 
Discussion 
This paper describes a novel autoantibody specificity reacting 
with proteins associated with snRNAs Ul and U2 which we 
detected in four out of 400 sera of patients with connective tissue 
diseases The four sera precipitated selectively the snRNAs Ul 
and U2 which excluded the presence of anti-Sm antibodies, 
known to react with proteins common to all nucleoplasmic 
snRNPs (Lemer and Steitz, 1979, Pcttersson et al, 1984) When 
total proteins of purified U1 — U6 snRNPs were used as antigenic 
material for immunoblotting studies, all four sera showed reac­
tivity with the Ul RNP-specific A protem and a second polypep­
tide of mol wt 28 500 (B' ' protem. Figure 2) This protein could 
be shown to be distinct from the В and B' antigens and not to 
be contained in punfied Ul RNP particles (Figure 2C), indicating 
that the B " protein is unique to U2 RNPs and that precipitation 
of U2 RNPs was due to ¿"-specific autoantibodies in the four 
sera In this respect it was surprising that purified В "-reactive 
antibodies not only precipitated U2 RNPs, but also recognized 
Ul RNPs (Figure 4B, lane 9, 4C, lane 11) This suggested that 
co-precipitation of U1 RNPs was either due to interaction of UI 
with U2 RNPs m vitro, or due to cross-reaction of B"-reactive 
antibodies with one of the Ul-specific polypeptides The latter 
possibility is the more likely one as we could demonstrate cross-
reactivity of anü-B" antibodies with the A polypeptide (Figure 
4B, lane 4, 4C, lane 5) At least with serum V26 the reverse 
was also found to be true, ι e , antibodies eluted from the A band 
cross-reacted with the B" antigen and precipitated both Ul and 
U2 RNPs (Figure 4C, lane 9) This clearly demonstrates that 
both polypeptides have at least one antigenic determinant m 
common 
It should be pointed out that the A antigen also bears antigenic 
sites which are unique to this protein and which are recognized 
by anti-A antibodies contained in anti-(Ul)RNP sera The 
presence of this antibody specificity in serum B2S would explain 
our finding that the punfied A-reactive antibody fraction did not 
cross-react with the B " polypeptide though this serum contains 
antibodies reacting with antigenic sites common to both proteins 
(Figure 4B, lane 3) It would further suggest that recognition of 
the respective antigenic sites on the A polypeptide by the two 
classes of autoantibodies is mutually exclusive 
The observed immunological cross-reactivity between the 
polypeptides A and B" is a further example to demonstrate struc­
tural relatedness between snRNP proteins encompassed in distinct 
snRNP particles It has previously been shown that the proteins 
B, B' and D react with the same monoclonal antibody, indicating 
that these antigens also share common epitopes (Mimon et al, 
1984, Pettersson et al, 1984) 
We characterized the В" antigen as a 28 500 mol wt polypep­
tide migrating in between the B' and В antigen upon PAGE, while 
exhibiting a more acidic pi upon 2D gel electrophoresis This 
antigen is probably identical with a third В polypeptide, occa­
sionally observed as a very faint band in 3SS-labeled im-
munoprecipitates obtained with anti-Sm sera (Billings and Hoch, 
1984, Pettersson et al , 1984) Further fractionation of these 
Ul — U6 snRNP precipitates indeed revealed that this third В 
polypeptide co-punfied with U2 RNP (Hinterberger et al, 1983, 
Mimon et al , 1984) 
Sequential immunoaffinity chromatography utilizing suc­
cessively the anti-mjG antibody, ami-(Ul,U2)RNP serum V26 
and a patient anti-(Ul)RNP serum enabled us to select highly 
pure Ul and U2 RNP moieties Protein analysis of these punfied 
fractions support the conclusions drawn above, the A protein is 
exclusively contained m the Ul RNP fraction while B" is specific 
for U2 RNP (P Bringmann and R Luhrmann, in preparation) 
Very recendy, the anti-(Ul,U2)RNP serum P21 described in 
this paper was used to determine the binding site of specific 
snRNP proteins on mutant U2 RNAs (Mattaj and De Robertis, 
1985) From their results and the immunoblotting profiles of 
serum P21 (Figure 2, lanes 5) it can be deduced that it is most 
probably the B" antigen which interacts with the two 3' loops 
of the U2 RNA molecule 
All these results strongly suggest that the B" antigen is a uni­
que polypeptide specifically associated with U2 RNA The ques­
tion of whether this protein is a primary translation product or 
a result of post-translational modification (from one of the other 
snRNP-associated proteins) can only be answered unequivocal­
ly when the genes coding for snRNP proteins have been cloned 
One anti-(Ul,U2)RNP serum also decorated a polypeptide on 
snRNP immunoblots migrating just below the A protein (refer­
red to as A') Recendy, Mimon et al (1984) used a human 
autoimmune serum (Ya) to identify this A' protem as a 
methionine-deficient, exclusively U2 RNA-associated polypep­
tide We have several reasons to assume that the A' antigen 
recognized by serum V26 is identical with the polypeptide iden­
tified by the Ya serum Both antigens exhibit identical mol wts 
when sera V26 and Ya were probed on blots (not shown) and, 
as is the case with the Ya serum, serum V26 recognizes the A' 
antigen only on protein blots containing Ul — U6 RNPs and not 
in punfied Ul RNP blots Moreover, anti-A' antibodies punfied 
from serum V26 recognize almost exclusively U2 RNP particles 
In contrast with anti-(Ul)RNP and anti-Sm antibodies, the oc­
currence of anti-(Ul,U2)RNP antibodies does not seem to be 
syndrome-specific (Table I), and is therefore of little diagnostic 
value However, these sera might serve as an important tool in 
the fractionation of snRNP into its individual constituents and 
so greatly facilitate the investigations on their function and 
structure 
Materials and methods 
Reference sera 
Immunological identity of sera was tested by immunodiffusion and 
counter Immunoelectrophoresis using extractable nuclear antigen (ENA, Kurata 
and Tan, 1976) and reference sera obtained from the Centers of Disease Control 
(CDC) m Atlanta, GA Human sera were further obtained from patients treated 
at the St Radboud Hospital in Nijmegen, the Hospital Stadsmaten in Enschede 
and the Dijkzigt Hospital Rotterdam, The Netherlands, and from the Centre 
Hospitalier, Luxembourg Ya serum was a kind gift of Dr Τ Мшюп (New Haven, 
CT) Clinical data of the patients from which ann (U1,U2)RNP sera were ob­
tained are listed in Table I Monoclonal ami Sm and anti-(Ul)RNP antibodies 
— 75 — 
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(Billings and Hoch, 1984 Billings ei al , 1982) were used as references in RNA 
immunoprecipitation assays (see below) 
Preparation of radwlabeled cell extracts 
Hel-a S3 cells were maintained in suspension culture as desenbed (van Eekelen 
and van Venrooij 1981) 
For RNA analyses, 1 5 χ 10· HcLa cells were labeled for 15 h with ("P] 
phosphate (30 /¿Ci/ml) at 5 χ IO5 cells/ml in phosphate free essentia] medium 
supplemented with 10% dialysed fetal calf semm After harvesting, cells were 
washed twice with PBS (20 mM Na phosphate pH 7 3, 130 mM NaCl) and 
resuspended in 3 ml sonication buffer (100 mM NaCl, 1 mM EDTA, 20 mM 
К phosphate buffer pH 7 5) The suspension was sonicated 2 χ 60 s at setting 
3 of a Branson somfier and clarified by centnfugation at 10 000 g for 30 mm 
The supernatant was used either immediately for immunoprecipitation assays or 
stored at - 70 CC 
RNA immunoprecipitation asvav 
Analysis of unmunopreupitated RNA was based on the method desenbed by Maner 
et al (1982) Non specifically binding material in "P-labeled cell extracts was 
pre adsorbed by incubation with one volume of 10% protein A Sephaxose in IPP 
and two volumes of IPP (500 mM NaCl, 10 mM Tns pH 7 5, 0 05% Nomdet 
P40) for 1 h at 4 0 C Meanwhile, 10 μΐ serum was adsorbed on 250 μΐ 10% pro­
tein A Sepharose in PBS and washed five limes with IPP After centnfugation, 
the pellet was incubated with 400 μΐ of the pre-adsorbed 32P-labeled cell extract 
by end over-end rotation for 1 h at 4 0 C , and washed five times with IPP After 
the final wash, the pellet was re-suspended in NET 2 (150 mM NaCl, 50 mM 
Tns HCl pH 7 4 0 05% Nonidet P40) and 20 ιΔ of 10% SDS was added After 
phenol extraction, RNAs were ethanol precipitated separated by electrophoresis 
on 10% Polyacrylamide gels containing 7 M urea, 0 l M Tns borate pH 8 3 and 
2 mM EDTA and delected by autoradiography 
Affiniti purification of snRNPs 
Anli-mjG affinity columns were used lo punfy Ul — U6 RNPs from nuclear ex 
tracts of HeLa cells (Brmgmann et al, 1983, 1984) From this fraction Ul RNPs 
were purified according to Hinterberger et al (1983) using DEAE-Sepharose 
chromatography 
Immttnoblutting 
For blotting anal> ses either purified snRNPs or a total nuclear protein fraction 
(Habets et al , 1983a, 1983b) was used An appropnate amount of protein was 
dissolved in 2% SDS-containing sample buffer and loaded over the entire width 
of a 13% Polyacrylamide gel (Laemmli, 1970) After electrophoresis, gels were 
blotted overnight onto nitrocellulose in a Bio-Rad trans blot cell at 60 V/0 3 A 
in 192 mM glycine, 25 mM Tns pH 8 3 and 20% methanol After transfer, the 
blots were dried and cut from top to bottom into strips of — 7 mm Individual 
strips were saturated with 3% BSA and incubated with serum as desenbed (Hab-
betse/a/ 1983a, 1983b) Antigen bound antibody specificities were visualized 
either with [125I]protein A or with horseradish peroxidase-conjugated second anti­
body (Habets et al , 1985) 
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CHAPTER 6 
FURTHER CHARACTERIZATION AND 
SUBCELLULAR LOCALIZATION OF Sm AND U1 
RIBONUCLEOPROTEIN ANTIGENS 
Reprinted with permission from: Eur. J. Immunol. (1985) 15, 992-997. 
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Further characterization and subcellular localization of 
Sm and Ul ribonucleoprotein antigens* 
Sera from patients with systemic autoimmune diseases often contain antibodies 
against small nuclear ribonucleoprotein (snRNP) particles Anti-Sm antibodies react 
with the entire set of Ul, U2, U4, U5 and U6 (U1-U6) RNP particles whereas anti-
(Ul)RNP sera specifically recognize particles containing Ul RNA Here we per-
formed semi-quantitative immunoblotting using 16 human anti-Sm, 15 human anti-
(Ul)RNP sera and two mouse monoclonal antibodies to establish which snRNA-
associatcd proteins carry antigenic determinants Almost everv (15'16) human anti-
Sm sera recognized epitopes present on a 28-kDa (B/B') protein doublet and on a 16-
kDa (D) polypeptide Nine anti-(Ul)RNP sera also recognized the B/B' doublet, but 
in all cases a much stronger reaction was observed with one or more of the specifically 
Ul RNA-associated 70 kDa, A or С antigens With affinity-purified antibody frac­
tions eluted from individual antigen bands on nitrocellulose blots it is shown that the 
anti-Sm-reactive polypeptides B/B' and D contain common epitopes We also report 
the finding of one human anti-Sm serum with exclusive specificity for the B/B' doublet 
and a mouse monoclonal anti-Sm antibody recognizing onlv the D protein, indicating 
that these antigens also carry unique epitopes In immunoprecipitation assays, 
purified anti-B/B' and -D antibodies react with (U1-U6) RNP while purified anti-
70 kDa, anti-A and anti-C antibodies precipitate exclusively Ul RNP particles 
Finally, we established the subcellular localization of Sm and Ul RNP antigens using 
a biochemical cell fractionation procedure Part of the 70 kDa and B/B' antigens were 
found in a nuclease and high salt-resistant nuclear substructure, usually referred to as 
nuclear matrix, while the A and D antigens could be extracted completely from HeLa 
nuclei by nbonuclease treatment and subsequent high salt extraction 
1 Introduction 
One of the characteristics of systemic autoimmune diseases is 
the presence of circulating autoantibodies directed towards 
nuclear antigens (reviewed in [1, 2]) Although these autoanti­
bodies mostly show a wide vanety in disease specificity, some 
of them are quite restneted to a certain syndrome (e g anli-
Sm in systemic lupus erythematosus (SLE) patients, anli-
(Ul)RNP, in patients with mixed connective tissue disease 
(MCTD) [3] and anti-Scl-86 in scleroderma [4]), and can 
therefore be used as a marker antibody [2] 
In recent years more precise chemical analyses of the various 
antigens recognized by these autoantibodies have been per­
formed Many of them recognize ribonucleoprotein (RNP) 
particles and several of such RNP classes have been described 
so far Anti-Sm antibodies recognize RNP particles containing 
the small nuclear RNA (snRNA) species Ul, U2, U4, U5 and 
U6 (U1-U6) whereas anti-(Ul)RNP sera precipitate particles 
exclusively containing Ul-snRNA [5] Anti-SS-B (anti-La) 
antibodies react with RNP particles containing RNA poly-
[I 4995] 
* This work was supported bv grants from the "Praeventietonds", The 
Hague and the Netherlands League against Rheumatism 
Correspondence: Winand J Habets, Department of Biochemistry, 
University of Nijmegen, Geert Grooteplein noord 21, Ρ О Box 9101, 
6500 HB Nijmegen, The Netherlands 
Abbreviations: SLE: Systemic lupus erythematosus RNP: Ribonu­
cleoprotein snRNP: Small nuclear RNP snRNA: Small nuclear 
RNA SDS: Sodium dodecyl sulfate CIE: Countcnmmunoelectro-
phoresis ID: Immunodiffusion PBS: Phosphate-buffered saline 
merase III products [6], and anti-SS-A (anti-Ro) antibodies 
recognize a subset of SS-B particles containing a few discrete 
cytoplasmic RNA [7, 8] 
Since the protein components of all these RNP particles are 
required for antigenicity, the immunoblotting technique seems 
to be ideally suited for examining the antigens recognized by 
these sera [9] With this technique a large number of anti-SS-B 
and anti-SS-A sera have already been analyzed and shown to 
recognize predominantly a single 50-kDa and 60-kDd protein, 
respectively [10-12] In contrast, immunoblot analyses of anti-
(Ul)RNP and anti-Sm sera show a much greater variation in 
antigenic polypeptides [13-23] although the prevalence of 
antibodies against a 70-kDa protein in anti-(Ul)RNP sera 
[14-17] and against B/B' and D proteins in anti-Sm sera [24] 
has been noted 
Our results show that most human anti-Sm sera recognize B/B' 
and D antigens simultaneously This seems to support a previ­
ous hypothesis that B/B' and D antigens exclusively contain 
common epitopes [25] However, B/B' as well as D antigens 
also carry unique antigenic determinants, as is shown by their 
individual recognition by one patients' anti-Sm serum and a 
mouse monoclonal antibody 
All anti-(Ul)RNP sera recognized at least one of the Ul 
RNA-specific polypeptides although some also reacted 
(weakly) with the (Ul-U6)-associated B/B' doublet Using a 
recently described antibody purification procedure [26] we 
show that monospecific antibody fractions can be purified 
from sera containing both anti-(Ul)RNP and anti-Sm anti­
bodies Finally, using a biochemical cell fractionation proce­
dure we were able to establish the subcellular localization of 
Sm and (Ul)RNP antigens 
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2 Materials and methods 
2.1 Sera 
Human sera were obtained from patients treated at the St. 
Radboud Hospital in Nijmegen, and from the Department of 
Clinical Immunology, University of Groningen, and were 
tested by counterimmunoelectrophoresis (CIE) and 
immunodiffusion (ID) for anti-Sm or anti-RNP activity. 
Immunological identity with reference sera obtained from the 
Centers of Disease Control (CDC) in Atlanta (anti-Sm refer­
ence serum 5, lot 82-0011 and anti-RNP reference serum 4, lot 
82-0010) was in all cases established. Additional anti-Sm sera 
were obtained from Dr. E. M. Tan (Scripps Clinic, La Jolla, 
CA), and from the Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service (Amsterdam). Mouse mono­
clonal antibodies 2.73 and 7.13 were prepared from culture 
supernatants as previously described [17, 27]. Both antibodies 
were used as standards in immunoblotting and RNA 
immunoprecipitation assays. 
2.2 Antigen substrates, gel electrophoresis and 
immunoblotting 
Extractable nuclear antigen was obtained commercially (Pel-
Freez, Rogers, Arkansas) and was also prepared from rabbit 
thymus acetone powder (Pel-Freez) as described by Kurata 
and Tan [28]. A nuclear protein fraction from HeLa S3 cells to 
be used in the immunoblotting experiments was prepared as 
described [10, 14]. Gel electrophoresis and protein blotting 
were performed as described previously [10, 14, 29]. In brief, 
13% Polyacrylamide gels were loaded over the entire width 
with a nuclear protein fraction of HeLa cells. After elec­
trophoresis, gels were blotted overnight onto nitrocellulose 
paper and the resulting blots were then cut from top to bottom 
into 20 identical strips of about 7 mm. Immunodetection of 
bound IgG on blots was performed as described previously 
[10, 14, 29]. 
2.3 Preparation of radiolabeled cell extracts 
For use in RNA and protein immunoprecipitation assays, 
1.5 x 108 HeLa cells were labeled for 15 h either with '%-
phosphate (30 μΟ/πιΙ = 1.15MBq/ml) or with [35S]methionine 
(5 μέί/ιηΐ) at 5 x IO5 cells/ml in phosphate- or methionine-free 
essential medium supplemented with 10% dialyzed fetal calf 
serum. After harvesting, cells were washed twice with phos­
phate-buffered saline (PBS) (20 mM sodium phosphate, 
pH 7.3, 130 mM NaCI) and resuspended in 3 ml sonication 
buffer (100 т м NaCI, 1 т м EDTA, 20 т м potassium phos­
phate buffer, pH 7.5). The suspension was sonicated 2 χ 60 s 
at setting 3 of a Branson sonifier and clarified by centrifuga­
tion at 10000 x g for 30 min. The supernatant was used either 
immediately for immunoprecipitation assays or stored at 
-70 0C. 
2.4 RNA and protein immunoprecipitation assays 
incubating 1 vol. of 10% protein A-Sepharose in PBS and 
2 vol. of IPP (500 т м NaCI, 10 т м Tris, pH 7.5, 0 05% 
Nonidet-P40) for 1 h at 4°C. Meanwhile, 10 μΐ serum was 
adsorbed on 250 μΐ 10% protein A-Sepharose in PBS and 
washed 5 times with IPP. After centrifugation the pellet was 
incubated with 400 μΐ of the preadsorbed cell extract by end-
over-end rotation for 1 h at 4°C and washed 5 times with IPP 
After the final wash the pellet was resuspended in NET-2 
(50 mMTris-HCl, pH 7.4, 150 mMNaCl, 0.05% Nonidet-P40) 
and 20 μΐ of 10% sodium dodecyl sulfate (SDS) was added. 
After phenol extraction, RNA was ethanol precipitated, sepa­
rated by electrophoresis on 10% Polyacrylamide gels contain­
ing 7 M urea, 0.1 M Tns-borate, pH 8.3 and 2 т м EDTA and 
detected by autoradiography Proteins were recovered from 
immunoprecipitates by heating the Sepharose beads at 100 0C 
in SDS gel sample buffer for 3 min and separated by elec­
trophoresis on 15% polyacrylamide-SDS gels. 
3 Results 
3.1 Characterization of patients' sera 
From our stock of about 400 patients' sera we selected 12 sera 
that contained anti-Sm activity, 4 sera with both anti-Sm and 
anti-RNP (Sm/RNP) activity and 27 sera containing anti-RNP 
activity as detected by CIE and ID using extractable nuclear 
antigen from rabbit thymus powder as the antigen source. The 
precipitation lines in ID from these sera were immunologic .lly 
identical with the precipitation lines obtained with anti-Sm and 
anti-RNP reference sera. Further characterization of these 
sera was performed by RNA- and protein-immunoprecipita-
tion analysis. Anti-Sm sera precipitated (U1-U6)RNA 
(Fig. 1, lane 3) as well as a set of eight differently sized pro­
teins, known to be associated with snRNA (Fig. 1, lane 5). 
PRECIPITATION BLOTTING 
RNA ^ 0 ' " ' PROTEIN 
x l O 3 
li ¿asm 
Figure I. Characterization of human anti-Sm and anti(Ul)RNP sera. 
Precipitation: Polyacrylamide gel fractionation of unmunoprecipitated 
3zP-labeled RNA (lanes 1-3) or 35S-labeled proteins (lanes 4-6). Pre-
cipitates were obtained from a total HeLa cell sonicate (lanes Σ), 
using normal human serum (lanes 1 and 4), anti-(Ul)RNP serum 
(lanes 2 and 6) or an anti-Sm serum (lanes 3 and 5). Positions of mol. 
wt. markers run in an adjacent lane are indicated at the left of each 
panel. Asterisk indicates a nonspecifically precipitated polypeptide 
probably identical with actin. Blotting: identical blot strips originating 
from the same blot were incubated with; lane 7: normal human serum; 
lane 8: anti-(Ul)RNP serum; lane 9: anti-RNP/Sm serum; lane 10. 
anti-Sm serum. 
Analysis of itnmunoprecipitated RNA and protein was based 
on the method described by Matter et al. [30]. Nonspecifically 
binding material in labeled cell extracts was preadsorbed by 
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Anti-RNP sera precipitated the same set of proteins (Fig 1, 
lane 6) confirming the onginal findings of Lerner and Steitz 
[5]. The 70-kDa Ul RNA-associated polypeptide is not visible 
in these precipitates because of its methionine deficiency 
[22, 31]. Twelve of 27 anti-RNP sera as defined by CIE also 
precipitated (U1-U6)RNA, probably due to a minor anti-Sm 
activity not detectable in our CIE or ID assays. The remaining 
15 anti-RNP sera exclusively precipitated Ul snRNA (Fig. 1, 
lane 2) and will be further referred to as anti-(Ul)RNP sera. 
3.2 Immunoblotting patterns of anti-Sm and anti-(Ul)RNP 
sera 
A nuclear extract of HeLa cells, previously shown to contain 
the full complement of snRNA-associated proteins [14, 29], 
was used as a source of antigen for immunoblotting experi­
ments. A typical example of such an immunoblotting analysis 
is shown in Fig. 1. An anti-(Ul)RNP serum recognizing the 
• (UDRNP RNP s m ant. Sm 
ni I I 
pat<ent number 
patient number 
ІШ 
Oil 
panenl nuiriber 
IU995 2! 
Figure 2 Semi-quantitative analysis of presence of anti-70 kDa, A, 
В/В', С antibodies in patients' sera Identical blot strips were auio-
radiographed for 24 h after serum incubation and detection of bound 
IgG using l25I-labeled protein A Relative intensities of the respective 
bands were estimated independently by three investigators Mean val­
ues of their readings are depicted on an arbitrary scale from 0 to 8 
Fourty normal human sera all scored negative (0) 
70-kDa, the A and the С protein is shown in lane 8. while our 
standard anti-Sm serum recognizes the B/B' doublet and the D 
protein (lane 10). The immunoblotting pattern of a serum con­
taining both specificities is shown in lane 9 
We reported recently that the intensity of the immunorcdction 
on blots can be interpreted semi-quantitatively ]29] Here we 
used a modification of this method in a comparison of ann-
(Ul)RNP and anti-Sm sera concerning the 70-kDa. A, В/В . С 
and D antigens. The intensity of the reaction of anti-(Ul)RNP 
and anti-Sm sera with these antigens was scored on an arbi­
trary scale of 0 to 8 (Fig. 2). 
Almost all (87%) anti-(Ul)RNP sera recognized the 70-kDa 
protein. 67% showed reactivity towards the A antigen whereas 
60% recognized the С polypeptide. A weak but evident reac­
tion with the B/B' antigens was observed in 9 cases (60%) 
while no anti-D activity could be detected in these scia All 
anti-Sm sera (#20-31) showed a strong reaction with the B/B' 
antigen doublet. All but one (serum #24, see below) anti-Sm 
sera reacted with the D antigen and 9 (75%) contained anti A 
and anti-C antibodies. Eight anti-Sm sera contained antibodies 
against a 70-kDa protein, but, upon close examination, this 
antigen band exhibited a slightly different shape and elec-
trophoretic mobility as compared with the Ul RNA-associatcd 
70-kDa antigen (Fig. 1, lane 10, see Sect 4) Reaction with 
this antigen was nevertheless scored as anti-70-kDa activity in 
Fig. 2. 
These results demonstrate that the 70-kDa antigen is recog­
nized predominantly by anti-(Ul)RNP sera whereas piesence 
of anti-D antibodies is most characteristic for anti-Sm sera. 
Anti-B/B' activity can be found both in anti-(Ul)RNP and 
anti-Sm sera, but high levels are only present in anti-Sm sera 
In a separate set of experiments we analyzed anti-Sm anti­
bodies in the sera from 24 MRLMp-lprllpr (MRL/1) mice [32] 
All sera tested contained strong anti-B/B' and anti-D activity 
on HeLa nuclear protein blots (data not shown). 
3.3 Immunological relation between Sm and RNP antigens 
Evidence has been provided [23, 33| that the 70-kDa, А, В. Г 
and D antigens represent distinct polypeptides but several 
immunoreactive breakdown products have been described, in 
particular from the 70-kDa antigen [15, 16, 34]. To investigate 
whether certain antibodies could show a cross-reactive bind­
ing, antibodies reactive with specific antigen bands on nitrocel­
lulose blots were eluted (26) and their binding was reassessed 
on a new blot. After incubation of a blot with a patients' serum 
containing both anti-Sm and anti-(Ul)RNP antibodies (#17), 
the blot was immunostained with peroxidase-conjugated anti-
human IgG and antibodies were eluted from every reactive 
antigen. When fractions eluted from the Ul RNP-specific 70-
kDa, A or С polypeptide bands were subsequently incubated 
with separate blot strips, purified antibodies only reacted with 
the antigen they were eluted from (Fig. ЗА). The specificity of 
these purified antibodies is further substantiated by the obser­
vation that every individual antibody fraction precipitated 
exclusively Ul RNA from a 32P-labeled HeLa cell extract 
(Fig. ЗА). 
A different situation was encountered with the B/B' and the D 
antigens. As is shown in Fig. ЗА, antibodies eluted from the B/ 
B' region cross-reacted with the D proteins as did purified 
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anti-D antibodies with B/B' antigens. Elution experiments 
with a pure anti-Sm serum confirmed this cross-reactivity 
(Fig. 3B). Both anti-D and anti-B/B' antibodies precipitated 
U1-U6 RNA from a 32P-labeled HeLa cell extract (Fig. ЗА). 
5 ELUTED FRACTIONS g ELUTED FRACTIONS 
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Figure 3. Affinity purification of antibodies from nitrocellulose blots 
(A) A HeLa nuclear protein blot was incubated with anti-Sm/RNP 
serum # 17 (lane 1). After peroxidase staining, the regions marked on 
the left of lane 1 were excised from one blot over a length of 10 cm 
and reactive antibodies were eluted [26]. These eluates were then used 
either for RNA immunoprecipitation (lanes 8-14) or to probe sepa­
rate strips from the same blot (lanes 1-7). The following eluted frac­
tions were used: lanes 2 and 9; anti-70 kDa; lanes 3 and 10: anti-A, 
lanes 4 and 11: anti-B/B'; la^es 5 and 12 anti-C; lanes 6 and 13: anti-
D. Lanes 7 and 14 show control experiments performed with fractions 
eluted from the region indicated by an asterisk. Immunoblots of 
purified antibodies were stained for 15 min, while strips incubated 
with whole serum (lanes 1) were stained for 5 min. (В) As (A) using 
an anti-Sm serum (#23), Antibodies eluted from B/B' and D antigens 
(lanes 2 and 4) precipitated U1-U6 RNA (not shown), hist = Histone 
protein. 
These results indicate that simultaneous recognition of B/B' 
and D antigens is more likely due to cross-reactivity of one 
type of antibody rather than to the presence of two different 
antibody populations. 
It is therefore of particular interest that we found one anti-Sm 
serum which exclusively recognized B/B' antigens and showed 
no reaction with the D antigen (serum #24, Fig. 4, lane 2). 
Since also (monoclonal) anti-D antibodies have been 
described (Fig. 4, lane 3, see also [27]), it can be concluded 
that both these antigens contain unique epitopes in addition to 
those commonly recognized by anti-Sm antibodies. 
3.4 Subcellular localization 
For the subcellular localization of Sm antigens an earlier 
described cell fractionation procedure was used [4, 35, 36]. 
Polyacrylamide gel electrophoresis of the various cell fractions 
clearly shows that this fractionation procedure indeed seems to 
succeed in separating groups of proteins belonging to phy­
siologically different cell compartments (Fig. 5, CBB). When 
identical gels were used for immunoblotting with anti-SS-B 
sera, we found that the SS-B antigen was predominantly 
localized in the detergent-soluble fraction (Fig. 5, SS-B), 
although a nonextractable moiety reproducibly appeared in 
the nuclear matrix fraction [10, 37-39]. Incubation with an 
anti-Sm 
1 2 3 4 5 6 
anti-S S-B 
1 2 3 4 5 6 
anti-RNP 
"¡ta 
CREST19-
1 2 3 
Figure 4. Immunoblotting patterns of 
anti-Sm sera. Three identical nuclear 
protein blot strips originating from the 
same blot were incubated with: lane 1: 
reference human anti-Sm serum; lane 2: 
human anti-B/B'-specific serum (#24); 
lane 3: murine monoclonal anti-D anti-
body [27]. Serum #24 (lane 2) also con-
tained antibodies against CREST-19, a 
19-kDa centrometric antigen [48] as es-
tablished by its apparent mol. wt. Anti-
bodies eluted from the CREST-19 anti-
gen did not react with any other poly-
peptide. Unlike anti-B/B' antibodies 
contained in other anti-Sm sera (com-
pare lane 1), the anti-B/B' antibodies 
from serum #24 cross-react with several 
higher mol. wt. proteins (lane 2), a 
phenomenon also observed with the 
monoclonal anti-D antibody (lane 3) 
1 2 3 4 5 6 1 2 3 4 5 6 
IU995 5| 
Figure 5. Subcellular localization of antigens. Proteins from several 
cellular fractions obtained from 3 χ 106 HeLa cells [4] were separated 
on a 13% Polyacrylamide gel. Identical gels were stained either with 
Coomassie brilliant blue (CBB) or blotted onto nitrocellulose and 
incubated with a human anti-SS-B serum also containing some anti-
Scl-86 activity [4], an anti-(Ul)RNP serum or an anti-Sm serum 
Lane 1: total HeLa nuclear protein extract, Η marks histones; lane 2: 
detergent-soluble fraction; lane 3: DNase-extractable fraction; lane 4: 
RNase-extractable fraction; lane 5: high salt-extractable fraction; 
lane 6: residual nuclear matrix fraction. 
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anti-(Ul)RNP serum showed that the 70-kDa antigen is pres­
ent in the high-salt (= chromatin) fraction and in the insoluble 
nuclear matrix fraction The A antigen is preferentially 
released by the nbonuclease (RNase) treatment (Fig 5-RNP, 
lane 4), while the С antigen is not detected in any specific 
fraction, a phenomenon most likely due to a loss of antigenic­
ity upon high-salt treatment When an identical blot was incu­
bated with an anti-Sm serum it was found that the D protein is 
released by RNase A and high-salt treatment In the residual 
nuclear matrix fraction, no detectable amounts of D protein 
were present In contrast, the B/B' doublet is only partly 
released by these treatments and is still detectable in the nu­
clear matnx fraction (Fig 5, Sm) Only trace amounts of anti-
Sm and anti-(Ul)RNP-reactive antigens were detected in the 
detergent-soluble (predominantly cytoplasmic) fraction, a 
finding which agrees with their exclusive nuclear location as 
determined by indirect immunofluorescence and is in accord 
with the observation that such cytoplasmic extracts do not give 
precipitation lines in the CIE or ID assays with anti-(Ul)RNP 
and anti-Sm sera (unpublished observation) 
4 Discussion 
Besides their function as "marker antibody" in human autoim­
mune diseases [1-4], autoantibodies have proven to be valu­
able tools in molecular biology, therefore, exact biochemical 
characterization of autoantigens has become particularly 
important Recent developments have shown that U snRNP 
particles, which are the targets of human anti-(Ul)RNP and 
anti-Sm sera, play an important role in the processing of mes­
senger RNA [40-42] In this study we selected anti-Sm and 
anti-(Ul)RNP sera from SLE and MCTD patients, respec­
tively, by RNA and protein immunoprecipitation analysis, the 
most sensitive techniques currently available [24] 
Immunoreactive protein antigens were then identified in a sen­
sitive semi-quantitative immunoblotting assay 
Our mam results show that almost all anti-Sm sera contain 
high-titered antibodies against the B/B' and D antigens How­
ever, the presence of anti-D antibodies seems more charac-
tenstic for anti-Sm sera since they are not found in anti-
(Ul)RNP sera (Fig 2) Anti-(U1)RNP sera contain anti­
bodies against at least one out of three Ul RNP-specific poly­
peptides, ι e the 70-kDa, the A and the С proteins Most 
characteristic for anti-(Ul)RNP sera, however, was the pres­
ence of high-titered anti-70-kDa antibodies, while anti-A and 
anti-C antibodies less frequently occurred (Fig 2) 
The finding that almost all anti-Sm sera recognize both the B/ 
B' and the D antigens can be explained by the observation that 
these antigens share common epitopes as shown by the cross-
reactmty of purified anti-B/B' and anti-D antibodies (Fig 3) 
This is in apparent contrast with the findings of Guldner et al 
[23] who suggested that both antigens have no immunological 
relationship However, they purified antibodies using KSCN, 
an agent suspected to cause a dramatic decrease in specific 
activity of the eluted antibodies, when compared with the 
much milder elution by pH shock as performed here [26] 
Besides antibodies recognizing common epitopes on B/B' and 
D polypeptides, another antibody specificity reactive with B/ 
B' or D-specific epitopes (Fig 4) can be present in anti-Sm 
sera Anti-B/B' antibodies from the type contained in serum 
# 24 could also be present in other anti-Sm sera and would then 
contribute for the observed quantitative differences in the 
ratio of B/B' vs D recognition (Fig 2) 
Interestingly, almost all anti-Sm sera tested showed some reac­
tivity with a protein of 70 kDa as well (see also Fig 2) This 
protein thus could be identical with the 70-kDa Ul RNP-
associated antigen, which would mean that these anti-Sm sera 
all contain a minor anti-(Ul)RNP activity However, whereas 
the Ul RNP 70 kDa protein appears as a very typical triplet 
polypeptide on HeLa blots [29], the 70-kDa antigen recog­
nized by anti-Sm sera in all cases had another composition, 
containing polypeptides with a slightly higher electrophoretic 
mobility (Fig 1, lane 10, Fig 5, anti-Sm, lane 1) Companson 
of these antigen populations on two-dimensional gels is now in 
progress 
By several nommmunological isolation procedures, both B/B' 
and D antigens have been shown to be associated with Ul, U2, 
U4, U5 and U6 snRNA [22, 24, 43] It is therefore puzzling 
that some, exclusively Ul snRNA-precipitating sera contain 
antibodies against the B/B' antigens, although this activity is 
generally much weaker than the anti-B/B' activity from anti-
Sm sera (Fig 2) Two-dimensional gel separation followed by 
immunoblotting established that the B/B' proteins recognized 
by anti-(Ul)RNP sera are identical with the antigens recog­
nized by anti-Sm sera (data not shown) Therefore, it is possi­
ble that these anti-(Ul)RNP sera contain trace amounts of 
anti-Sm antibodies not detectable in the (very sensitive) RNA 
immunoprecipitation assay Another acceptable explanation is 
that the epitopes of B/B' antigens which are recognized on 
blots by these anti-(Ul)RNP sera are not available for reaction 
in intact snRNP particles but are buned inside the snRNP 
structure Antibodies directed against these epitopes would 
thus not be able to contribute to the precipitation of RNA 
from -"P-labeled cell extracts 
Cell fractionation studies showed that like the 70-kDa antigen 
[14], part of the B/B' antigens is assoaated with an insoluble 
nuclear substructure called the nuclear matrix [35-38] The 
lower band of this doublet, the В antigen, is preferentially 
released from HeLa nuclei by RNase A treatment and high-
salt wash Attachment of B/B' and 70-kDa antigens to the 
nuclear matrix is in accord with recent immunofluorescence 
studies showing that Ul as well as U1-U6 snRNP particles are 
associated with this nuclear substructure [38, 44] These B/B' 
and 70-kDa antigens might therefore function in snRNP-nuc-
lear matrix association The D proteins, on the other hand, 
can more easily be extracted from nuclei These findings are m 
agreement with the observations that extracts from several 
tissues contain predominantly the readily extractable D anti­
gen [13] as well as the single В protein [14, 45] In accord with 
recent observations made with punned snRNP [33], we found 
that the Ul RNA-associated A antigen was also released from 
isolated nuclei by RNase A treatment Only trace amounts of 
snRNP antigens were detectable in the detergent-soluble (pre­
dominantly cytoplasmic) fraction This possibly reflects the in 
vivo situation (see also [46, 47]) since snRNP proteins are 
made in the cytoplasm and have been shown to be important 
for the transport of mature U snRNA to the oocyte nucleus 
[46] 
Fisher et al showed that B/B' and D antigens are translated 
from differently sized messenger RNA [33] Thus, these anti­
gens are probably distinct polypeptides and not e g degrada­
tion products of one higher mol wt antigen, as occasionally 
has been suggested [34] Since both antigens, however, share 
common epitopes it would still be possible that their messen­
gers share common nucleotide sequences or are even (partly) 
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transcribed fi om the same genomic region Molecular cloning 
of genes encoding for B/B and D antigens mght provide defi­
nite answers to such questions 
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CHAPTER 7 
MONOSPECIFIC ANTIBODIES REVEAL DETAILS 
OF U2 snRNP STRUCTURE AND INTERACTION 
BETWEEN U1 AND U2 snRNPs 
lain W. Mattaj1, Winand J. Habets and Walther J. van Venrooij. 
1European Molecular Biology Laboratory, Meyerhofstrasse 1, Heidelberg FRG. 
The Ε M BO J. in press. 

Summary 
Monospecific antibodies directed against several U small nuclear 
ribonucleoprotein (U snRNP) particle proteins were affinity puri-
fied from a patient anti-(U1,U2)RNP serum. These were used to 
demonstrate that: 1. Proteins equivalent to the mammalian U2 
snRNP specific A' and B " proteins are present in Xenopus laevls 
oocytes. 2. Both proteins A' and B " have the same structural 
requirements for binding to U2 snRNA. 3· Proteins B, B' and D 
have the same structural requirement for binding to U2 snRNA. 4. 
Using very high specific activity RNA probes it is possible to 
detect a fraction of either U1 or U2 snRNA precipitable by antibo-
dies directed against proteins specific for the other U snRNP, in-
dicating an interaction between U1 and U2 snRNPs. The structural 
requirements of this interaction were studied for the U2 snRNP. 
All changes made to U2 snRNA or snRNP struture resulted in loss of 
the interaction with U1 snRNP. 
Introduction 
Since the discovery by Lerner and Steitz (1979) that sera from 
certain patients suffering from autoimmune disorders contain anti-
bodies directed against ribonucleoprotein particles, these antibo-
dies have been extensively used in studies of the structure and 
function of these RNPs (for reviews see Lerner and Steitz, 1981; 
Busch et al., 1982; Mattaj, 1984 and Brunei et al., 1986). The 
most extensively studied of the RNPs have been the U snRNPs. There 
is now strong evidence for an involvement of U1, U2 and U7 snRNPs 
in the processing of mRNA precursors (Hernandez and Keller, 1983; 
Padgett et al., 1983; Bozzoni et al., 1984; Kramer et al., 1984; 
Krainer and Maniatis, 1985; Black et al., 1985; Galli et al., 
1983; Strub et al., 1984) which lends additional interest to study 
of the structure of the RNP particles themselves. 
Studies on the particle proteins have been complicated by the dif-
ficulty of purifying the particles by standard biochemical frac-
tionation methods, and by the number, at least 11, of different 
proteins associated with the U snRNAs (Kinlaw et al., 1982, 1983; 
Hinterberger et al., 1983; Pettersson et al., 1984; Mimori et al., 
1984). Recently developed purification methods based on the use 
of antibodies to the unique tri-methyl cap structures of the U 
snRNAs have enabled purification in good yields of pure U snRNPs 
for the first time (Bringmann et al., 1983, 1984), and this in 
turn has enabled the preparation of monospecific antibodies to 
various U snRNP proteins by affinity purification from serum (Ha-
bets et al., 1985a). 
A complementary method of analysis of U snRNP structure, based on 
the analysis of mutant U2 snRNAs, their interaction with U2 snRNP 
proteins, and the correlation of these interactions with nuclear 
accumulation of the RNAs (De Robertis et al., 1982; Zeller et al., 
1983) has recently been developed (Mattaj and De Robertis, 1985). 
We have now combined the two methods to further analyse the RNA-
protein interactions involved in U2 snRNP structure. This analysis 
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has led us to the conclusion that epitopes on the U2 snRNP specif-
ic proteins A' and B " are highly conserved in evolution, as are 
other U snRNA-associated proteins, and that a small fraction of 
the U2 snRNPs exists in a complex with U1 snRNPs. 
Results 
U2 snRNP specific proteins in Xenopus oocytes 
By a variety of methods two U2 snRNP specific proteins, named A' 
and B", have been identified in mammalian cells. In Xenopus 
oocytes it has been possible to detect, by immunoblotting and im-
munoprecipitation, proteins equivalent to the common U snRNP pro­
teins B, D, E, F and G and the U1 snRNP specific proteins 70K, A 
and С and even putative tissue-specific variants of some of these 
proteins (Zeiler et al., 1983; Fritz, 1983; Fritz et al., 1984). 
It has not been possible, however, to identify unequivocally U2 
snRNP specific proteins in Xenopus by these methods (Fritz, 1983), 
although their existence can be inferred since anti-(U1,U2)RNP 
sera immunoprecipitate specifically U1 and U2 snRNPs from Xenopus 
oocytes (Mattaj and De Robertis, 1985). 
We used the anti-(U1 ,U2)RNP serum V26 (Habets et al., 1985a) to 
try to detect proteins equivalent to A' and B " in oocyte ex­
tracts, in the experiment whose results are shown in Fig. 1A. In 
lanes 1 and 5 the reaction of V26 with proteins 70K, A, A' and B " 
in HeLa nuclear extracts is shown. The lack of obvious equivalent 
bands in oocyte extracts can be seen in lanes 2-4. In order to in­
crease the sensitivity of detection we next purified U snRNPs from 
oocytes using anti-tri-methyl cap antiserum (Bringmann et al., 
1983, 1981»), and stained these with whole and fractionated V26 
serum. V26 was fractionated into monospecific antibodies by elu-
tion of antibodies bound to specific bands on Western blots of 
HeLa extracts (Habets et al., 1985a). Figure IB lanes 1 and 2 
show the staining patterns obtained using the anti-(U1,U2)RNP sera 
B25, which recognizes the HeLa A and B " proteins, and V26, which 
recognizes HeLa 70K, A, A' and B " proteins (Habets et al., 
1985a). Reaction of these antisera with the purified Xenopus 
oocyte U snRNP proteins allows the identification of equivalents 
to protein A (33,000 Da), A' (32,500 Da) and a triplet of proteins 
of around 26-28,000 Da equivalent to B". It is not clear whether 
these three bands correspond to different proteins or are modifi-
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cations or degradation products of a single protein. We do not 
detect a band equivalent to the HeLa 70K protein. This must be due 
to lack of sensitivity since monospecific anti-70K antibodies im-
munoprecipitate Xenopus oocyte U1 snRNP (see below). 
A 
Β ι 
1 2 4 5 
•70K 
2 3 4 5 6 7 8. 
A 
A' 
B" 
\= — 
B E 
- 70 
_ 
3^3 
-325 
- 28 
FIGURE 1 Immunoblot analysis of Xenopus proteins with anti-
(U1,U2)RNP sera. 
Panel A: Analysis of total Xenopus oocyte 12,000g supernatant with 
V26 serum. 
The U snRNP proteins 70K, A, A' and B"' are indicated. Lanes 1 
and 5; HeLa nuclear extract. Lanes 2, 3 and 4; Xenopus oocyte 
12,000g supernatant. The approximate amounts of protein loaded 
were 40, 20 and 10 ug. In comparison to the HeLa controls, there 
is no evidence for specific staining of particular U snRNP pro­
teins. 
Panel B. Analysis of Xenopus oocyte U snRNPs purified with anti-
trlmethyl cap antiserum. 
The antisera and monospecific antibodies used were: lane 1; serum 
B25, lane 2; serum V26, lane 3; affinity purified anti-70K lane 4; 
affinity purified anti-Α, lane 5; affinity purified anti-Α', lane 
6; affinity purified anti-B", lane 7; anti-Sm serum, lane 8; 
non-immune control serum. The position of the stained bands 
equivalent to HeLa A, A' and B " are indicated. 
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Staining of the purified U snRNP proteins with monospecific anti­
bodies (Fig. IB, lanes 3-6) shows that the cross-reativity between 
antibodies to proteins A and B", already observed in HeLa ex­
tracts (Habets et al., 1985a) is also present in Xenopus. The com­
mon epitope on these proteins has thus been conserved in evolu­
tion. The lack of cross-reactivity of antibodies to A' and 70K al­
low monospecific anti-(U2)RNP and anti-(U1)RNP antibodies to be 
prepared. 
An anti-Sm serum which recognizes proteins В and B' as well as D 
in HeLa extracts (Habets et al., 1985b) stains a single band in 
the region of protein В (27,000 Da) in Xenopus U snRNPs (Fig. IB, 
lane 7). A single band of this %tze has previously been observed 
using other anti-Sm antisera to stain Xenopus oocyte extracts 
(Fritz et al., 1984). It is not clear whether this band is a sin­
gle protein or two proteins which are not resolved. The lack of 
reactivity of anti-Sm serum with any of the triplet of B " bands 
underlines the difference between these different "B" proteins. 
In conclusion these results demonstrate the existence in Xenopus 
oocyte U snRNPs of proteins equivalent to the U2 snRNP-specific A' 
and B". The patterns of immunological crossreactivity, A and B " 
cross-reacting while A and A' and В and B " do not cross react, is 
identical to that observed in mammalian cell U snRNPs. 
Binding requirements of proteins B^  and ï3' on_ U£ snRNA 
A method for analysing protein-RNA interactions in RNPs has re-
cently been developed and used to analyse U2 snRNPs. Genes coding 
for wild-type Xenopus laevis U2 snRNA (Mattaj and Zeiler, 1983) or 
for a series of mutants called ΔΑ-ΔΕ in which portions of the RNA 
sequence have been changed (Mattaj and De Robertis, 1985) were in­
jected into Xenopus oocyte nuclei. The immunoprecipitability of 
these RNAs was then tested with various antibodies. In this way 
the RNA sequences required for the binding of particular antigens 
could be determined. Previous experiments have shown that pro­
teins D, E, F and G protect a short region of the U2 SNRNP against 
micrococcal nuclease digestion (Liautard et al., 1982) and that 
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this region of U2 RNA is required in order that the RNA be immu-
noprecipitated by antl-Sm antisera (MattaJ and De Robertis, 1985). 
Since most anti-Sm antlsera recognize at least proteins B, B' and 
D it was not possible- to determine what were the binding require­
ments of proteins B, B' and D separately. 
Recently an anti-Sm antiserum called M13 which recognizes proteins 
В and B' but not D has been described (Habets et al., 1985b). We 
compared the immunoprecipitation of the U2 mutants with this serum 
with their immunopreclpitatlon by antiserum K22, which recognizes 
proteins B, B' and D, as well as the U1 snRNP specific A and С 
proteins (Habets et al., 1985b). The transcripts of the wild-type 
and mutant genes are shown in Fig. 2, panel A. Their immunoprecip­
itation by K22 antiserum is shown in Fig. 2, panel B. This con­
firms that an anti-Sm antiserum recognizing B, B' and D immunopre-
cipitates wild type U2 and all the mutants with the exception of 
ДС, from which at least part of the Sm binding site has been 
deleted (Mattaj and De Robertis, 1985). 
M13 antiserum immunoprecipitates exactly the same U2 mutants as 
K22 (Fig. 2, compare panels В and C). Since this antiserum recog­
nizes only В and B' this indicates that these two proteins require 
the Sm binding site to bind to U2 snRNA. Since we already know 
from the results of Liautard et al. (1982) that one or more of the 
proteins D, E, F and G interact directly with this region of U2. 
This indicates that В and B' most likely bind to the U2 snRNP 
through protein-protein rather than protein-RNA interactions. This 
will be discussed further below. 
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FIGURE 2. Immunoprecipitation of wild-type and mutant U2 snRNAs 
with anti-Sm antisera. 
The two antisera used were K22, which recognizes U snRNP proteins 
B, B', D, A and C, and МІЗ which recognizes only В and B' (Habets 
et al., 1985b). The wild-type U2 and mutants ΔΑ-ΔΕ have been 
described (Mattaj and Zeiler, 1983; Mattaj ^ jid De Robertis, 1985). 
Xenopus oocytes were microinjected with α- Ρ GTP alone (lanes G) 
or in combination with either wild-type U2 DNA (lanes U2) or one 
of the mutant DNAs ΔΑ-ΔΕ (lanes A-E). 
Panel A: total transcription products from microinjected oocytes. 
The positions of 8S, U2, 5.8S and 5S RNAs are indicated. Note that 
on this gel ΔΒ transcripts co-migrated with 5.8S RNA. Panel B; RNA 
precipitated by K22 antiserum. Panel C; RNA precipitated by Ml 3 
antiserum. 
Binding requirements of A/ and _B" cm U2_ snRNA 
A previous analysis of binding both common U snRNP proteins and U2 
snRNA specific proteins (Mattaj and De Robertis, 1985), could not 
distinguish which of the two U2 snRNP proteins A' and B " were be­
ing studied. The monospecific antl-A' and anti-B" antibodies 
(described above) were therefore used to further the analysis of 
U2 snRNP structure. 
The results presented in Fig. 3 represent immunoprecipitated RNAs 
from control oocytes or from oocytes injected with either wild-
type or a mutant U2 gene. The antibodies used are either whole V26 
serum or monospecific antibodies prepared by elution from HeLa 
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protein immunoblots. It is important to note that the control 
used is serum eluted from part of the immunoblot showing no 
specific staining. In other words it shows the small but detect-
able amount of V26 serum sticking non-specifically to the nitro-
cellulose (Fig. 3, compare panels 1 and 2). The RNAs precipitable 
by \!'¿6 serum are shown in Fig. 3, panel 2. 
G U2 А В С D E 
'-U2 
-U2 
V26 
3 A' 
^ф' 
-U2 
В" 
•ui 70K 
FIGURE 3. Immunoprecipitation of 
mutant and wild-type U2 snRNAs 
with anti-(U1-U2)RNP and monos­
pecific antibodies. 
Xenopus oocytes were microinject-
ed with α- Ρ GTP alone (lane G) 
or in combination with either 
wild-type U2 DNA (lane U2) or one 
of the mutant U2 DNAs ΔΑ-ΔΕ 
(lanes A-E). 
Extracts of oocytes were then im-
munoprecipitated with either 
whole V26 serum or with affinity 
purified monospecific antibodies 
to 70K, A' or B". These were 
purified by elution of antibodies 
from immunoblots of HeLa nuclear 
proteins (Habets et al., 1985a). 
As a control non-specifically 
sticking antibodies were eluted 
from a blanc region of the immu­
noblot. Panel 1; control elution, 
panel 2; whole V26 serum, mock-
eluted, endogenous Ul and U2 are 
indicated, panel 3; anti-Α', en­
dogenous U2 is indicated, panel 
4; anti-B", endogenous U2 is in­
dicated, panel 5; anti-70K, en­
dogenous Ul is indicated. 
No endogenous Ul is detectable in 
anti-B" (or anti-Α, not shown) 
immunoprecipitates in spite of 
the crossreaction of these anti­
bodies with A. This is probably 
due to the antibodies having a 
lower affinity for A than for 
B". 
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Endogenous UI and U2 RNA are precipitated, as are wild-type U2, 
and RNAs transcribed from the U2 mutants ΔΑ and ΔΒ. RNAs tran­
scribed from mutants ΔΟΔΕ are not immunoprecipitated by this 
serum. This result is identical to that previously obtained using 
another anti-(U1,U2)RNP serum called Pick (Mattaj and De Robertis, 
1985a) or P21 (Habets et al., 1985a) which apparently recognized 
protein B " but not A' (Habets et al., 1985a). In order to test 
which parts of the U2 sequence were specifically required for 
binding A' and B " we next tested these two monospecific antibo­
dies separately. The results (Fig. 3, panels 3 and 4) show that 
both these proteins have the same structural requirements for 
binding to U2. They require the binding site for the Sm antigen, 
deleted in AC (Mattaj and De Robertis, 1985) and the sequences 3' 
to this site deleted in ΔΟ and ΔΕ. As expected from their immuno­
logical cross-reactivity, monospecific anti-Α and anti-B" antibo­
dies behaved identically in these assays (not shown). 
The structural information gleaned from these results is incor­
porated into the schematic model of U2 snRNP structure presented 
in Fig. 5. 
Interaction between U1 and U2 snRNPs 
An unexpected result was that monospecific anti-70K antibodies im­
munoprecipitated not only endogenous U1 , but also a significant 
amount of wild-type U2 RNA from oocytes injected with the wild-
type gene (fig. 3, panel 5). That this immunoprecipitation of U2 
is not due to unspecific binding is shown by comparison of control 
and anti-70K precipitations (Fig. 3, panels 1 and 5). The amount 
of mutants ΔΑ and ΔΒ precipitated by non-specifically bound V26 
antiserum and by monospecific anti-70K is similar. The amount of 
wild-type U2 precipitated by the 70K antibodies is clearly above 
the control value, and indicates an indirect precipitation of 
wild-type U2 snRNPs through interaction with U1 snRNPs. We are 
able to detect this interaction due to the very high specific ac­
tivity of U2 snRNA in oocytes injected with U2 genes. The specif­
ic activity of the endogenous RNA does not allow this detection 
(Fig. 3, panel 5, lane G). The fact that none of the mutant U2 
snRNAs is precipitable with anti-70K antibodies indicates that all 
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of the changes to U2 snRNA structure made in mutants ΔΑ-ΔΕ and the 
resulting changes in the composition of the U2 snRNPs, prevent in­
teraction with U1 snRNPs. 
As a further check on the interaction between U1 and U2 we carried 
out the reciprocal experiment. X.1.U1.3» a minor U1 snRNA gene 
from Xenopus whose structure and sequence have been described 
(Zeller et al., 1984; Mattaj et al., 1985) was injected into 
oocytes in order to obtain high specific activity U1 snRNA (Fig. 
4, panel A). Monospecific antibodies were then used to analyse 
immunoprecipitable RNAs in control and injected oocytes. 
The results from control oocytes show the expected pattern (Fig 
48). Whole V26 serum (lane 2) precipitates both U1 and U2, anti-
70K only U1 detectably (lane 3) and anti-Α' only U2 detectably 
(lane h). Anti-Α and anti-B" precipitate as expected both U1 and 
U2 (not shown). When the specific activity of U1 is increased by 
gene injection, the immunoprecipitation pattern observed is that 
given in Fig. 4, panel C. V26 precipitates endogenous U2 plus U1 
(lane 2), anti-70K only detectably U1 (lane 3), while anti-Α' pre­
cipitates endogenous U2 and a small amount of U1 (lane 4). Com­
parison with the control (lane 1) indicates that the U1 precipita­
tion is significant, arising from interaction with U2 snRNP rather 
than non-specific contamination with whole V26 serum. This result 
together with those presented above suggest that a small fraction 
of U1 and U2 snRNPs exist in a coprecipitable form. The possible 
basis of this interaction will be discussed below. 
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FIGURE Ц. Immunoprecipitation of Ul RNA. 
Xenopus oocytes were injected either with α- Ρ GTP alone or to­
gether with DNA of the clone X.1.U1.3. Total RNA extracted from 
these oocytes is shown in panel A. Lane 1; GTP injection, lane 2; 
X.1.U1.3 injection. Extracts of the injected oocytes were then im-
munoprecipitated with monospecific anti-Α' or anti-70K antibodies 
eluted from immunoblots of HeLa nuclear extracts or with mock-
eluted whole V26 serum or non-specifically sticking serum from a 
blank region of the immunoblot. Panel B; GTP injected oocytes, 
panel C; X.1.U1.3 injected oocytes. Lanes 1; control elution, 
lanes 2; whole V26, lanes 3; anti-70K, lanes 4; anti-A'. 
1 2 3 4 
-U2 
Ul 
1 2 3 4 
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— 9 8 — 
Discussion 
The results presented here, together with previous results ob­
tained by the same method (Mattaj and De Robertis, 1985) can be 
combined with results from micrococcal nuclease digestion experi­
ments in which the regions of U2 snRNA protected against nuclease 
in U2 snRNPs were determined (Liautard et al., 1982; Reveillaud et 
al·, 1985) and results obtained from the study of assembly of U 
snRNP particles in vivo (Fisher et al., 1985). In this way a con­
sistent model of RNA protein interactions in the U2 snRNP particle 
can be obtained. This is diagrammed schematically in Fig. 5. Pro­
teins D, E, F and G, which associate with one another in the ab­
sence of RNA to form a 6S particle (Fisher et al., 1985), bind to 
and protect a region near the centre of the U2 RNA molecule from 
micrococcal nuclease digestion (Liautard et al., 1982). 
FIGURE 5. Schematic representation of the U2 snRNP. 
The U2 snRNP secondary structure is based on data from Reddy et 
al. (1981), Branlant et al. (1982), and Black et al. (1985). The 
shaded blocks represent the sequences altered in mutants ΔΑ-ΔΕ 
(Mattaj and De Robertis, 1985). 
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This region is required in order that the RNA be precipitated by 
anti-Sm antibodies which recognize proteins B, B' and D (Mattaj 
and De Robertis, 1985) or В and B' alone (this paper). The logical 
conclusion is that one or more of proteins D, E, F and G bind 
directly to this region of U2, and that В and B' are attached to 
this particle through protein-protein interactions. 
The U2 snRNP specific proteins A' and B " bind only to wild-type 
U2 and mutants ΔΑ and ΔΒ. In other words they require for binding 
not only that the Sm binding site was present, but also RNA struc­
ture 3' to this. They therefore appear to interact both with RNA 
in the 3' half of the U2 RNA molecule directly and with proteins 
bound to the Sm binding site. The interaction of these proteins 
with the 3' half of the U2 RNA molecule is likely to be the cause 
of the protection of this region against micrococcal nuclease 
digestion of the U2 RNPs observed by Reveillaud et al. (1985). The 
results are combined in the model of U2 snRNP structure shown in 
Fig. 5. The model of course is based upon several simplifying as­
sumptions, of which perhaps the most unjustified is that the pro­
teins are all present in all particles in equal molar ratio. It 
may well be that there exist several different U2 snRNPs which 
differ in their protein composition, and thus are structurally, or 
even functionally, distinct. For example in any given U2 snRNP 
only protein A' or B " might be present. 
The interaction of U1 and U2 snRNPs is of interest given that both 
of these RNAs are involved in the removal of introns from mRNA 
precursors in splicing (Hernandez and Keller, 1983; Padgett et 
al., 1983; Bozzoni et al., 1984; Kramer et al., 1984; Krainer and 
Maniatis, 1985; Black et al., 1985). This process occurs in a 
particle which has been called the spliceosome (Brody and Abelson, 
1985; Grabowski et al., 1985; Frendewey and Keller, 1985). The 
interaction which we see is however unlikely to represent the im-
munoprecipitation of splicing complexes since our immunoprecipita-
tions are carried out in 0.5M NaCl. At this ionic strength spli-
ceosomes are at least partially dissociated (Grabowski et al., 
1985), and in fact earlier studies of U1 interaction with hnRNPs 
showed that U1 dissociates from hnRNP at roughly 0.15M NaCl (Zieve 
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and Penman, 1981). It is therefore more likely that we are study-
ing a direct U1-U2 snRNP interaction, although this may well 
represent a sub-component of the spllceosome. It is interesting 
that none of the mutant U2 snRNAs is capable of forming an RNP 
which can interact with U1 RNP. This indicates that the interac-
tion Is not a simple one Involving one binding site, but that it 
requires structural integrity of the U2 RNP. It will be of in-
terest to study the entry of the mutant U2 snRNAs into splicing 
complexes, which may reveal whether the U1-U2 interaction is a 
step along the pathway to spllceosome formation. 
Materials and Methods 
Immunoblotting and preparation of monospecific antisera 
Whole oocyte extracts (Fritz et al., 1984), HeLa nuclear extracts 
(Habets et al., 1983) and oocyte U snRNPs purified by affinity 
chromatochraphy on anti-trimethyl cap antibody columns (Bringmann 
et al., 1983, 1984) were analysed as described (Habets et al., 
1985a,b). Monospecific antisera were eluted (Smith and Fisher, 
1984) from high resolution immunoblots of HeLa nuclear extract 
(Habets et al., 1985a,b). 
Oocyte microinjection and Immunoprecipltatlon 
Oocytes were injected, fractionated and extracted, and the ex-
tracted RNAs were analysed as described in Mattaj and De Robertis 
(1985). 
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CHAPTER 8 
SUMMARY / SAMENVATTING 

Sera from pa t i en t s with rheumatic diseases often contain an t ibo-
dies that react with various normal ce l l u l a r components. Some of 
these autoantibodies are very c h a r a c t e r i s t i c for the disease in 
which they occur and therefore frequently used as a "marker" and 
help in d iagnos i s . Apart from a diagnost ic and possible prognos-
t i c value, human autoantibodies are useful too l s in molecular 
biology. In 1979 Lerner and S t e i t z f i r s t showed tha t some sera 
from pa t ien t s with SLE contained ant ibodies against small nuclear 
r ibónucleoprotein (snRNP) p a r t i c l e s pa r t i c ipa t i ng in the process-
ing of mRNA precursors . Since then, sera from pa t i en t s with v a r i -
ous autoimmune syndromes were screened with modern biochemical 
techniques, one of the most prominent being immunoblotting. The 
use of t h i s technique allowed a more accurate determination of a 
pa t ien ts antibody p r o f i l e , in pa r t i cu la r when more than one spec i -
f i c i t y was presen t . 
Chapter 2 of t h i s t he s i s describes an immunoblotting study upon 
the presence of marker ant ibodies in sera from pa t i en t s with mixed 
connective t i s s u e disease (MCTD). The r e s u l t s ind ica te tha t so-
cal led anti-70K ant ibodies (70K i s a protein exclusively present 
on U1 snRNP p a r t i c l e s ) are quite spec i f i c for t h i s d i s ea se . 
To inves t iga te whether antl-70K ant ibodies might a lso have a prog^ 
nos t ic value , we developed a quant i ta t ive immunoblotting assay 
(QIBA, chapter 3 ) . This assay enabled us to follow pa t i en t s longi -
tud ina l ly with respect to the exact autoantibody composition of 
t he i r serum. The r e s u l t s showed tha t in a pa t ient with a r a the r 
f luc tua t ing disease a c t i v i t y an exacerbation of disease coincided 
with a peak in h is anti-70K antibody l e v e l . No co r re l a t ion could 
be found between severeness of the disease and anti-70K leve l when 
21 sera of SLE and MCTD pa t ien t s were examined in a one point 
s tudy, I . e . one serum sample from every Individual pa t ien t taken 
a t an a r b i t r a r y stage of the disease (chapter 3 ) . 
Chapters 4, 5 and 6 deal with the molecular charac te r iza t ion of 
the autoantigens SS-B, (U1,U2)snRNP and Sm, r e s p e c t i v e l y . 
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SS-B or La is a cellular antigen with a molecular weight of about 
50,000 Daltons, in most cases recognized by antibodies in sera 
from patients with Sjoegren's syndrome. In adeno- and Epstein-Barr 
virus infected cells this antigen associates with several small 
virus-encoded RNAs whereas in uninfected cells a great variety of 
polymerase Ill-transcribed RNAs binds to it. The SS-B antigen has 
been proposed to function as an RNA polymerase III transcription 
factor, whereas others suspect that it might be an RNA modifying 
enzyme because of its association with precursor RNAs. No con-
clusive evidence has as yet been provided for any of these possi-
bilities . 
Anti-(U1,U2)RNP antibodies, described in chapter 5 are a relative-
ly new autoantibody specificity that greatly have facilitated the 
investigations towards the structure of U2 RNP. As described in 
chapter 5, U2 RNA is associated with at least two unique proteins, 
one of which shares a common epitope with the U1 RNA specific A 
protein. Both these RNAs are involved in the splicing process of 
pre-mRNA; U1 has been shown to bind to the 5' splice-site of pre-
mRNAs in _in vitro systems, U2 is proposed to associate with the 
so-called branch point of the lariat-shaped intron, an intermedi-
ate in the cascade of splicing events. 
Binding requirements for RNA-protein interactions in U2 RNP parti-
cles are described in chapter 7. These investigations also re-
vealed that a small portion of the U2 RNPs _in vivo exists in a 
complex with U1 RNP. This association may represent a functional 
subunit of the spliceosome, a particle in which the splicing event 
takes place. 
Chapter 6 describes the characterization of other U-snRNP-
associated proteins. Some of these proteins are common in at least 
U1 , U2, U4, U5 and U6 (=U1-U6) RNPs (U3 RNA is located in the nu-
cleolus). Antibodies directed against any of these proteins pre-
cipitate U1-U6 RNA from (radiolabeled) cell extracts, whereas 
anti-(U1)RNP sera react exclusively with one of the three U1 RNP 
specific proteins. Some of these antigens appeared to be associat-
ed with the so-called nuclear matrix, a nuclear substructure on 
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which RNA transcription takes place. This attachment of snRNP as-
sociated proteins provides another argument in favor of the hy-
pothesis that splicing occurs while pre-mRNAs are still matrix-
associated. 
In het serum van patiënten met reumatische aandoeningen worden 
vaak antistoffen gevonden die gericht zijn tegen verschillende 
komponenten uit cellen van het eigen lichaam. Sommige van deze au-
toantistoffen zijn karakteristiek voor de ziekte waarbij ze voor-
komen en worden daarom gebruikt als een zogenaamde "marker" bij de 
diagnose van een patient. Aan enkele autoantistoffen kan ook een 
prognostische betekenis worden toegekend. Daarnaast zijn humane 
autoantistoffen een hulp bij de bestudering van verschillende 
molekulair-biologische processen. In 1979 toonden Lerner en Steitz 
voor het eerst aan dat sommige sera van patiënten met systemische 
lupus erythematodes (SLE) antistoffen bevatten die gericht waren 
tegen zogenaamde "small nuclear ribonucleoprotein particles" 
(snRNP), deeltjes bestaande uit eiwit en RNA die betrokken zijn 
bij het rijpingsproces van boodschapper RNA. Sindsdien zijn tal-
loze sera van patiënten met autoimmuunziekten onderzocht met 
behulp van moderne biochemische methoden. Met name de 
immunoblotting-techniek maakte het mogelijk om van iedere patient 
een zogenaamd antistof-profiel te bepalen, wat vooral nuttig is 
als er meerdere autoantistoffen tegelijk in een serum aanwezig 
zijn. 
Hoofdstuk 2 van dit proefschrift beschrijft een onderzoek naar de 
aanwezigheid van "marker"-antistoffen in sera van patiënten met 
"mixed connective tissue disease" (MCTD). De resultaten hiervan 
tonen aan dat het voorkomen van zogenaamde anti-70K antistoffen 
(70K is een eiwit dat alleen voorkomt in UI snRNP partikels) 
specifiek lijkt te zijn voor deze ziekte. 
Om een mogelijk prognostische waarde van deze anti-70K antistoffen 
te kunnen onderzoeken hebben we een kwantitatieve immunoblotting 
methode ontwikkeld (QIBA, hoofdstuk 3). Deze test stelde ons in 
staat om het antistof-profiel van een patient longitudinaal te 
vervolgen. De resultaten wezen erop dat bij een patient met een 
nogal fluctuerende ziekteactiviteit een plotselinge verergering 
van de ziekte samenviel met een anti-70K piek in zijn antistof-
profiel. Geen samenhang kon worden ontdekt tussen de ernst van de 
ziekte en anti-70K antistof nivo in een onderzoek met eenmalig af-
genomen serum van SLE en MCTD patiënten 
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De hoofdstukken Ч, 5 en 6 behandelen de molekulair-biologische 
karakter i se r ing van r e s p e c t i e v e l i j k de autoantigenen SS-B, 
(UIIU2)RNP en Sm. 
SS-B, ook wel La genoemd, i s een c e l l u l a i r antigeen met een 
molekuulmassa van ongeveer 50.000 Dalton waartegen vooral pa t iën-
ten met Sjoegren 's syndroom ant is tof fen b e z i t t e n . In adeno- en 
Epstein-Barr v i rus geïnfecteerde cel len assoc iee r t d i t antigeen 
met verschi l lende kleine door het virus gekodeerde RNAs, t e rwi j l 
in ongeinfecteerde cellen een grote verscheidenheid aan polymerase 
I I I t r ansc r ip t en met het SS-B antigeen i s gecomplexeerd. Sommige 
onderzoekers hebben daarom geponeerd dat het SS-B antigeen een po-
lymerase I I I t r an sc r ip t i e f ac to r zou zijn t e rw i j l anderen vermoeden 
dat het een RNA-modificatie enzym zou kunnen zi jn vanwege de 
gevonden a s s o c i a t i e met zogenaamde "precursor"-moleculen. Tot nu 
toe i s echter geen overtuigend bewijs gevonden voor deze 
theor ieën . 
Hoofdstuk 5 beschr i j f t een r e l a t i e f nieuwe soort au toan t i s to f , 
anti-(U1,U2)RNP, waarmee bijvoorbeeld onderzoek kan worden gedaan 
naar de s t ruc tuur van U2 RMP. Zoals in hoofdstuk 5 wordt 
beschreven i s U2 RNA geassocieerd met tenminste twee unieke e iwi t -
ten , waarvan een een gemeenschappelijk epitoop heeft met het UI 
RNA-specifieke A e iwi t . Deze beide RNAs zijn betrokken bi j het 
r i jp ingsproces van de voorloper van boodschapper RNA, het pre-
mRNA. Van UI RNA i s in in_ v i t r o systemen aangetoond dat het bindt 
aan de zogenaamde " 5 ' sp l ice s i t e " van pre-mRNAs, t e rwi j l U2 zou 
binden aan de zogenaamde "branch point" van het lasso-vormige in -
t ron , een intermediair in het pre-mRNA r i jp ingsproces . 
Factoren die belangri jk zi jn voor de i n t e r a c t i e tussen eiwit en 
RNA in U2 RNP p a r t i k e l s worden beschreven in hoofdstuk 7. Tevens 
wezen de r e s u l t a t e n van d i t onderzoek u i t dat een kle in gedeelte 
van de U2 RNPs Jji vivo geassocieerd i s met UI RNPs. Hierdoor zou 
een functionele eenheid gevormd kunnen worden die een ro l vervult 
in het zogenaamde "spliceosome", een complex waarin het mRNA 
r i jp ingsproces zich a f s o e e l t . 
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Hoodstuk 6 beschrijft de karakterisering van andere met U-snRNP 
geassocieerde eiwitten. Sommige van deze eiwitten komen voor in 
zowel UI, U2, U4, U5 als U6 (U1-U6)RNPs. Antistoffen, gericht 
tegen deze eiwitten precipiteren allen U1-U6 RNA uit (radioactief 
gelabelde) celextracten, terwijl anti-(U1)RNP antistoffen alleen 
reageren met een van de drie eiwitten specifiek voor UI RNPs. 
Sommigen van deze antigenen bleken geassocieerd met de zogenaamde 
kernmatrix, een structuur in de celkern waaraan onder andere RNA 
transcriptie plaatsvindt. Deze associatie vormt een extra argu-
ment voor de hypothese dat het rijpingsproces van pre-mRNAs zich 
afspeelt terwijl het pre-mRNA gebonden is aan de kernmatrix. 
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Future outlook 
Elucidation of the primary structure of autoantigens has come 
within reach now a variety of well-characterized autoimmune sera 
enable the large scale isolation of several autoantigens. Recom-
binant DNA technology allows the identification of genes coding 
for autoantigens and provides tools to study their regulation, 
whereas monoclonal antibodies raised against autoantibodies or 
their target antigens can provide Insight in the mechanisms in-
volved in autoimmunity. 
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laboratorium voor biochemie aan de Katholieke Universiteit van 
Nijmegen. Daar werd met financiële steun van het "Praeventiefonds" 
en het "Reumafonds" het in dit proefschrift beschreven onderzoek 
uitgevoerd in de werkgroep van Dr. W.J. van Venrooij. In 1984 wer-
den het ANA symposium te Leuven en de Bertine Koperberg Conference 
te Oosterbeek bezocht en in 1985 het Colloquium Protides of the 
Biological Fluids te Brussel. Tevens werden werkbezoeken afgelegd 
aan de groepen van Dr. R. Luhrmann (Berlijn) en Dr. E. Penner 
(Wenen). Tijdens de promotieperiode werd een bijdrage geleverd aan 
het practisch biochemie-onderwijs aan eerste en tweede jaars stu-
denten medicijnen en werd tevens de functie van plaatselijk 
veiligheidsdeskundige m.b.t. stralingshygiëne vervuld. 
Vanaf juni 1985 is hij op bovengenoemde afdeling werkzaam op een 
door het "Reumafonds" gesubsidieerd project dat de verdere karak-
terisering van autoantigenen bij reumatische ziekten tot doel 
heeft. 
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STELLINGEN 
I 
Bij zijn conclusie dat UI en U2 snRNPs op identieke plaatsen in de 
celkern gelocaliseerd zijn gaat Spector er ten onrechte van uit 
dat het door hem gebruikte serum antistoffen bevat die uitsluitend 
gericht zijn tegen U2 snRNPs. 
Spector, D.L. (19810 B l o l . C e l l , 51., 109-112. 
II 
Bepaling van circulerende auto-antistoffen in het serum van pa-
tienten met reumatische aandoeningen middels immuunfluorescentie 
op levercoupes is ontoereikend en dient te worden vervangen door 
een bepaling met een groter differentiërend vermogen. 
Dit proefachrlft 
III 
De conclusie van Fritzler et al. dat sera van MCTD patiënten an-
tistoffen bevatten tegen hnRNP kan niet gebaseerd worden op de 
door hen gepresenteerde resultaten. 
Fritzler, M.J., Rashld All, Tan E.M. (19811) J. Immunol. Д 2 , 1216-1222. 
IV 
Goede reumaserologie omvat ook bepaling van de anti-perinucleaire 
factor. 
V 
De eerste door Gazit et al. voorgestelde initiatie site in exon 1 
van het humane c-sls proto-oncogen zal in vivo niet gebruikt kun­
nen worden. 
Gazlt, Α., Igaraahl, H., Chlu, I-M., Srlnlvasan, Α., ïanlv, Α., Tronlok, S.R., Robblns, 
K.C., Aaronaon, S.A. (1981) Cell 39, 89-97. 
VI 
De regionale localisatie van een aantal anonieme chromosoom 19 
"markers" die Brook et al. vinden uit studie aan somacelhybriden 
is onjuist. 
Brook, J.D., Shaw, D.J., Thomas, N.S.T., Meredith, A.L., Corvell, J., Harper, P.S. (1986) 
Cytogenet. Cell Genet, in, 30-37. 
VII 
Het ontbreekt Ozaki et al. aan de juiste controle experimenten om 
te mogen concluderen dat er eiwitsynthese in de kern van de 
ooglens plaatsvindt. 
Ozaki, L., J a p , P . , Bloemendal, H., (1985) Exp. Eye Res. j n , 569-575. 
VIII 
De door Crabbe gepresenteerde homologie tussen c-myc en β- en Ύ-
crystallines getuigt niet van inzicht in de evolutionaire 
verwantschap van deze ooglenseiwitten. 
Crabbe, M.J.C., (1985) FEBS Letters 181, 157-159. 
IX 
De exponentiele toename in het gebruik van computers leidt tot een 
verarming van de nederlandse taal. 
X 
Het is niet zinvol om iedere radiologische werker van een film-
badge te voorzien. 
XI 
Gezien de bruikbaarheid van immunoblotting voor het aantonen van 
antistoffen tegen onder andere LAV/HTLV III getuigt de benaming 
"Golden Blot" van commercieel inzicht. 
Brada, D., Roth, D. (1984) Anal. Bloohem. 112, 79-83. 
XII 
Het omkopen van stemgerechtigden bij (2 kamer) verkiezingen is 
blijkbaar alleen te veroordelen wanneer dat op kleine schaal ge­
beurt. 
Nijmegen, 22 mei 1986 
WInand Habets. 


